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1
Each year approximately 2200 very premature infants, with a gestational age < 32 weeks, 
are born in the Netherlands.1 Anemia of prematurity (AOP) is a condition which is often seen 
in these infants. This AOP is an exaggerated form of the normal physiologic anemia seen in 
full term infants and is inversely related to gestational age at birth.2 More than 50% of the 
infants born before 32 gestational weeks receive RBC transfusions early in life because of this 
anemia.3-5 The aetiology of AOP is multi-factorial. The shorter life span of hemoglobin (Hb) F 
bearing red blood cells (RBC) and the relatively rapid growth, contribute to the fall in neonatal 
Hb.6 Another important factor contributing to the decrease in neonatal Hb is blood loss due to 
frequent phlebotomies for diagnostics during the first weeks of life. Several studies have shown 
that replacement of iatrogenic blood loss is one of the major reasons for administering RBC 
transfusions.7-8 Clinical symptoms of AOP are rather non-specific and include poor weight gain, 
tachycardia, bradycardia, apnea, and an increased need for supplemental oxygen.9 Studies that 
investigated which clinical parameters could predict the transfusion needs in premature infants, 
showed that gestational age and birth weight were the only independent variables.10-11  In one 
other study, the combination of gestational age and Apgar score contributed to the prediction of 
transfusion needs in infants born after 32 weeks of gestation.12 Cardiac output, heart rate and 
respiratory rate did not help in predicting blood transfusion needs. Laboratory parameters, such 
as erythropoietin, initial Hb, vascular endothelial growth factor (VEGF) and lactate, have also been 
studied as predictive markers for transfusion needs.13-15 Of these laboratory parameters, a high 
initial Hb is associated with reduced transfusion needs.14 VEGF levels > 140pg/ml indicate tissue 
hypoxia and probably can serve as a marker for transfusion.15 Because there is no single factor 
predictive for transfusion needs in these infants, in practice the decision to transfuse is frequently 
based on a combination of postnatal age, hematocrit value and clinical manifestations.16
Neonatal transfusion practice
In the Netherlands, the Dutch Institute for Health Care Improvement has set up a transfusion 
guideline in which specific triggers are recommended for use in neonatal intensive care. These 
thresholds vary depending on postnatal age and the presence of cardio-respiratory problems. 
Infants suffering from such problems are transfused at a higher threshold. In absence of these 
problems, the triggers become more restrictive with increasing postnatal age.17
The standard RBC transfusion product, a pedi-pack (one-fifth of an adult unit), consists of pre-
storage filtered red blood cells (RBC) derived from voluntary healthy adult donors, stored in 
extended storage medium consisting of saline, adenine, glucose and mannitol (SAG-M), and has 
a hematocrit between 0.55-0.65 L/L. The shelf life of this product is 35 days.18 Transfusion volume 
per kg recipient bodyweight differs per neonatal center. In international literature, a transfusion 
volume range of 10-20 mL per kg body weight is reported. For infants with a birth weight of 









































12  |  Chapter 1
In some countries, single donor programs have been evaluated, in which one adult RBC donation 
is dedicated to one or two premature infants.20-23 Such strategies to reduce the donor exposure 
have been shown to be feasible22 and cost-effective 23, but are not standard practice in every 
neonatal center around the world. 
Several randomized studies compared a restrictive transfusion strategy with a more liberal 
threshold.24-26 Use of restrictive transfusion triggers resulted in either a lower number of 
transfusions per infant,24,26 or fewer infants receiving transfusions.25 However, with respect to 
outcome these studies reported different results. Bell and colleagues suggested that infants under 
a more restrictive transfusion policy were more at risk for neurologic sequelae.24 This was not 
observed by Kirpalani et al and Chen et al.25-26 However, the latter study reported that the infants 
who received a total transfusion volume of more than 30 mL over 30 days were more prone to 
develop chronic lung disease. This risk could decline by the use of more restrictive triggers.26 The 
infants enrolled in the multi-center study by Kirpalani were evaluated at 18 to 21 months of 
corrected age. The primary composite outcome in this study was death or survival with any of 
either severe visual or the presence of cerebral palsy, or cognitive delay, or hearing impairment. 
They observed no statistically significant difference in such worse primary outcome, but the 
difference in cognitive delay (Mental Development Index score < 70) approached statistical 
significance. A post-hoc analysis with redefined cognitive delay (Mental Development Index score 
< 85) showed a significant difference favoring the liberal threshold group. This study provided 
some evidence of benefit from a higher hemoglobin threshold for transfusion primarily through 
this secondary analysis of cognitive delay.27 In contrast to this finding, Nopoulos et al reported 
that premature infants receiving transfusions according to the liberal guideline, earlier included 
in the study by Bell et al, had a reduced brain volume at a mean age of 12 years.28 These findings 
indicate that further research is required regarding the transfusion effect on neuro-developmental 
outcome in premature infants. Altogether, lowering the transfusion triggers may be feasible but 
not without potential clinical risks. As such, additional controlled clinical trials are desirable.
The broad transfusion volume range from 10 to 20 mL per kg body weight used for infants, 
an equivalent of 2 to 4 units of RBC in adults, has hardly been investigated. Paul et al studied 
the effect of RBC transfusions with 10 and 20 mL per kg and found higher hematocrit and 
hemoglobin values after transfusion with 20 mL per kg in accordance with the double dose. 
However, whether the higher volume resulted in a lower total number of transfusions per infant 
could not be confirmed.29 Wong et al examined transfusion volumes of 15 mL and 20 mL per kg 
and also reported higher post-transfusion hematocrits. A higher transfusion volume did not result 
in a lower number of transfusions per infant.30 Comparison of transfusion volume relies on the 
hematocrit of the used product. For instance, although the transfusion volume per kg was similar 
in the randomised studies by Bell and Kirpalani, the transfused products were different.24-25 Bell et 
al transfused products with a hematocrit between 0.80 and 0.85 L/L.24 The products transfused 
in the study by Kirpalani et al were washed before transfusion and the actual hematocrit of these 
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1
Furthermore, there is evidence that allogeneic RBC transfusion suppresses premature 
hematopoiesis. Several clinical series demonstrated a decrease in endogenous EPO concentration 
in premature infants after RBC transfusion.30-33 These studies, however, used a more liberal 
transfusion strategy than the current transfusion guidelines. How differences in total RBC volume, 
transfused according to the current transfusion practice or RBC product volume, affect total 
transfusion needs and outcome is unknown. 
Compliance to neonatal transfusion guidelines is still a subject of research.34-35 Implementation 
of an electronic transfusion ordering and monitoring system and the inclusion of care-givers 
perception of patients transfusion needs in the guideline have been suggested as options to 
provide better adherence.35-36 With more uniform neonatal transfusion practice, we could gain 
more and better evidence for transfusion related effects on neonatal outcome.
Clinical sequelae associated with RBC transfusion
Allogeneic RBC transfusions have often been incriminated to have clinical disadvantages.37 
Despite the stringent quality control of the Blood Banks regarding donor recruiting and product 
preparation, a very small risk of blood transmitted infectious diseases still exists.38 Furthermore, 
RBC transfusion has shown to be associated with higher risk for severe neonatal conditions like 
bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP) and necrotizing enterocolitis 
(NEC).37, 39-42 Despite many efforts to relate these free radical associated disorders with the 
administration of a RBC transfusion, causality has not been proven.43-46 In addition, several studies 
have shown that blood transfusion may suppress neonatal hematopoiesis at 6-7 weeks after 
birth.30-33
Blood transfusions also have beneficial effects. Several studies demonstrated that RBC transfusions 
improve cerebral, splanchic tissue and renal oxygenation in anemic premature infants.47-49 A 
hemoglobin level of 6 mmol/l has been proposed as a critical threshold for cerebral oxygenation 
to be at risk.49 Next to this, possible beneficial neuro-developmental effects cannot be ruled out.27
To investigate whether a causal relation exists between allogeneic RBC transfusions and the 
occurrence of neonatal complications, one has to overcome several difficulties. Transfused 
premature infants are more often born at a younger gestational age and suffer from multiple 
organ insufficiencies because of their immaturity.50-51 To evaluate a transfusion effect in these 
infants, a well controlled non-transfused group would be necessary. However, with decreasing 
gestational age, more infants receive transfusions, making formation of a control group not 
possible most of the time. Another hurdle in investigating transfusion effects is to equalize the 
amount of blood needed for investigation, as phlebotomies for diagnostic purposes are a major 
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Alternatives for RBC transfusion in premature infants
Recombinant Human Erythropoietin
Several studies found low plasma levels of endogenous erythropoietin (EPO) in premature 
infants.30-33 These measured levels were below expected levels for the degree of anemia in adults. 
Comparison with anemic adults with similar degrees of anemia, showed 10-100 times lower 
EPO values in infants.52 This finding provided the rationale to investigate the use of recombinant 
human EPO (rH-EPO) in premature infants. Over 40 randomized trials investigating the effects 
of rH-EPO have been performed. Aher and Ohlsson published three meta-analyses on behalf of 
the Cochrane Collaboration, which investigated respectively: the use of early administration of 
rH-EPO (within 8 days after birth), late administration of rH-EPO (between day 8-28 after birth) 
and also compared the effect of early versus late administration of rH-EPO. Primary objective was 
to assess safety and efficacy of the use of rH-EPO in reducing the number of administered RBC 
transfusions and the volume of transfused blood in mL per kg body weight. Use of both early and 
late rH-EPO resulted in a small reduction of RBC transfusions, but this decrease was of limited 
clinical importance because many infants already had received blood transfusions before study 
entry. The reduction in donor-exposure was < 1 donor per transfused infant and a reduction of 6 
mL transfused blood per kg. However, early rH-EPO administration was associated with a higher 
incidence of severe ROP (grade 3).53-55 This potential adverse effect of rH-EPO was supported by 
experimental studies.56-57
Altogether, administration of rH-EPO was not associated with a clinical significant reduction in 
RBC transfusions, neither in the volume of RBCs transfused per kg nor in a significant reduction 
in donor exposure, and therefore cannot be recommended as an alternative in the treatment 
of AOP. In addition, treatment of premature infants with rH-EPO should not be done without 
considering the higher risk of ROP.53-55
Autologous umbilical cord blood transfusion
Autologous umbilical cord blood (UCB) has often been suggested as an alternative for allogeneic 
RBC transfusions in the treatment of AOP.58-60 Due to increasing use of UCB for transplantation 
purposes, progress has been made on aseptic collection of UCB and processing of small blood 
volumes. Some studies reported that approximately 20 mL of UCB per kg of body weight could be 
harvested irrespective of birth weight.59-60 In other studies the amount of harvested UCB was only 
correlated to gestational age.12,58 The potential coverage of transfusion needs with autologous 
UCB has been investigated in a preclinical study. This study suggested that collection of UCB 
could be efficient for premature infants born between 29 and 31 gestational weeks.12 However, 
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Autologous transfusion by delayed clamping
Transfusion of autologous cord blood can also be carried out by delaying the moment of cord 
clamping after birth or by repeated milking of the cord towards the infant.61-62 Rabe et al 
performed a systematic review of ten randomized studies comprising 454 premature infants. 
A delay in cord clamping of at least 30 seconds was associated with lower transfusion needs, 
and more importantly, a significant lower rate of intra-ventricular haemorrhage.61 Delayed 
cord clamping is also associated with better cerebral oxygenation and may protect very low 
birth weight male infants against motor disability at 7 months corrected age.63-64 Strauss et al 
performed a randomized trial in which premature infants born between 30 and 36 gestational 
weeks without the need for resuscitation were allocated to either early or delayed clamping. 
A 1 minute delay in clamping resulted in an increased Hct and RBC volume, but more infants 
in the delayed group were in need of phototherapy and the bilirubin levels and duration of 
phototherapy were similar between both groups.65 Although this simple manoeuvre has benefits, 
there may be potential risks like polycythemia and increased jaundice needing phototherapy. 
Besides these clinical aspects there are also methodological considerations. Definitions regarding 
the time interval for delayed clamping differ among studies, but a delay of 30 seconds has shown 
to be safe. Furthermore, the body position of the newborn after birth has shown to affect the 
amount of auto-transfusion.66 Premature infants are often in need of direct resuscitation after 
birth and this should be taken into account when one intends to apply delayed cord clamping 
practice. Lastly, the amount of blood transfused during delayed clamping cannot be measured 
by a reliable method.67 
Altogether, there is a need for a robust methodology in which the delay in cord clamping and 
position of the infant after birth is well defined, although a delay of about 30 seconds as routine 
practice in premature infants without need for resuscitation offers a clear clinical benefit.
Ex vivo expansion of UCB hematopoietic stem cells
UCB contains a high amount of hematopoietic stem and progenitor cells. In the past few years, 
progress has been made in culturing these precursor cells ex vivo towards the erythroid lineage.68-70 
Using either a murine or human stroma layer or a specific combination of growth factors and 
cytokines, it is possible to obtain in vitro expanded mature RBC.69 The protocols reported in the 
medical literature have several disadvantages. Most protocols consist of multiple stages, each 
with a specific growth factor and cytokine combination, which makes them rather laborious 
and expensive. In addition, some protocols use culture medium with animal protein. Altogether, 
this makes ex vivo expansion of (autologous) hematopoietic UCB stem and progenitor cells not 
easy to translate into a clinical grade process. To provide a clinical grade transfusion product, 
the expanded product should be well defined and the development of these products need a 
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Objective of this thesis
In this thesis, we investigated to following objectives:
1. Short term and long term clinical effects of allogeneic RBC transfusions in premature 
infants.
2. The effect of different RBC transfusion volumes on neonatal outcome in premature 
infants.
3. The use of autologous cord blood as an alternative for allogeneic RBC transfusions.
Outline of this thesis
Dutch neonatal transfusion practice was evaluated in two tertiary neonatal centers. Main points 
of study were transfusion outcome and short-term clinical follow-up (Chapter 2). Long-term 
follow-up of developmental disabilities of extreme low gestational age premature infants, born 
before 28 gestational weeks, in relation to RBC transfusion were evaluated at a corrected age 
of 24 months (Chapter 3). The effects of RBC transfusions in premature infants were evaluated 
by erythropoietin (EPO) measurement in serum using an ELISA assay. EPO levels were measured 
in waste material from blood drawn for diagnostics in the first month of life, because most 
premature infants receive the most RBC transfusions early after birth (Chapter 4). 
In Chapter 5, the current literature on the use of UCB for autologous and allogeneic transfusion 
purposes is reviewed. Topics regarding UCB collection methods, UCB processing into a transfusion 
product and clinical experience with allogeneic and autologous UCB transfusions are discussed. 
In Chapter 6, the red cell lesion parameters of stored whole blood premature UCB products 
and premature UCB derived RBC products stored in SAG-M or Additive Solution 3 (AS-3) are 
described. The use of autologous cord blood RBC transfusion for the treatment of AOP was 
investigated in a randomized clinical trial (Chapter 7).
In Chapter 8 we discuss whether ex vivo expansion of UCB derived hematopoietic stem and 
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Abstract
Objective: To investigate how a red blood cell transfusion volume of 15 or 20 mL/kg 
bodyweight affects total number of administered transfusions and neonatal complications in 
premature infants born before 32 gestational weeks. 
Methods: In this observational study we analysed clinical data from two cohorts of 218 and 
241 premature infants admitted to two neonatal centers which used the same transfusion 
guideline and product, but different transfusion volumes. Outcome parameters were number 
of administered transfusions and the composite outcome of bronchopulmonary dysplasia, 
retinopathy of prematurity, intra-ventricular haemorrhage and mortality.
Results: The proportion transfused infants was significantly lower (59% vs 77%) in the 
center using a lower transfusion volume of 15 mL/kg. In infants born between 24+0-27+6 
gestational weeks a similar proportion received transfusions in both centers, with an equal 
number of transfusions per infant. In infants born between 28+0-31+6 gestational weeks the 
proportion of transfused infants (49% vs 74%) was significantly higher in the center using 
a larger transfusion volume. In these infants transfusion with 20 mL/kg resulted however in 
a mean reduction of 1 transfusion episode per infant. The higher proportion of transfused 
infants was associated with a higher pre-transfusion hematocrit in less ill infants, suggesting 
the use of different triggers based on clinical grounds. Composite clinical complications were 
similar in both cohorts. 
Conclusion: Clinical neonatal outcome was similar disregard of a higher proportion of 
transfused patients and a higher total amount of RBC transfused in one of the centers. A 
larger transfusion volume of 20 mL/kg prolonged the interval until next transfusion and can 
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Introduction
The number of red blood cell (RBC) transfusions in premature infants has successfully declined the 
past decade due to the use of specific transfusion guidelines.1-3 These comprise recommendations 
for transfusion triggers based on the post-natal age of the infant and the need for respiratory 
support, as well as a recommended transfusion volume range from 10 to 20 mL/kg body weight, 
an equivalent of 2-4 units of RBC in adults. These guidelines are however not evidence based. 
In addition, strategies to limit donor exposure by dedicating a blood product to one or two 
premature infants have been evaluated.4-5 Single-donor programs have been shown to be 
feasible6 and cost-effective7, but are not standard practice in every neonatal center. In spite of 
these guidelines, premature infants are still frequently transfused. 
Recently the use of restrictive transfusion triggers has been addressed in several randomized 
controlled trials.8-9 Two randomized studies, in which a restrictive and a more liberal transfusion 
strategy were compared, showed that the use of restrictive transfusion triggers resulted in a 
lower number of transfusions per infant or fewer infants receiving transfusions.8-9 The results of 
the first study by Bell et al, suggested that infants under a more restrictive transfusion policy may 
experience a higher rate of neurologic sequelae.8 These adverse effects were not observed in the 
larger so called Premature Infants in Need for Transfusion (PINT) study by Kirpalani.9 Lowering 
the transfusion triggers may be feasible; however; this should still be conducted in well designed 
clinical trials. Studies on the impact of a higher transfusion volume per kg body weight on the 
total number of transfusions per infant are scarce. Paul and colleagues compared transfusion 
with 10 and 20 mL/kg in 13 very low birth weight infants and found higher post-transfusion 
hematocrits when transfused with 20 mL/kg. Whether the higher volume resulted in a lower 
number of transfusions per infant could not be confirmed in this study.10 Wong et al compared 
15 mL with 20 mL/kg and reported significant higher post-transfusion hematocrits, but a higher 
transfusion volume did not result in a lower number of transfusions per infant.11
It is difficult to compare transfusion volume reliably as the RBC volume is dependent on the 
product used. For instance, although the transfusion volume per kg in the studies by Bell and 
Kirpalani was similar, the transfused products were different. Bell et al transfused products that 
had a hematocrit between 80 and 85%.8 The products transfused in the PINT study were washed 
before transfusion and the actual hematocrit of these products was not mentioned.9 How 
differences in RBC volume in transfusion products affect total transfusion needs and outcome 
is unknown. 
In this study we compared clinical data from two of the ten Dutch tertiary neonatal centers, using 
the same transfusion thresholds12 and the same transfusion product, but a different transfusion 
volume per kg bodyweight. Our aim was to investigate whether a different transfusion volume 
affected the total number of received transfusions until discharge to home and clinical relevant 








































24  |  Chapter 2
Material and Methods 
This study was approved by the medical ethical committees of the Leiden University Medical 
Center and the University Medical Center Utrecht. Informed consent was obtained from the 
parents of all included infants.
Subjects Studied
Between December 2004 and October 2006, clinical data from premature infants born before 
32 weeks of gestation were registered in Unit A. In Unit B, data collection was performed 
from March 2005 until October 2006. Infants suffering from allo-immune haemolytic disease, 
congenital infections or those in need of major surgery (ie gastro-intestinal or cardio-thoracic 
surgery) were excluded from analysis. All other infants were included. Data on gestational age, 
birth weight, gender, Apgar score, mortality, endotracheal ventilation, transfusion parameters 
(number of transfusions, increase in hematocrit, time interval until next transfusion and volume 
transfused) and the CRIB (Clinical Risk Index for Babies) II score were collected on clinical request 
forms from birth until discharge.13 The CRIB II score is a risk adjustment tool that comprises 5 items 
(gestational age, gender, birth weight, temperature and base excess at admission) and a score 
ranging from 0 to 27, with higher scores indicating a higher risk of mortality and morbidity. Data 
on neonatal complications, i.e. retinopathy of prematurity (ROP)14, bronchopulmonary dysplasia 
(BPD)15 and intra-ventricular haemorrhage (IVH)16, and length of stay until discharge home, were 
obtained from our hospitals or the referral hospitals. 
Transfusion guideline
All infants were transfused according to the Dutch consensus for blood transfusion.12 The 
recommended transfusion triggers vary with postnatal age and need for respiratory support. 
-  In the first 24 hours after birth:<Hb 8 mmol/L (13g/dL) (hematocrit range 0.38-0.40 L/L) 
capillary (or < 7 mmol/L arterial (11g/dL)) (hematocrit range 0.32-0.35 L/L)
-  Stable infants with cardio-respiratory problems and/or mechanical ventilation: Hb 7 mmol/L 
(11g/dL) (hematocrit range 0.32-0.35 L/L) capillary
-  Infants with a postnatal age < 4 weeks: Hb 6 mmol/L (10g/dL) capillary (hematocrit range 0.27-
0.3 L/L); and infants with a postnatal age > 4 weeks: Hb 4.5 mmol/L (7g/dL) (hematocrit range 
0.2-0.23 L/L) capillary. In case of symptomatic anemia, it is recommended that transfusion 
should take place at higher triggers.
Transfusion volume per kg body weight was different between the hospitals; 15 mL/kg in Unit 
A and 20 mL/kg in Unit B. These transfusion volumes were not specially chosen for this study, 
but were part of the standard practice in the neonatal intensive care units. The same transfusion 
product was used in both hospitals. All products consisted of pre-storage filtered RBC stored 
in additive solution SAG-M, with a hematocrit between 0.55 and 0.65 L/L. The products were 
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Outcome parameters
Primary outcome included mortality and a composite of clinical relevant morbidities (ROP, BPD and 
IVH). The total number of transfusions, transfused volume, transfusion triggers, post-transfusion 
hematocrit measured 24 hrs after transfusion and length of stay were specified as secondary 
outcome parameters.
Statistical analysis 
All variables were analysed by univariate analysis for continuous variables and Chi-Square or 
Fishers exact probability test for nominal variables (SPSS 12). Backward stepwise logistic regression 
analysis was used for the independent effect of the Apgar score, CRIB II score, mechanical 




In the, respectively, 22 and 19 month study period, a total of 221 infants in Unit A and 248 
infants in Unit B were born before 32 weeks of gestation. After admittance three and seven 
infants respectively were in need of major surgery, and were excluded from analysis. A total of 
459 infants were included in this study, 218 infants in Unit A and 241 infants in Unit B. Both 
groups were comparable with regard to birth weight, gestational age, gender, median Apgar 
scores, median CRIB II scores and need for endotracheal ventilation (Table 1). The CRIB II score 
was incomplete in 27 infants from the Unit B cohort and these were indicated as missing in 
further analysis. All data on other variables were complete.
Administered transfusions and transfusion parameters 
In Unit A 128 out of 218 (59%) infants born before 32 weeks of gestation received red blood 
cell transfusions, compared to 186 out of 241 (77%) infants in Unit B (p <0.001). In the infants 
born between 24+0-27+6 weeks of gestation respectively 95 % and 91% of the infants received 
transfusions. In the group born between 28+0 and 31+6 weeks the proportion of infants receiving 
blood transfusions was respectively 49% (n=86) in Unit A and 74% (n=147) in Unit B (p <0.001). 
(Table 1) Because of this difference, we also analysed the cohorts according to gestational age. 
In the following two paragraphs the results from the infants born between 24+0-27+6 weeks and 
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Table 1: Clinical characteristics of the study population
Unit A (n=218) Unit B (n=241)
Birth weight, g (mean ± SD) 1256 ± 358 1261 ± 343
Gestational age weeks (mean, range) 29+3 (25+0-31+6) 29+3 (25+0-31+6)
- 24+0-27+6 weeks, % (n) 20% (44) 18% (43)
- 28+0-31+6 weeks, % (n) 80% (174) 82% (198)
Born from singleton pregnancy, % (n) 62% (134) 66% (159)
Born from multiple pregnancy, % (n) 38% (84) 34% (82)
Male gender, % (n) 57% (125) 56% (135)
CRIB II Score (median, range) 7 (1-16) 6 (1-14)*
AS 5’ <7, % (n) 12% (27) 11% (26)
Cord clamping time, s (median, range) 5 (0-30) 10 (0-120)
Endotracheal ventilation % (n) 48% (105) 42% (100)
Ventilation days, median (range)  4 (1-89)  6 (1-95)
Infants requiring transfusion, % (n) 59% (128)# 77% (186)#
-24-28 weeks, % (n) 95% (42) 91% (39)
-28-32 weeks, % (n) 49% (86)# 74% (147)#
Abbreviations: CRIB: clinical risk index for babies; AS: Apgar score
*Median CRIB II score of 214 infants, 27 scores in Unit B were incomplete 
#p-value <0.01
In the group infants born between 24+0-27+6 weeks, the number of infants receiving transfusions 
was comparable, respectively 42 out of 44 (95% ) in Unit A and 39 out of 43 (91%) in Unit B 
(p= 0.43). Also the mean number of transfusions per infant was similar, 5.1 ± 2.9 in Unit A and 
5.2 ± 2.3 in Unit B (p= 0.88, mean difference 0.1, 95% CI (-1.2 – 1.1)). Consequently this resulted 
in a significant difference in total transfusion volume of 77 versus 104 mL per kg body weight. 
The median first day of transfusion was day 5 (range 1-33) in Unit A and day 3 (range 1-49) in 
Unit B (p <0.01). The median interval until the next transfusion was 7 days (range 0-44) in Unit A 
and 9 (range 0-59) in Unit B (p= 0.02). The pre-transfusion hematocrit and hematocrit increment 
after transfusion (±24 hours) were not statistically different. (Table 2) 
The number of infants born between 28+0-31+6 weeks that received transfusions was significantly 
higher in Unit B. The mean number of transfusions per transfused infant was respectively 3 ± 2.7 
in Unit A and 2 ± 1.5 in Unit B (p < 0.01, mean difference 1.0, 95% CI (0.3 – 2.0)). The mean 
volumes transfused per kg body weight were comparable (45 mL per kg in Unit A and 40 mL per 
kg in Unit B). The median first day of transfusion was comparable in Unit A and B, respectively 
day 8 (range 1-77) and day 8 (range 1-84), but the interval until the next transfusion was 9 days 
(range 0-97) in Unit A and 14 days (range 0-65) (p <0.01) in Unit B. Transfusion trigger and 
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Table 2: Transfusion parameters in the transfused infants according to gestational age










Total number Tx, mean ± SD 5.1 ± 2.9* 5.2 ± 2.3* 0.88 3.0 ±2.7*  2.0 ± 1.5* <0.01
Total volume transfused, mL/kg, 
mean ± SD
77 ± 44 104 ± 46 <0.01 45 ± 41 40 ± 30 0.20
1st Tx day, median (range) 5 (1-33) 3 (1-49) <0.01  8 (1-77) 8 (1-84) 0.99
Interval until next Tx, 
days median (range)
 7 (0-44)  9 (0-59) 0.02  9 (0-97)  14 (0-65) <0.01
Hematocrit trigger, % 34.9 ± 4.7 35.4 ± 2.9 0.18 34.6 ± 4.6 34.6 ± 3.6 0.99
Hematocrit increment#, % 10.1 ± 5.0  9.7 ± 4.3 0.38 10.1 ± 5.9 10.7 ± 4.2 0.33
*transfusion volume per kg: unit A 15ml/kg and unit B 20ml/kg; # calculated ± 24hours after transfusion. 
Abbreviation: Tx: transfusion
Transfusion triggers in practice
Within the first 24 hours after birth, a Hb of lower than 8 mmol/L (13g/dL) is recommended as 
transfusion trigger. Respectively 17 (8%) and 32 (13%) infants were transfused in Unit A and B 
within 24 hours after birth. The mean hematocrits before transfusion were respectively 34.3 ± 
8.1 and 33.6 ± 5.8 (p= 0.71). After 24 hours, the recommended trigger depends on whether 
an infant suffers from cardio-respiratory problems. We compared the proportion of transfused 
infants in both units that also had endotracheal ventilation. These proportions were similar in 
both cohorts, 85 infants out of 218 in Unit A (39%) and 90 infants out of 241 in Unit B (37%). 
The mean hematocrit before transfusion was respectively 35.1 ± 4.6 and 35.2 ± 3.1 in both 
cohorts.
The proportion of transfused infants without endotracheal ventilation was 43 out of 218 in 
Unit A (19%) and 96 out of 241 in Unit B (40%). The mean hematocrit before transfusion was 
respectively 32.1 ± 4.3 in Unit A and 34.4 ± 3.7 in Unit B (p= 0.001 mean difference 2.3; 95%CI 
(-3.7; -0.78)). 
Clinical outcome 
Composite mortality and neonatal complications in both total cohorts as well when analysed 
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Table 3A: Neonatal mortality and morbidity in the study cohorts
Unit A (n=218) Unit B (n=241) p-value
Composite mortality, 
BPD, ROP and IVH, % (n)
 47% (102/218) 41% (100/241) p= 0.26 OR 1.2 (0.9-1.8)
Mortality, n (%) 5% (11/218) 5% (13/241) p= 1.00 OR 1.1 (0.5-2.4)
Survived with BPD (total), n (%) 26% (53/207) 22% (51/228) p= 0.43 OR 0.8 (0.5-1.3)
  ≥ grade 2, n (%) 10% (20/207) 12% (28/228) p= 0.44 OR 1.3 (0.7-2.4)
Survived with ROP (total), n (%) 9% (18/207) 5% (11/228) p= 0.12 OR 0.5 (0.3-1.2)
  ≥ grade 3, n (%) 4% (7/207) 2% (5/228) p= 0.56 OR 0.6 (0.2-2.1)
Survived with IVH (total), n (%) 23% (47/207) 21% (47/228) p= 0.64 OR 1.1 (0.7-1.8)
  ≥grade 3, n (%) 3% (7/207) 3% (7/228) p= 1.00 OR 0.9 (0.3-2.6)
Length of stay, median (IQR) 58 days (45-76) 56 days (47-69) p=0.41
Abbreviations: BPD: bronchopulmonary dysplasia, ROP: retinopathy of prematurity, IVH: intraventricular 
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Predictors of receiving a transfusion
The variables Apgar score, mechanical ventilation, CRIB II score and hospital of admittance 
were included in a multivariate analysis. The hospital of admittance (OR 4.7 (95% CI 2.7-8.0)), 
mechanical ventilation (OR 3.6 (95% CI 1.9-6.4)) and the CRIB II score (OR 1.5 (95% CI 1.4-1.7)) 
were independent predictors of transfusion needs (p <0.001). (Table 4) Because the median CRIB 
II scores, the number of infants with mechanical ventilation and duration of ventilation were 
comparable between both cohorts (Table 1), differences in proportion of transfused infants and 
transfusion outcome could only be explained by differences in hospital transfusion practice.
Table 4: Predictors of receiving transfusions after premature birth < 32 gestational weeks
p-value* OR 95% CI of OR
Hospital of admittance <0.001 4.7 2.7-8.0
CRIB II score <0.001 1.5 1.4-1.7
Mechanical Ventilation <0.001 3.6 1.9-6.4
*included variables: CRIB II score, Apgar score, mechanical ventilation, hospital of admittance
Discussion 
More than half of the infants born before 32 weeks of gestation received blood transfusions early 
in life. This is in accordance with published practice since the introduction of specified transfusion 
guidelines for premature infants.1,17 Postulated transfusion triggers and transfusion volumes per 
kg body weight in the current guidelines remain topics of discussion. In the Netherlands, all 
ten perinatal centers use transfusion triggers that are recommended in the Dutch transfusion 
guideline. The transfusion volume per kg body weight however varies within a range of 10-20 mL/
kg. In this observational study we aimed to investigate whether a different standard transfusion 
volume per kg body weight had impact on the total number of administered transfusions and 
clinical outcome in two cohorts of premature infants born before 32 gestational weeks.
Although the demographic parameters were similar between both cohorts, we surprisingly 
observed a significant difference in the number of infants receiving RBC transfusions, 59% in Unit 
A and 77 % in Unit B (Table 1). When we analysed the cohorts according to their gestational age 
at birth, almost all infants born between 24+0-27+6 weeks of gestation received RBC transfusions 
in both units. Transfusion with 20 mL/kg did not reduce the total number of transfusions and 
increased the transfused RBC volume by 35%. As we observed no differences in hematocrit before 
and after transfusions between Unit A and B, we can only speculate about possible explanations 
for this difference. These may be due to larger phlebotomy losses in Unit B, or differences in fluid 
intake or less use of diuretics. The greater volume transfused in infants in Unit B and thereby a 
greater volume of hemoglobin A, was not associated with a deleterious effects on the health 
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considerable mortality and such extensive morbidity that a possible deleterious effect of a larger 
transfused volume remains undetected (Table 3B).
Analysis of the two cohorts born between 28+0-31+6 weeks of gestation showed a significant 
difference in the proportion of transfused infants (49% versus 74 %) between both units. 
Although the number of administered transfusions per infant in Unit A was higher; when 
adjusted for the smaller transfusion volume per kg bodyweight; the transfused infants received 
comparable volumes of donor blood (Table 2). If a center does not apply a donor reduction 
policy by reservation of a RBC unit for the same patient, transfusion with a lower volume can 
lead to a higher donor exposure. The first transfusion day was similar between both cohorts. 
The interval between transfusions however was significantly shorter in Unit A, which used a 
lower transfusion volume. Comparing the clinical outcome of both 28+0-31+6 week cohorts, we 
observed no statistical differences. Although in Unit A, fewer infants received transfusions, this 
was not associated with a poorer clinical outcome, compared to Unit B.
Surprisingly, we did not observe a higher hematocrit increase after transfusion with a larger 
amount of red cells. In the study performed by Paul et al, the higher hematocrit increment after a 
larger transfusion volume was measured 8 hours after transfusion instead of after 24 hours as in 
our study. The use of furosemide or other diuretics given as a single dose post-transfusion is not 
standard practice in our centers. Nevertheless we saw benefit of the larger volume with respect 
to a longer interval to next transfusion.
In view of the difference in number of transfused infants that were born after 28+0-31+6 gestational 
weeks, we looked at the transfusion triggers that had been used in infants in relation to the 
recommended transfusion triggers, i.e. infants less than 24 hours after birth and infants with and 
without endotracheal ventilation. Only in infants older than one day and without endotracheal 
ventilation, we observed a higher pre-transfusion hematocrit in Unit B. This higher trigger could 
explain the larger number of transfused infants. The decision to transfuse could be influenced 
by a difference in clinical symptoms that were not recorded, e.g. apnea or arrhythmia or to a 
different perception of clinical symptoms by the physicians. In view of these possible differences, 
a scenario-based survey between the neonatal intensive care units could help to identify under 
which circumstances the decision to transfuse differs most. 
Logistic regression analysis confirmed the hospital of admittance as an important independent 
predictor of the administration of transfusions. Since the median CRIB II scores and number of 
infants with mechanical ventilation in both units were comparable, differences in the proportion 
of transfused infants and outcome could only be explained by different transfusion and/or other 
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Observational studies like this have many limitations. All data were collected and analysed in 
retrospect. Because we expected that the indication for transfusion would be similar, we 
anticipated on investigating the effect of a different transfusion volume using the same 
transfusion product. This clinical research question was initiated by observations in critically ill 
adult patients after cardiac surgery revealing that postoperative complications were associated 
with transfusions of 4 units or more, representing more than 15 mL/kg bodyweight.18 Overall we 
observed no differences in clinical composite complications and cannot conclude that a smaller 
or larger transfusion dose is to be preferred. Transfusing with 20 mL/kg may reduce donor 
exposure in infants born between 28+0-31+6 weeks of gestation if a single donor program is not 
used. Despite the use of the same national guideline, the clinical motivation for the decision to 
transfuse appeared to differ between both hospitals, in our study especially in case of more stable 
infants. Audits among neonatal intensive care units, could be used to better understand why such 
differences exist when the same guidelines are supposedly being used. 








































A comparative cohort study on transfusion practice and outcome in two Dutch tertiary neonatal centers  |  33
2
Reference list
1.   Maier RF, Sonntag J, Walka MM, Liu G, Metze BC, Obladen M. (2000) Changing practices of red 
blood cell transfusions in infants with birth weights less than 1000 g. Journal of Pediatrics 136 
(2):220-224.
2.   Gibson BE, Todd A, Roberts I, Pamphilon D, Rodeck C, Bolton-Maggs P, Burbin G, Duguid J, Boulton 
F, Cohen H, Smith N, McClelland DB, Rowley M, Turner G; British Commitee for Standards in 
Haematology Transfusion Task Force: Writing group. (2004) Transfusion guidelines for neonates and 
older children. British Journal of Haematology, 124(4):433-453. 
3.   Miyashiro AM, Santos N, Guinsburg R, Kopelman BI, Peres Cde A, Taga MF, Shinzato AR, Costa Hde 
P. (2005) Strict red blood cell transfusion guidelines reduces the need for transfusions in very-low-
birthweight infants in the first 4 weeks of life: a multicentre trial. Vox Sanguinis, 88, 107-113
4.   Straatten van HL, Wildt-Eggen de J, Huisveld IA. (2000) Evaluation of a strategy to limit blood donor 
exposure in high risk premature newborns based on clinical estimation of transfusion need. Journal 
of Perinatal Medicine. 28(2):122-128
5.   Fabres J, Wehrli G, Marques MB, Phillips V, Dimmitt RA, Westfall AO, Schelonka RL. (2006) Estimating 
blood needs for very-low-birth-weight infants. Transfusion, 46:1915-1920 
6.   Strauss RG, Wieland MR, Randels MJ, Koerner TAW. (1992) Feasibility and success of a single-donor 
red cell program for pediatric elective surgery patients. Transfusion 32 (8): 747-749
7.   Hilsenrath P, Nemechek J, Widness JA, Cordle DG, Strauss RG. (1999) Cost effectiveness of a limited-
donor blood program for neonatal red blood cell transfusions. Transfusion, 39(9): 938-943
8.   Bell EF, Strauss RG, Widness JA, Mahoney LT, Mock DM, Seward VJ, Cress GA, Johnson KJ, Kromer 
IJ, Zimmerman MB. (2005) Randomized trial of liberal versus restrictive guidelines for red blood cell 
transfusion in preterm infants. Pediatrics, 115 (6):1685-1691
9.   Kirpalani H, Whyte RK, Andersen C, Asztalos EV, Heddle N, Blajchman MA, Peliowski A, Rios A, 
LaCorte M, Connelly R, Barrington K, Roberts RS. (2006)The Premature Infants in Need of Transfusion 
(Premature Infants in Need for Transfusion) study: a randomized controlled trail of a restrictive (low) 
versus liberal (high) transfusion threshold for extreme low birth weight infants. Journal of Pediatrics, 
149(3):301-307
10.   Paul DA, Leef KH, Locke RG, Stefano JL. (2002) Transfusion volume in infants with very low birth 
weight: a randomized trial of 10 versus 20 ml/kg. Journal of Pediatric Hematology/Oncology 24 (1): 
43-46
11.   Wong H, Connely R, Day A, Flavin MP. (2005) A comparison of high and standard blood transfusion 
volumes in premature infants. Acta Pediatrica, 94:624-625
12.   Dutch Institute for health care improvement CBO Guideline Bloodtransfusion. (2004) Guideline Blood 
transfusion. Utrecht: van Zuiden Communication BV: 133-139 
13.   Parry G, Tucker J, Tarnow-Mordi W. (2003) CRIB II: an update of the clinical risk index for babies score. 
Lancet, 361(9371):1789-1791
14.   The International Classification of Retinopathy of Prematurity revisited. (2005) Archives of 
Ophthalmology, 123(7):991-999
15.   Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, Wrage LA, Poole K; National 
Institutes of Child Health and Human Development Neonatal Research Network (2005) Validation of 
the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics, 116 
(6):1353-1360
16.   Volpe JJ. (2001) Neurology of the Newborn. Fourth ed. Philadelphia, PA: WB Saunders; 428–493
17.   Jansen M, Brand A, von Lindern JS, Scherjon S, Walther FJ. (2006) Potential use of autologous 
umbilical cord blood red blood cells for early treatment of anemia of prematurity. Transfusion, 46: 
1049-1056
18.   Bilgin YM, van de Watering LM, Eijsman L, Versteegh MI, Brand R, van Oers MH, Brand A. (2004) 
Double blind, randomized controlled trial on the effect of leucocyte depleted erythrocyte transfusions 
in cardiac valve surgery. Circulation, 109 (22):2755-60

Long term outcome in relationship to neonatal 
transfusion volume in extremely premature infants: 
a comparative cohort study
Jeannette S. von Lindern*, Chantal M. Khodabux*, Karien E. Hack, 
Ingrid C. van Haastert, Corine Koopman-Esseboom, Paul H.T. van Zwieten, 
Anneke Brand, Frans J. Walther










































36  |  Chapter 3
Abstract
Background: In premature born infants, red blood cell (RBC) transfusions have been 
associated with both beneficial and detrimental sequels. Upon RBC transfusion, improvement 
in cerebral blood flow and oxygenation have been observed, while a more liberal transfusion 
policy may be associated with a better developmental outcome. The effect of the transfusion 
volume on long-term outcome is not known.
Methods: We performed an observational follow-up study of a cohort of extremely premature 
born infants, treated in two neonatal intensive care units using a different transfusion volume 
(15 mL/kg in Unit A and 20 mL/kg in Unit B). The primary outcome was a composite of post 
discharge mortality, neuromotor developmental delay, blindness or deafness, evaluated at 
a mean corrected age (CA) of 24 months related to the transfusion volume/kg bodyweight
administered during the postnatal hospital stay.
Results: Despite the difference in transfusion volume in two groups of clinically comparable 
infants, they received a similar mean number of transfusions (5.5 ± 3.2 versus 5.5 ± 2.3 
respectively in Unit A and B). The total transfused volume in unit A was 79 ± 47 mL/kg and 
108 ± 47 mL/kg in unit B (p = 0.02). The total transfused RBC volume per kg bodyweight 
was not an independent predictor of the composite outcome (p = 0.96, OR 1.0 (CI 0.9-1.1).
Conclusion: There was no relationship between the composite outcome at 24 months CA 
and transfusion volume received during the postnatal hospital stay. As there was no clinical 
advantage of the higher transfusion volume, a more restrictive volume will reduce total 
transfusion volume and donor exposure. Future research on the optimal transfusion volume 
per event to extreme preterm infants should include larger, prospective studies with a longer
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Background
There is ongoing uncertainty whether transfusion of red blood cells (RBC) in the neonatal period 
influences the clinical outcome and development of premature infants. In the international 
literature there is discussion about the optimal transfusion volume and trigger.1 We previously 
published a study comparing two transfusion dosages of the same RBC product in two Dutch 
tertiary care neonatal units (NICUs) using the same transfusion trigger protocols.2 No difference 
in short term outcome and mortality was observed in extremely and very preterm infants when a 
dose of 15 mL/kg had been administered compared to a volume of 20 mL/kg bodyweight. Little is 
known about the long term follow-up of extremely premature infants after RBC transfusion. Only 
a few randomized trials have been published on long term outcome in premature infants with 
difference in transfusion practice.3-4 However, these were studies (the Premature Infants in Need 
of Transfusion (PINT) trial and the Iowa trial) comparing liberal and restrictive transfusion triggers, 
exposing the infants in the restrictive group to the possible risks of a low hemoglobin level.5-6 In 
sequel to our study on short term outcome we also wanted to compare long term outcome in 
the same group of extremely premature infants treated with different transfusion volumes but 
with otherwise comparable transfusion triggers and transfusion products. In our follow-up study 
we evaluated post discharge mortality, neuromotor developmental outcome and disabilities in 




In the Netherlands no ethical approval is required for this type of research as no new intervention 
or treatment is studied. All collected data were anonymous.
Study population
This is a follow-up study of a cohort of extremely premature infants born before 28 gestational 
weeks that participated in an earlier study on transfusion practice and short term outcome in two 
Dutch NICUs. All infants were transfused according to the same transfusion triggers and with a 
similar RBC blood product with only a different transfusion volume per event, i.e. 15 and 20 mL/
kg bodyweight. The study design was previously described.2 The primary outcome measure was 
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Transfusion guideline and product
All infants were transfused according to the Dutch consensus for blood transfusion 2004.7 
The recommended transfusion triggers vary with postnatal age, degree of illness and need for 
respiratory support:
-  Hb < 8 mmol/L (13 g/dL) (hematocrit (Hct) range 0.38-0.40 L/L) capillary (or < 7 mmol/L arterial 
(11 g/dL) (Hct 0.32-0.35 L/L)): the first 24 hours after birth in all infants with clinical symptoms 
of anemia (tachycardia, supplemental oxygen need, apnoea, bradycardia); in all infants on 
mechanical ventilation or severely ill.
-  Hb < 7 mmol/L (12 g/dL) (Hct 0.32-0.35 L/L) capillary: reasonably stable infants with cardio-
respiratory problems (patent ductus arteriosus, apnoea, bronchopulmonary dysplasia, need for 
supplemental oxygen).
-  Hb < 6 mmol/L (10 g/dL) (Hct 0.27-0.30 L/L) capillary: stable premature infants with a postnatal 
age < 4 weeks. 
-  Hb < 4.5 mmol/L (7 g/dL) (Hct 0.2-0.23 L/L) capillary: stable infants with a postnatal age > 4 
weeks if there are no signs of anemia (apnoea, tachycardia, poor weight gain, poor feeding).
In case of symptomatic anemia, transfusion is recommended at a higher threshold. Transfusion 
volume per kg bodyweight was different between the two hospitals; 15 mL/kg in Unit A and 20 
mL/kg in Unit B. This transfusion volume was part of the standard practice in the hospitals and 
was not chosen for study purposes. The same transfusion product was used in both hospitals. All 
products consisted of pre-storage filtered RBC stored in additive solution Saline Adenine Glucose 
Mannitol (SAG-M) (maximum storage time 35 days), with a Hct of 0.58 ± 0.05 L/L. The products 
were irradiated with 25 Gy less than 24 hours before transfusion. Preventative measures for 
anemia of prematurity were not standardized. Erythropoietin was not used in the study units. 
Iron supplementation was started 6 to 8 weeks after birth if there had been no previous RBC 
transfusion. After RBC transfusion iron supplementation was postponed for four weeks because 
of the assumed iron load given with the transfusion.
Data collection and outcome parameters
Infants with a syndrome or congenital/hereditary anomaly known to cause a neuromotor 
developmental delay were excluded from analysis. Data on neuromotor developmental outcome, 
major disabilities (deafness, blindness) and survival at a mean (± SD) corrected age (CA) of 24 ± 
3.4 months were obtained from each child’s outpatient follow-up physician, child-psychologist 
and/or pediatric physiotherapist, who were all trained in neonatal follow-up. Developmental 
examination was done in different hospitals. The children were assessed with various instruments 
depending on the hospital of follow-up. Instruments used were the Dutch 2nd version of the 
Bayley Scales of Infant Development-II (BSID-II-NL)8, the Griffiths Mental Development Scales9, 
Alberta Infant Motor Scale (AIMS)10, and the Hempel11, Touwen12, and van Wiechen13 assessments 
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delayed, using the cut-off values of each test, classifying severe neuromotor developmental delay 
as a score of more than 2 SD below average and mild neuromotor developmental delay as a 
score 1 to 2 SD below the mean. Non-cooperative children received a general assessment by the 
physician, pediatric physiotherapist and/or child-psychologist. A parental questionnaire was sent 
to the parents of the children if follow-up at age 2 years was unknown by any of the previously 
mentioned professionals. Our primary outcome was the composite of post discharge mortality, 
severe hearing or visual impairment, or neuromotor developmental delay at 24 months CA.
Visual impairment was defined as <20/200 of best eye, hearing impairment was defined as the 
need for a hearing aid or cochlear implant. Neuromotor developmental delay was defined as a 
score more than 1 SD below the mean. The definition for bronchopulmonary dysplasia (National 
Institutes of health Consensus, USA) was used as described by Ehrenkranz et al.14 For retinopathy 
of prematurity the revised international classification was used.15 Intraventricular hemorrhage was 
graded according to Volpe.16
Statistical Analysis
All variables were analyzed by univariate analysis for continuous variables and Chi-Square or 
Fishers exact probability test for nominal variables. Backward step wise logistic regression analysis 
was used for the independent effect of the following factors: hospital (representing transfusion 
dose and unknown factors), number of RBC transfusions, total transfused RBC volume per kg 
bodyweight, gender, gestational age, birth weight, CRIB II score and Apgar- score at 5 minutes. 
(SPSS 17 Chicago, United States of America). A p-value of less than 0.05 was considered 
significant.
Results
Eighty-seven extremely premature infants were included in our earlier cohort study (44 in Unit A, 
43 in Unit B). Four infants died the first day of life and were excluded from this follow-up study 
(1 lung hypoplasia, 1 massive pulmonary hemorrhage, 1 severe perinatal asphyxia and 1 cause 
unknown). None of these children had received a RBC transfusion. Twelve other patients died in 
the neonatal period for various reasons; they had all received RBC transfusions. They were also 
excluded from follow-up. Seventy-one of the 87 infants (82%) left the hospital alive (in total 9 in 
unit A and 7 in unit B died (p = 0.78). There were no deaths after discharge from the units. One 
other patient was excluded from follow-up analysis because of a severe myopathy. Three children 
were lost to follow-up in the first year of life; one due to emigration, of the other two (twins) the 
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There were no statistically significant differences when comparing the baseline characteristics 
of the patients from both units (Table 1). The number of transfusions administered was similar, 
5.5 ± 3.2 (Unit A) versus 5.5 ± 2.3 (Unit B) respectively. As the volume per transfusion event per 
center differed, the mean total volume transfused in unit A and B was significantly different 
(79 ± 47 mL/kg versus 108 ± 47 mL/ kg (p = 0.02) respectively). Neuromotor development was 
evaluated at a mean 24 ± 3.4 months CA. One infant had a severe visual impairment and one 
child had severe hearing loss. Forty-seven of 67 (70.1%) infants showed normal neuromotor 
development for corrected age. Seventeen infants (25.4%) had a mild developmental delay and 
three infants were severely impaired (4.5%). There was no statistically significant difference in the 
transfused volume for the primary outcome (composite of post discharge mortality, neuromotor 
developmental delay, blindness or deafness) compared to children with a normal outcome (105 
± 52 mL versus 90 ± 47 mL respectively) (p = 0.96, OR 1.0 (0.9-1.1). In our multivariate analysis 
none of the tested variables reached statistical significance for an independent association with 
the composite outcome (Table 2).
Table 1: Characteristics of patients per unit included in follow-up study*
Variable Total (n=67) Unit A (n=31) Unit B (n=36) p-value
Male 41 (61) 23 (74) 18 (50) 0.05
Gestational age, weeks 26 6/7 ± 4/7 26 6/7 ± 4/7 26 6/7 ± 4/7 0.65
Birth weight, g 900 ± 187 906 ± 178 895 ± 197 0.59
Apgar Score at 5 minutes , median (IQR) 8 (7-9) 8 (7-9) 8 (7-9) 0.88
Intraventricular hemorrhage ≥ grade 3 6 (9) 4 (13) 2 (6) 0.40
Bronchopulmonary dysplasia ≥ grade 2 23 (34) 9 (29) 14 (39) 0.35
Retinopathy of prematurity ≥ grade 3 8 (12) 4 (13) 4 (11) 1.00
Total number of transfusions 5.5 ± 2.7 5.5 ± 3.2 5.5 ± 2.3 0.98
mL per kg RBC administered 95 ± 49 79 ± 47 108 ± 47 0.02
Composite outcome 21 (31) 9 (29) 12 (33) 0.71
*Data are reported as number (%) or mean ± SD, or as indicated otherwise
Abbreviations: IQR: interquartile range
Table 2: Predictors of the composite outcome* 
Variable p-value OR CI of OR (95%)
Hospital 0.8 1.6 0.1-24.7
Number of RBC tranfusions 1.0 1.0 0.2-4.8
mL per kg RBC transfused 1.0 1.0 0.9-1.1
Gender 0.2 0.4 0.0-1.6
Gestational age 0.8 1.0 0.9-1.1
Birth Weight 0.4 1.0 1.0-1.0
CRIB II score 0.6 1.0 1.0-1.0
Apgar Score 0.3 1.2 0.8-1.9
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Discussion
Transfusion of RBC has been associated with negative and positive effects on clinical outcome. 
Our study showed no significant differences between a smaller and a larger transfusion volume 
regarding a composite outcome of post discharge mortality, neuromotor developmental outcome 
and disabilities at 2 years CA. This would imply that a smaller transfusion volume rather has 
advantages (generally limiting donor exposure and costs), than negative effects on neuromotor 
developmental outcome. It is possible that no effects were seen because the difference in 
transfusion volume per transfusion event was not large enough. On the other hand, the total 
transfusion volume/kg during the post natal hospital stay was significantly different in the two 
NICUs. Several studies associated RBC transfusion with the development of retinopathy of 
prematurity17-20 and chronic lung disease.21-23 It is hypothesized that iron overload, caused by 
multiple RBC transfusions, increases oxidative stress leading to free radical-induced injury to the 
premature retina and developing lungs.24-25 However, anemia has been associated with negative 
effects as well and in particular the brain may be susceptible to low hemoglobin levels. Bell et al, in 
a randomized study, found a statistically significant higher incidence in the number of infants with 
intracranial hemorrhage grade IV or periventricular leukomalacia when a restrictive transfusion 
threshold was applied as compared to a more liberal threshold.5 On the other hand, neither Chen24 
nor Kirpalani (PINT trial)6 found a statistically significant difference in the occurrence of (severe) 
intracranial pathology. However, the follow-up study by Whyte et al, suggested that preterm 
infants treated with a more liberal transfusion regime may have a better developmental outcome.4 
The premature infants included in this multicenter PINT trial were analyzed at 18-21 months CA 
with regard to mortality, cerebral palsy, severe visual impairment, hearing-loss, a Bayley-Mental 
Developmental Index (MDI) score < 70, and a composite of these variables. Although there was 
no statistically significant difference in composite outcome (45% in the restrictive and 38% in the 
liberal group), the difference in cognitive delay (MDI score < 70) approached statistical significance 
in favor of the liberal group. A post-hoc analysis with cognitive delay redefined (MDI score more 
than 1SD below the age-standardized mean) showed a significant difference favoring the liberal 
threshold group. This suggests that premature infants may benefit from a higher hemoglobin 
threshold for transfusion.4 In the study by Nopoulos et al on the brain structure of 12 year old 
children previously enrolled in the Iowa trial by Bell and colleagues, only 44 of the 100 children 
participated.3 The children who were exposed to the liberal transfusion threshold appeared to 
have a substantially smaller intracranial volume compared to the children transfused according to 
the restrictive guideline. Nopoulos mentions unpublished data on long-term cognitive follow-up 
showing (non-significant but) overall poorer outcome in the group of liberal transfused children. 
Another recent study has shown that RBC transfusions increase cerebral oxygenation, thereby 
decreasing the risk of tissue hypoxia.26 Mercer et al showed that premature male infants after 
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to infants after immediate cord clamping.27 It is conceivable that upon transfusion of a larger 
volume, an increase in cerebral flow and better oxygenation can be obtained with a similar effect 
as described by Mercer. In transfusion guidelines, the range of recommended RBC volume per 
kilogram bodyweight is rather wide, 10-20 mL/kg. Given the variation in Hct between used RBC 
products, the guidelines result in a huge variation in actually transfused RBC. We observed no 
influence of transfused volume RBC per kg bodyweight on a composite of impaired neuromotor 
development, post discharge mortality and deafness or blindness in extremely preterm born infants 
evaluated at 24 months CA. This finding remained unchanged after logistic regression analysis 
correcting for other factors relevant for outcome. The two Dutch NICUs participating in this study 
used the same transfusion guideline, transfusion trigger and transfusion product, which virtually 
excludes important differences in degree of anemia between infants. Our study has its limits 
being a retrospective, non-randomized trial. The neuromotor development was assessed using 
various different tests. In Unit B all children were assessed by the same special educator who is 
also a pediatric physiotherapist (ICvH) using the same test (BSID-II-NL) in 95% of the children. The 
children from Unit A were assessed using various validated tests, performed in different hospitals 
by different professionals. It may be an incentive to perform a larger, prospective randomized 
controlled trial, focusing not only on the transfusion trigger but also on the total transfused RBC 
volume to recommend an optimal transfusion trigger and dose.
Conclusion
A high total transfused volume of RBC per kg was not correlated with the composite outcome 
of impaired neuromotor developmental outcome, post discharge mortality, blindness or deafness 
when analyzed at 24 ± 3.4 months CA, hereby questioning the previously presumed possible 
detrimental effects of RBC transfusions.
Recommendations
Due to differences in neonatal transfusion practice, conclusions on the effect of maintaining a 
higher Hb value by the use of liberal transfusion triggers or a larger volume of RBC per transfusion 
are not based on strong evidence. A larger transfusion volume may not be associated with 
deleterious effects, whereas a smaller transfusion volume may limit donor exposure. Through 
randomized clinical studies, the effect of more liberal or restrictive triggers on long-term outcome 
can be studied, as well as the combination with a low (10 mL/kg) or high (20 mL/kg) transfusion 
volume. A longitudinal study to school age or even adolescence looking for instance at academic 
competencies might give further insight in the effects of different transfusion volumes.
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Abstract
Objective: The role of erythropoietin (EPO) in physiological anemia of the premature 
newborn (AOP) and its relation with red blood cell (RBC) transfusions is still unclear and may 
depend on neonatal complications, frequent phlebotomies and transfusion policy. 
Study design: Using waste material we frequently measured endogenous EPO levels in 46 
premature neonates born < 36 gestational weeks, in their first month of life. These levels 
were correlated to hematological parameters when concomitantly determined, clinical 
parameters and administered transfusions. 
Results: Thirty-six of 46 neonates received ≥1 transfusions starting at median day 4. EPO 
levels were not correlated with individual (pre-transfusion) hemoglobin levels, although 
overall higher EPO levels were present in the transfused cohort in the first 4 days after birth 
(8mU/mL; 5-95 percentile range <1.4–112.5 mU/mL) compared to the period thereafter 
(3mU/mL; 5-95 percentile range <1.4–23.9 mU/mL) (p <0.001). In neonates with a lower 
Apgar score and respiratory failure higher EPO levels were observed. EPO levels declined after 
every administered RBC transfusion; albeit this was only statistically significant after the first 
transfusion. Incidental high EPO levels > 500mU/mL were associated with life-threatening 
conditions.
Conclusion: Newborns with AOP and requiring transfusions had higher initial EPO levels, 
which declined after starting transfusion treatment. We did not find a statistically significant 
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Introduction
Transfusion of red blood cells (RBC) is an important element in the treatment of premature 
neonates. These transfusions have been associated with potential negative clinical outcomes, 
although causality has not been proven.1-2 Introduction of transfusion guidelines has led to fewer 
administered transfusions. Nowadays, most transfusions are administered in the first month of life 
after premature birth.3 The transfusion needs in these first weeks result from a combination of 
physiological and iatrogenic factors. These include the short life span of fetal RBCs, an increasing 
blood volume due to relative rapid growth, an inadequate erythropoietin (EPO) response to 
the level of anemia and frequent phlebotomies for diagnostics.4-5 In premature neonates EPO 
is mainly produced by the liver, which is less prompt responsive to hypoxia. This results in a 
lower EPO level than would be expected for the degree of anemia.6 Per transfusion, premature 
neonates receive 10 to 20 mL packed RBCs (with an hematocrit (Ht) between 0.60 and 0.80 L/L) 
per kg bodyweight, depending on local transfusion practice and guideline.7 This results in a wide 
range of RBC volume administered. These differences in transfusion practice probably suppress 
EPO production in variable degrees. Few studies investigated the effect of RBC transfusion on 
EPO levels and they reported transfusion related suppression of EPO within 48 hours to 7 days 
after RBC transfusion.9-10 This suppression normalized 14 days after transfusion.10 However, most 
studies reported on premature neonates with a postnatal age of > 4 weeks who already had 
received multiple transfusions before the EPO levels were measured.9-10 A small recent study 
which used a RBC product with a Ht of 0.80-0.85 L/L, transfused approximately twofold of 
the hemoglobin (Hb) mass that was lost due to blood withdrawal and in this study the EPO 
production was found suppressed by every transfusion.8 
The effects of a liberal transfusion policy, aiming to maintain a higher hematocrit, on the 
neuro-development of premature neonates have been studied. These studies however showed 
conflicting results. Maintaining a higher hematocrit was associated with a better cognitive 
development at the age of 18-21 months corrected age11, but also associated with a worse neuro-
cognitive profile and a reduced brain volume.12-13 A postulated explanation was the suppression 
of endogenous EPO production due to liberal transfusion management. Lower EPO levels could 
result in a decreased anti-inflammatory function and impaired cell recovery after brain injury.12-14 
However, in a recent report on acute physiological effects of RBC transfusions, the mean EPO 
levels before RBC transfusion were similar between the patients in the group transfused at a 
higher hematocrit compared to the lower hematocrit group.15 Unfortunately, in this study the 
effects of multiple RBC transfusions on EPO levels were not reported, so a stronger reduction of 
EPO after a liberal transfusion strategy cannot be precluded. 
Recently it was proposed that administration of EPO after severe brain injury resulting from 
asphyxia or intra-ventricular hemorrhage could be neuro-protective, but the most optimal EPO 
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of prematurity, also neuro-toxic effects of high dose EPO are possible.14 More subtle brain damage 
in newborns could however be negatively affected by early RBC transfusions by lowering the 
endogenous EPO level that may intercede with a potential physiological neuro-protective EPO 
effect.12-13, 16 Evaluation of intrinsic EPO levels after premature birth in presence or absence of RBC 
transfusions can attend studies investigating optimal EPO dosages, especially those focusing on 
early treatment. Few studies are available that report endogenous EPO levels and the effect of 
RBC transfusions through the first weeks of life after premature birth. Non-transfused premature 
neonates were reported to have a mean EPO level of 9.7 mU/mL (range ± 1 SE 7.4-10.3 mU/
mL) during the first month of life.17 Anemic premature neonates were reported to have higher 
(anemic 20 ± 1.08 mU/mL vs non-anemic 14 ± 1.06 mU/mL) EPO levels.18 Yamashita studied 
both non-transfused and transfused very low birth weight premature neonates and reported EPO 
levels in the first week of life ranging from < 5-307 mU/mL, while beyond this first week EPO 
levels were <20 mU/mL (day 7-50 after birth).19 
In this report we frequently measured EPO levels in the first weeks of life using waste material in 
relation to pre-transfusion Hb and administered RBC transfusions using a restrictive transfusion 
trigger in a group of 46 premature neonates born before 36 gestational weeks. 
Material and Methods
Study population and material
In six consecutive months, 46 premature neonates born before 36 gestational weeks admitted 
at our neonatal intensive care unit were included in this study. Exclusion criteria were congenital 
abnormalities, hemolytic disease of the newborn and neonates in need of surgery. None of the 
neonates received recombinant human EPO. The follow-up period was up to 1 month after 
delivery or until discharge to another hospital or home. Clinical data of the study patients were 
collected retrospectively. Data on birth weight, gender, Apgar scores, number of RBC transfusions, 
type of respiratory support, sepsis (clinically suspect and/or positive blood culture), severe intra-
ventricular hemorrhage (≥ grade 3) and mortality were registered. 
Transfusion policy and RBC product
All patients were transfused according to the operative Dutch guideline for blood transfusion. 
The triggers in short; within the first 24 hours after birth < Hb 8 mmol/L (13g/dL); stable neonates 
with cardio-respiratory problems and/or mechanical ventilation < Hb 7 mmol/L (11g/dL); postnatal 
age < 4 weeks: < Hb 6 mmol/L (10g/dL).20 The standard transfusion product consisted of pre-
storage filtered adult RBC stored in saline adenine glucose-mannitol with a hematocrit of 0.60 ± 
0.05 L/L, irradiated if transfused to an neonate weighing <1500 g or gestational age < 32 weeks. 
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EPO measurements
Waste material from these neonates was collected from our clinical chemical laboratory. Before 
collection, all material was kept between 2-6˚C up to 72 hours after blood withdrawal, thereafter 
all material was frozen and kept at -40˚C. The EPO Enzyme Linked Immuno Sorbent Assay (ELISA) 
(IBL, Hamburg, Germany) was used for all measurements. The lower limit of detection of the EPO 
ELISA was 1.4 mU/mL. Per single measurement, at least 50 μL material was necessary. To validate 
the use of waste material refrigerated for up to 72 hours, we aliquoted plasma from premature 
neonates, cord blood and adult blood bank donors which was kept at varying time intervals at 
2-6˚C; <24 hours, between 24-48 hours and up to 72 hours until freezing at -40˚C. Additional 
spiking experiments were performed with respectively 10 and 20 mU EPO alpha per sample. All 
tests were performed in duplicate. EPO levels remained stable at 2-6˚C during the time series in 
all samples (R2: 0.998), indicating that the waste material could be used for testing.
 
Outcome parameters and statistical analysis
EPO levels were correlated to hematological parameters (Hb, hematocrit, number of nucleated 
RBC) if the waste material was drawn at the same time as the complete blood count. The 
first EPO value after birth was correlated to clinical parameters at birth (gestational age, birth 
weight, Apgar score ≤ 6 at 5 minutes after birth). We also examined EPO levels according to 
the method of respiratory support and to clinical and/or proven sepsis. Subsequent EPO levels 
were correlated to the number of administered RBC transfusions prior to EPO measurement. All 
EPO measurements that fell below the detection level of 1.4 mU/mL, were counted as 0 mU/
mL. To test the correlation between continuous variables the coefficient of determination R2 was 
calculated. We used a linear mixed model analysis for repeated measures to test changes in EPO 
levels before and after a RBC transfusion. The fixed effect was the number of administered RBC 
transfusions up to that moment. The number of measurements per patient differed as well as 
the number of administered transfusions per patient. Therefore both the patient variable and the 
number of administered transfusions at the time of EPO level measurement, were included as 
covariates to correct for inter-patient and intra-patient variability. The distribution of EPO levels 
was highly skewed, with the most data having low values and a some (extreme) high values. To 
normalize the data distribution, logarithmic transformation was applied to the values. To include 
the measurements of ‘0’ mU/mL, a constant was added to all measurements The log-transformed 
data were used in the analysis. The mean estimates were computed by back-transformation of 
the log-means. A p-value of <0.05 was considered statistically significant.
Ethics
In the Netherlands no ethical approval is required for this type of research with the use of waste 
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Results
Study population
The 46 neonates are described in Table 1. Thirty-six neonates (78%) received RBC transfusions, 
with a mean of 2.6 ± 1.5 transfusions per neonate in the first month after birth. The first RBC 
transfusion was administered at median day 4 after birth (95% range 1-9 days). The mean pre-
transfusion hematocrit was 0.34 ± 0.04 L/L and the mean post-transfusion hematocrit was 0.40 
± 0.04 L/L. The mean Ht of non-transfused neonates was 0.46 ± 0.03 L/L in the first week 
after birth, and 0.36 ± 0.05 L/L in the weeks thereafter. The transfused neonates were more 
premature compared to the non-transfused neonates, had a lower birth weight and suffered 
from more complications. More material had been collected from transfused neonates compared 
to non-transfused premature neonates; reflecting that these children were sicker and exposed to 
more phlebotomies for diagnostic purposes and consequently more anemic. Transfused and non 
transfused neonates differed significantly (Table 1); both patient groups were analyzed separately 
as the non-transfused neonates could not serve as controls for the transfused neonates.
Table 1: Patient characteristics and measured erythropoietin levels
Transfused (n=36)* Non-transfused (n=10)*
Gestational weeks, mean (range) 27 4/7 (25 4/7-35 0/7)* 31 0/7 (29 1/7-32 2/7)*
Birth weight, g mean ± SD 1052 ± 256* 1359 ± 258*
Gender - Boys: Girls, n 26:10* 4:6*
Apgar score at 1 minute, median (range) 5 (1-9) 7 (2-10)
Apgar score at 5 minutes, median (range) 8 (6-9) 9 (5-10)
Respiratory support, % neonates (n) 100% (36) 70% (7)
Mechanical ventilation‡, days median (range) 9 (1-22)* 0 (0-3)*
Clinical Complications
Sepsis §, % neonates (n) 64% (23) 40% (4)
Severe IVH (≥ grade 3), % (n) 8% (3) 0% (0)
Mortality, % (n) 6% (2) 0% (0)
Mean Hb level, mmol/l, week 1 8.3 ± 1.0 10.1 ± 1.4
Mean Hb level, mmol/l, after week 1 8.3 ± 0.9 8.4 ± 1.5
Samples collected after premature birth, n 336 69
-Week 1, n samples 151 37
-After week 1, n samples 185 32
Median Erythropoietin levels mU/mL - first 4 days
(5-95 percentile range)
8.0 (<1.4 – 112.5)† <1.4 (<1.4 – 60.6)
Median Erythropoietin levels mU/mL - after day 4
(5-95 percentile range)
3.0 (<1.4 – 23.9)† 3.0 (<1.4 – 45.6)
Abbreviations: IVH: intra-ventricular hemorrhage
* p-value <0.05, † p-value <0.001
‡ Synchronized Intermittent Mandatory Ventilation or High Frequency Oscillation, §defined by clinically suspect 
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Figure 1: EPO levels measured in the group of transfused neonates (n=36). 
The mean and 95% Confidence Interval of the EPO levels (mU/mL) were plotted against the number of 
administered RBC transfusions at the time of EPO measurement. 
0 = before RBC transfusion
Endogenous EPO levels
Seventy percent (n=405; n=336 from transfused neonates / n=69 from non-transfused neonates) 
of the collected waste samples could be used for EPO measurements in duplicate. Most samples 
were collected in the first two weeks of life. In the group of neonates that required RBC transfusion 
(n=36), the first EPO levels measured within 24 hours after birth were not correlated with the 
first measured Hb concentration (R2: 0.102), birth weight (R2: 0.204), gestational age (R2: 0.102). 
EPO levels from neonates with an Apgar score of ≤ 6 at 5 minutes after birth were 25 ± 34.4 mU/
mL (n=11) compared to the neonates with a better start after birth 8.6 ± 11.9 mU/mL (n=25) 
(p-value = 0.17).
During the first month in general, EPO levels were not significantly correlated to Hb concentration 
(R2: 0.003) and nucleated RBC count (R2: 0.153) when examined concurrently.
EPO levels during the first week after premature birth were highly variable and after the first 
week of life we observed overall lower EPO concentrations. As the first RBC transfusion was 
administered at median day 4, we examined the EPO levels in the first 4 days and the period 
thereafter. Median EPO level in the first 4 days was 8 mU/mL (5-95 percentile range <1.4 – 112.5 
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percentile range <1.4 – 23.9 mU/mL) (p-value <0.001). EPO levels measured in neonates requiring 
mechanical ventilation (22.4 ± 97.2 mU/mL) was higher compared to neonates requiring CPAP 
(8.7 ± 52.8 mU/mL) or requiring no respiratory support (7.2 ± 13 mU/mL). This however was 
not statistically significant (p-value 0.147, one way ANOVA for differences between groups). 
Neonates in the transfused group who suffered from sepsis had similar EPO levels compared to 
the other neonates in the same group. (data not shown) 
The non-transfused neonates (n=10) were analyzed in a similar manner. EPO levels after birth 
were not correlated with the first Hb level (R2:0.044), birth weight (R2: 0.511), gestational age 
(R2:0.011). Only 1 out of 10 neonates had an Apgar score of ≤ 6 at 5 minutes after birth. Median 
EPO level in the first 4 days after birth was <1.4mU/mL (5-95 percentile range (<1.4 – 60.6 mU/
mL) and in the period thereafter 3 mU/mL (5-95 percentile range <1.4 -45.6 mU/mL). 
A significant proportion of the samples had EPO levels below the detection limit of 1.4 mU/mL. 
This was the case in respectively 35% of the samples from the transfused neonates and 48% of 
the non-transfused neonates. 
EPO levels were correlated to the number of RBC transfusions administered prior to EPO 
measurement with the use of a linear mixed model to correct for repeated measurements within 
the patients. Both the patient variable and the number of administered transfusions were included 
to correct for random effects. Per transfusion administered, the decline in EPO level was between 
-1.3 and -1.9 mU/mL. The decline in EPO after every administered RBC transfusion is reported in 
Table 2. This decline in EPO was only statistically significant after the first RBC transfusion, a drop 
of -1.3 mU/mL (p-value 0.018). The decline in EPO values after subsequent RBC transfusions were 
not significantly correlated.
In the first week after birth, incidental high EPO levels were observed, exceeding adult reference 
values, ranging from over 100 mU/mL to 1200 mU/mL. Two out of three extremely high EPO 
levels (>500 mU/mL) were observed in neonates who died early after birth. One neonate born 
at a gestational age of 26 weeks suffered from severe intra-ventricular hemorrhage (≥ grade 
3); the other neonate was born after 32 gestational weeks but had severe intra-uterine growth 
retardation and died because of cardio-respiratory failure. The third surviving neonate was born 
after 30 gestational weeks and suffered from severe intra-ventricular hemorrhage (≥ grade 3) 
and sepsis.
Table 2: EPO in relation to administered RBC transfusions. 
Mean estimate 95% confidence interval p-value
After 1 RBC transfusion -1.3 mU/ml -1.9 ; -0.45 0.018
After 2 RBC transfusions -1.5 mU/ml -2.0 ; -0.76 0.066
After 3 RBC transfusions -1.7 mU/ml -2.1 ; -0.95 0.166
After 4 RBC transfusions -1.6 mU/ml -2.1 ; -0.95 0.128
After 5 RBC transfusions -1.9 mU/ml -2.3 ; -1.34 0.606
Mean estimates (back transformation of the log means) were calculated after every increase in number of 
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Discussion
In this observational study we measured endogenous EPO levels in premature neonates born 
before 36 gestational weeks during their first month of life. To avoid extra bloodletting we 
validated EPO measurement in waste material from blood withdrawn for other clinically indicated 
diagnostic tests. This enabled us to determine EPO levels approximately 4 times during the first 
week of life and 1-3 times per week in the period thereafter. 
In 37% of all samples, EPO levels were below the detection limit of our assay of 1.4 mU/mL 
(35% in the transfused group and 48% of the samples in the non-transfused group). Other 
studies reported higher17-18 or similar19 ranges of endogenous EPO levels during the first month 
of life. These differences could be secondary to the use of different techniques as in most studies 
a radio-immuno assay (RIA) was used. Comparison of EPO measurement kits showed that the 
performance of RIA methods was best across the range of 40-150 mU/mL, but more poorly at 
the lower end of the detection range. The ELISA method we used showed good precision across 
lower EPO levels.21 
Thirty-six neonates received RBC transfusions during their first month of life. Ten neonates did not 
receive transfusions. Both groups differed significantly in basic demographics and were analyzed 
separately. Transfused neonates suffered from more respiratory and infectious complications and 
more blood samples had been withdrawn for diagnostic tests, which probably contributed to 
the transfusion needs. During the first 4 days after premature birth, EPO levels were higher 
in the anemic neonates who needed transfusions, albeit with a wide range. We observed no 
relationship between individual EPO concentrations and the Hb levels. Although the differences 
were not statistically significant; the EPO levels of both neonates with an Apgar score of ≤ 6 at 
5 minutes after birth and neonates requiring mechanical ventilation, were clearly higher. This 
rather suggests that the higher EPO concentrations in the first week of life may be explained by a 
higher clinical stress level and/or more other sources of hypoxic stimuli. Higher EPO levels in cord 
blood have previously been found associated with neonatal stress and severe intra-ventricular 
hemorrhage.22-23 Also in septicemia higher EPO levels have been recorded.24 In our cohort EPO 
levels were however not higher in neonates suffering from sepsis. Extremely high EPO levels in 
three of our patients were probably indicative for life-threatening events and two of these three 
neonates died. Because in extremely stressful situations EPO levels can be extraordinary high, it 
may be advised to measure EPO prior to administration of recombinant human EPO for neuro-
protective indications to avoid extreme high EPO levels in severely ill premature neonates.
In the transfused neonates the EPO concentrations declined significantly after the first week of 
life. To unravel cause or coincidence, we performed a linear mixed model analysis to examine 
the relation between measured EPO levels and the administered transfusions. Per administered 
RBC transfusion the EPO levels declined. After the first RBC transfusion this decrease was 
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not significantly related to the number of administered RBC transfusions. Although statistically 
not significant the cumulated decrease in EPO could still be clinically important; i.e. after the 
mean number of administered transfusions (approximately 3), the cumulative decline in EPO level 
could be more than 4 mU/ml. It is possible that the decline in EPO in our cohort is less distinct 
after transfusion due to the relative low RBC volume administered per transfusion compared to 
a RBC product with a higher hematocrit or transfused at a higher volume per kg bodyweight, 
which also could worsen the suppression of nucleated red blood cells.8, 25 
In the non-transfused premature neonates EPO levels slightly increased and after the first week of 
life the EPO levels in both transfused and non-transfused neonates were similar, albeit that after 
day 18 no samples were available of non-transfused patients.
In conclusion, in a large group of prematurely born infants, we showed by frequent determination 
of EPO levels in waste material, an initial higher EPO value in the first week of life in the premature 
newborns that needed RBC transfusions, without a relationship with the individual Hb levels. 
EPO levels tended to be higher with other causes of hypoxic stress, although we did not find a 
significant relationship with a low Apgar score at 5 minutes after birth, need for respiratory support 
or sepsis. In agreement with other studies, EPO levels declined after every RBC transfusion.8-10 This 
decline could only be significantly correlated to the first RBC transfusion. It is however possible 
that differences in transfusion policy (amount of RBC transfused per kg body weight) result in 
variable degrees of EPO suppression.   
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Abstract
Although the use of umbilical cord blood (UCB) for transfusion purposes has been proposed 
decades ago, the employ is still limited. In this article we review studies evaluating UCB 
collection efficiency and sterility, examine processing and storage of UCB derived red blood 
cells (RBC) and discuss clinical studies in which UCB was used for transfusion purposes.
Efforts to provide preterm newborns with autologous RBC derived from UCB have not been 
very successful. UCB collected after full term deliveries can however easily be processed into 
RBC products and could be used autologous in case surgery of the neonate is indicated 
early after birth, or for allogeneic small volume paediatric transfusions. To harvest enough 
UCB volume, immediate clamping of the umbilical cord is commonly used as standard 
practice. Although delayed cord clamping has shown to improve the iron status in full term 
infants; for small for gestational age infants this has not been demonstrated. In addition, an 
increased need for phototherapy after delayed clamping exists. Altogether, we could find no 
disencouraging evidence to collect UCB, which could be processed into an easy available RBC 
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Introduction
The use of umbilical cord blood (UCB) has become widely established for haematopoietic stem cell 
transplantation. Although most collections of UCB are merely for its haematopoietic progenitor 
cell content; the remainder of the red blood cells (RBCs) could serve transfusion purposes. Since 
Halbrecht in 1939 published his experience on using placental blood for transfusions,1 many 
efforts have been undertaken to investigate its use in clinical practice.2-5 Many concerns existed 
however, mainly about the bacterial contamination rate and the risk of blood clotting.6-7 The 
improved methods to collect UCB in a sterile manner and the development of RBC storage media, 
stimulated investigations on the use of UCB derived RBCs for clinical purposes.2,4,8 Although the 
number of cord blood banks worldwide has increased significantly in the past years, there is still 
no international consensus on the procedure of UCB collection. As low volume is one of the most 
common reasons to discard a UCB unit9, this is of course also a challenge when one aims to use 
cord blood RBCs for transfusion purposes. 
To evaluate its state of the art, we have reviewed the current literature on 4 major topics that 
contribute to the feasibility of the use of UCB derived RBCs for transfusion purposes, namely; 
UCB collection efficiency and sterility, UCB processing into a RBC product, storage of UCB derived 
red cells and the clinical use of UCB transfusion.
Material & Methods
Literature searches were performed in Pubmed and Medline (period until December 2008) 
using the following keywords; ‘umbilical cord blood’; ‘blood volume’; ‘collection method’ and 
‘umbilical cord blood or placental blood transfusion’. After excluding all duplicates, 696 papers 
were screened on title and topic. After the first screening, 154 papers remained and were read 
thoroughly by both authors. The reference lists of all included papers were also screened for 
additional relevant titles. Papers were included if they met at least one of the following outcome 
parameters: 1. UCB collection method, harvested UCB volume and sterility; 2. The influence 
of cord clamping time and harvested UCB volume; 3. UCB blood component processing also 
reporting on the RBC volume after processing; 4. storage parameters of UCB derived RBC; or 5. 
the use of UCB for autologous or allogeneic RBC transfusion.
Results
Comparison of UCB collection methods
The most common methods to collect UCB is by puncture of umbilical cord vessels either before 
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Randomised studies 
Four randomised studies, conducted by 2 groups of investigators, comparing in and ex utero 
UCB collection after full term deliveries, were found. Surbek and colleagues have performed 
two studies in which they compared both methods, using random allocation before delivery. 
In their first study they investigated whether in or ex utero collection was superior after vaginal 
deliveries.10 The mean harvested UCB volumes were respectively 83.26 ± 7.9 mL and 48.42 ± 
4.07 mL, respectively using the in and ex utero collection method (p=0.0007). In their second 
study they used the same design after caesarean deliveries.11 In this study the mean UCB volumes 
were respectively 93 ± 7.5 mL and 66 ± 6.6 mL using the in and ex utero collection method 
(p=0.004). Although the studies are rather small, the results suggest that in both vaginal and 
caesarean deliveries, in utero UCB collection resulted in significant higher UCB volumes. Two other 
randomised studies performed by Pafumi and colleagues, compared in and ex utero collection 
after caesarean deliveries and supported the results from Surbek et al.12-13 In the first smaller study 
in utero collection resulted in a mean UCB volume of 90.7 ± 6 mL compared to 60.9 ± 13.7 mL 
after ex utero collection. Although the mean volumes collected in their second larger study were 
lower than in their first study (74.9 ± 7 mL vs 35.8 ± 3.6 mL), in utero collection in both studies 
resulted in higher harvested UCB volumes compared to ex utero collection.13 (Table 1) 
Table 1: Randomised studies comparing UCB collection methods after full term deliveries
Authors (ref nr) Mode of 
delivery







1 Surbek et al (10) V 42 <30 sec 83.26 ± 7.9 (n=23) 48.42 ± 4.07 (n=19) 0.0007
2 Surbek et al (11) CS 40 <10 sec 93 ± 7.5 (n=21) 66 ± 6.6 (n=19) 0.004
3 Pafumi et al (12) CS 47 nm 90.7 ± 6.0 (n=21) 60.9 ± 13.7 (n=26) <0.001
4 Pafumi et al (13) CS 149 nm 74.93 ± 7.1 (n=73) 35.78 ± 3.6 (n=76) 0.013
Data are indicated as mean ± SD
Abbreviations: ref nr: reference number; UCB: umbilical cord blood; V: vaginal delivery; CS: Caesarean Section; 
nm: not mentioned, decided by the operator; Symbols: * excluding anti-coagulant
Observational studies 
Most of these studies are retrospective reports of the cord blood bank experience using one or two 
collection methods. To be able to evaluate the efficiency by method, we included only the studies 
that reported at least on both collection method and harvested volume. In 33 observational 
studies, the efficacy of the collection method could be evaluated. In Table 2, nine studies are 
shown which reported on both in and ex utero collection, and if possible, divided per mode of 
delivery. Most of the studies report only data of processed and banked products. In addition, 
however, the discard rate after collection was reported in some studies, which we could also 
use to compare the collection method efficiency within one center, but not between the centers 
as the discard cut-off values differed significantly. The most common reasons to discard UCB 
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In seven studies, comprising a range of 151 to 1722 deliveries per study, the comparison of an 
in and ex utero collection method showed no statistically significant differences in harvested 
UCB volumes.14,15,18,20-23 In three of these studies, the collection method depended on the mode 
of delivery18,20, 23 and in two other studies the collection method was evaluated solely after 
caesarean deliveries.21-22 In the studies by Reboredo et al, Sparrow et al and Kögler et al, in case 
of a caesarean section only an ex utero collection method was used.18,20, 23 Sparrow et al found in 
a rather small cohort of 157 deliveries no differences between in and ex utero harvested volume 
after vaginal deliveries, but ex utero collection after caesarean sections resulted in a higher 
median UCB volume compared to the volumes collected after vaginal deliveries.18 Tamburini et al 
and Solves et al compared an in and ex utero collection method after caesarean sections.21-22 Their 
results, showing no differences between both methods, are in contrast to the results reported by 
Surbek et al and Pafumi et al in controlled randomised studies, which reported higher harvested 
volumes when an in utero method was used after caesarean section.11-13 
Solves and colleagues reported a significant higher harvested UCB volume when an in utero 
collection method was used after vaginal deliveries in two studies.16-17 Because the discard 
rates in both studies were similar we included only the largest study in Table 2.16 When an in 
utero collection method was used the discard rate was lower compared to ex utero harvesting, 
respectively 25% vs 33%, thereby supporting the results found by Surbek et al.11, 16-17 
Merely one smaller observational study reported a significant higher harvested UCB volume when 
an extra uterine collection method was used. In this study by Yamada et al, the ex utero collection 
method after caesarean section resulted in a significant higher mean UCB volume compared to 
vaginal deliveries after which an in utero method was used.19 This is however in contrast to the 
study by Reboredo et al, which found similar harvested UCB volumes after in utero collection 
after vaginal deliveries and ex utero collection after caesarean section.20  An explanation for these 
different observations may be small differences in timing of cord clamping, although reported 
within 30 seconds after birth, and the position of the newborn after birth, between the two types 
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Twenty-five centers reported on either in utero or ex utero UCB collection. (Table 3-4) Like the 
earlier studies mentioned, these studies reported characteristics of processed or banked products. 
In some studies the discard rate was reported or could be calculated. The nine studies in which 
only in utero collection was used, comprising over 13.000 deliveries (range 79-8623 deliveries per 
study) reported a broad range in harvested UCB volume, 20-256 mL in individual cases but also 
an approximately twofold difference, from 56 mL to over 130 mL (the last including 25 mL anti-
coagulant) in mean harvested UCB volumes, between centers. (Table 3) 25-33 In four studies the 
discard rate was reported. In the study by Reed and colleagues, the proportion unbanked units 
was rather low compared to the other studies.29 This could be explained by the different setting 
of this study, which had a specific focus on sibling cord blood banking for children with malignant 
and non-malignant disease. In the other studies by Wada et al, Nakagawa et al and Wu et al, a 
discard rate range between 40-48% was reported.28-30 
The nine studies reporting on over 22.000 deliveries (range 130 – 9205 per center) and ex utero 
collections of UCB are mentioned in Table 4, if possible, divided per mode of delivery.17-18, 34-40 
A discard rate range between 18% and 46% was reported in 5 out of 9 studies. Exceptional is 
the 18% discard rate of one study by Donaldson et al, which is likely due to the pre-collection 
assessment of the placenta by the mid-wife collectors attempting only collection when they were 
anticipated to be successful, and thereby lowering the total discard rate. The studies by Sparrow 
et al, Kurtzberg et al, and Donaldson et al showed higher harvested UCB volumes after caesarean 
section when an ex utero collection method was used.18, 37, 39 (Table 4) 
Altogether; although the data from the randomised studies suggest that after caesarean deliveries 
the in utero collection method is superior,11-13 this is not supported by large observational studies. 
The superiority of in utero collection after vaginal deliveries in harvesting larger UCB volumes was 
shown in one randomised study10, supported by two large observational studies.16-17 Analysis of 
all studies show that efficacy of the UCB collection used is closely related to the mode of delivery. 
Differences in cord clamping time and the position of the newborn before clamping could not be 
evaluated from these studies as either early clamping or discretion of the obstetrician regarding 
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Other UCB collection methods
Besides the comparison of in or ex utero collection, seven studies applied a modified UCB 
collection technique.19,41-46 In five of these studies it was investigated whether additional in or ex 
utero perfusion using heparinized NaCl or another anti-coagulant resulted in a higher yield of 
UCB. In one study an additional pressure device was tested to collect the remaining UCB from the 
placenta ex utero. One other study compared the influence of position of the infant after birth on 
the in utero collected UCB volume. When the newborn was kept above the level of the placenta 
before cord clamping, the harvested volume was significantly higher, compared to a lower 
position below the level of the placenta, 87.7 ± 14.5 mL vs 41.7 ± 8.9 mL.19 With each of the 
adaptations tested, the researchers were able to enlarge the harvested UCB volume. (Table 5)19, 41-46 
As most of these modified techniques make use of additional punctures and or a combination of 
a collection bag-system and syringe, it is not unconceivable that bacterial contamination could 
occur at a higher rate. Next to this it is important to work out whether such modifications could 
be easily and ethically implemented in a standard procedure in the delivery room.
Microbial Contamination
In the majority of the observational studies the bacterial contamination rate was mentioned. 
(Tables 2-5) Some studies mentioned that due to extensive training the contamination rates could 
be lowered significantly.20,23 Many studies did however not mention the cultured volume, shown 
to be of relevance for the chance of finding bacterial contamination.47 Overall, the percentage 
of contaminated UCB collections was below 5%, suggesting that there is no difference in 
contamination risk when an in or ex utero collection method is used. Only the study by Ademokun 
et al reported a higher contamination rate of 12%.27 
In regard to the other collection methods mentioned in Table 5, the study by Elchalal et al showed 
a rather high contamination rate because of the open systems that were used.42 The proportion 
contaminated UCB products used in the clinical studies on autologous UCB transfusion was 
between 0% and 9%, a similar range compared to the other rates reported.48-51
Collection of UCB after preterm birth
In several studies UCB was also collected after preterm deliveries. Brune et al and Garritsen et al 
used both in and ex utero UCB collection methods and showed that it was possible to harvest 
approximately 20 mL per kg bodyweight independent of the birth weight.52-53 In the study by 
Eichler and colleagues, the harvested UCB volume per kg birth weight decreased with the infants’ 
maturity. A maximum of 43 mL per kg body weight was harvested in the most immature infants. 
The absolute amount of harvested UCB did however increase with the birth weight.48 Surbek et al 
collected a median volume of 21 mL (range 8-38) after deliveries between 22 and 32 gestational 
weeks and a median volume of 49 mL (range 21-103) after deliveries between 33 and 36 weeks 
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Also in the studies by Jansen et al and Khodabux et al, the collected UCB volume could be 
correlated to gestational age but this however could not be correlated to the birth weight.51,56
UCB collection, cord clamping practice in relation to the effects on newborns
Bertolini and colleagues showed that when the cord was clamped within 30 seconds after birth, a 
significant larger volume UCB could be harvested, but that this resulted in a lower Hb level of the 
infants during the first four days of life. When UCB was collected after early clamping, within 30 
second, compared to late clamping within 35-180 seconds, respectively a volume of 76 ± 22 mL 
vs 39 ± 17 mL was collected. The mean neonatal haemoglobin levels were respectively 16 ± 1.1 
g/dL in the early clamping group and 17.4 ± 1.3 dL in the late clamping group.26 This indicated 
that early clamping resulted in a small decrease of haemoglobin, raising ethical questions of 
whether this small deprivation of the newborns own cells should be allowed.57 The WHO has 
recommended in 2007 that ‘the cord should not be clamped as early as necessary’, this was 
however graded as a low evidence recommendation.58 This means that cord clamping practice 
is still at the discretion of the obstetrician or midwife. A recent Cochrane review investigated 
the effects of cord clamping time on the neonatal outcome of full term newborns. Early cord 
clamping was associated with a significant decrease in haemoglobin level during the first 48 
hours after birth (WMD -1.34 g/dL, 95% CI -1.88 to -0.88) compared to delayed clamping, which 
in addition also approved the iron status at the age of 6 months. One important disadvantage 
of delayed clamping was however a 2% (95% CI 0.04 to 0) higher risk of jaundice requiring 
phototherapy.59 In taking the decision to clamp the cord early or late, on should considerate the 
potential risk of either deprivation of iron or the risk of jaundice requiring phototherapy.
In the case of preterm infants born before 37 weeks, a recent systematic review showed that a 
brief delay in cord clamping of at least 30 seconds was safe to use and this was also associated 
with lower transfusion needs and a significant lower incidence of intra-ventricular haemorrhage. 
There is however still need for a standardized delayed clamping method regarding, timing of 
the delay, position of the child after birth and consensus about possible resuscitation, to test the 
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Cord blood RBC products and storage parameters
Studies reporting on UCB processing into a RBC product are scarce. Armitage et al and Godinho 
et al used centrifugation to deplete the buffy-coat from the RBC.61-62 The mean RBC loss in these 
studies were respectively 53% and 34% (range 5-77) in UCB units smaller than 80 mL, compared 
to 56% (range 32-75) in UCB units that were larger than 80 mL. Two studies, investigating the 
use of autologous UCB transfusion in premature infants, used a similar processing method, by 
centrifugation and extraction using the Optipress, to prepare UCB derived RBC. In the study 
performed by Eichler and colleagues, 81 % of the premature UCB collections (34 out of 42) 
could be processed in this manner. A minimal net volume of 30 mL UCB appeared necessary 
for this procedure. The successfully processed UCB units (n=34) had a mean hematocrit of 62.7 
± 12.4 L/L and a RBC component volume of 28.6 ± 18.8 mL.48 Garritsen and colleagues used 
a similar semi-automated processing method, but did not report the UCB derived RBC recovery 
after processing. The final autologous UCB products in this study had a mean volume of 23.4 ± 
9.1 mL and a mean hematocrit of 52.6 ± 10 L/L.53 
Another method to process UCB into a RBC product is by filtration. Brune and colleagues showed 
that hollow fibre in-line filtration by gravity could be used for RBC separation from UCB. The 
filtrated RBC units had a mean volume of 63.3 ± 13.5 mL, a mean hematocrit of 56 ± 6 L/L 
and there was no white blood cell contamination. The recovery of RBC in the filtered unit was 
unfortunately not mentioned.63 The advantage of this method is that it is less laborious compared 
to the semi-automated centrifugation method. Filtration was however only possible with a 
minimal volume of 60 mL UCB or larger, whereas centrifugational separation was also possible 
with smaller volumes; although the RBC loss was proportionally higher when the initial UCB 
volume was lower. 
To investigate whether harvested cord blood could be banked for transfusion purposes, several 
studies were performed which investigated red cell lesions in stored cord blood units (Table 6). 
Brandes et al stored whole blood UCB during 8 days in CPD at 2-6°C degrees. During this storage 
period, there was a modest loss in ATP, but 2.3 DPG declined very rapidly. Hemolysis remained 
below 1% and potassium rose to a mean value of 16.7mmol/L.2 Horn stored whole blood UCB 
during 21 days in either CPD or CPDA and showed that UCB red cells were more affected by 
storage compared to adult red cells. Storage in CPDA was better than in CPD resulting in higher 
ATP levels, 47 μmol/gHb vs 1.2 μmol/gHb, after 21 days compared to CPD. The decline in 2.3 
DPG and pH were similar between both storage media.4 Bifano et al stored placental whole 
blood in CPDA for 28 days.8 Hemolysis rate was minimal, from 0.29 ± 0.07 % at day 0 to 0.39 
± 0.05 % at day 28 and the increase in potassium mmol/L was comparable to stored adult red 
blood cells during a similar period. The studies performed by Garritsen et al, Brune et al and 
Widing et al, showed however different results.52, 63-64 In these last three studies, cord blood was 
processed into RBC units and stored in SAG-M or PAGGS-M for 35 days. In contrast to the results 
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time. After 35 days of storage a mean haemolysis rate of respectively 1.1 ± 0.8 % was seen in 
the study by Garritsen et al and 1.0 ± 0.7% in the study by Brune et al.53, 63 The use of storage 
medium PAGGS-M was however superior to SAG-M in the study performed by Widing et al. The 
haemolysis rates were respectively 0.3 % (range 0.2-0.4) compared to 0.9 % (range 0.6-1.1).64 
Altogether these results show that at a considerable part of the stored UCB derived RBC units 
had surpassed the European haemolysis limit of 0.8% and the American haemolysis limit of 1%. 
The pH levels in the UCB products after 35 days storage were also significant lower, compared to 
adult RBC products.63 The decline in pH level in the filtered RBC products was lower compared 
to the products processed by centrifugation. At day 35 the pH levels were respectively 6.4 ± 
0.1 and 6.1 ± 0.1. It is possible that small differences in the ratio of SAG-M to the amount of 
RBC could explain this observation.53,63 (Table 6) All studies show that UCB red cells deteriorate 
faster during storage compared to adult red cells, estimated from haemolysis increase and pH 
decrease. The results suggest that whole blood storage causes less deterioration than RBC 
enrichment by centrifugation or filtration and storage in preservation solutes. From the better 
results obtained with the storage solution PAGGSM, which contains additional phosphate and 
guanosine compared to SAG-M, it is suggested that not the manipulation of cord blood, but 
rather the preservative solution may contribute to the storage damage of the RCB. When adapted 
to a shorter storage period, it is likely that the UCB products would have a similar metabolic 
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Clinical use of UCB derived red cells for autologous transfusion purposes
The total volume of UCB that can be harvested for transfusion is of course limited. Therefore, 
as a single transfusion product, it could only be used for small volume RBC transfusions for 
paediatric patients. In particular premature infants receive frequently RBC transfusions early in 
life. In a study by Ballin and colleagues, several aspects of UCB collection for neonatal autologous 
transfusion were investigated. They evaluated the thrombin activation by quantification of 
prothrombin fragments, one and 10 minutes after cord clamping. All cultures were negative and 
similar amounts of prothrombin fragments 1 and 2 were seen at one and ten minutes after cord 
clamping. These results encouraged the authors to administer autologous UCB to a premature 
infant. The collected UCB served two packed cell transfusions in this case. No untoward transfusion 
reactions were seen.65 In the study performed by Eichler et al mentioned above, 4 products 
were used for autologous transfusion without any untoward adverse effects.48 Until present, 
one randomised study has been performed that investigated the clinical use of autologous UCB 
for the treatment of anemia of prematurity. In this trial, autologous UCB derived RBC products 
were available for 27% of the transfused infants and could cover 58% (range 25-100%) of the 
administered transfusions. This study also showed that harvesting of enough UCB from preterm 
placentas was more problematic when the infants were born before 28 weeks of gestation.51 
Next to premature infants, autologous UCB transfusion could also serve transfusion requirements 
of newborns in need of surgery after birth, for instance due to congenital malformations. 
In a case report by Hosono et al, an infant with a huge saccrococcygal teratoma underwent 
autologous UCB transfusion safely and no additional allogeneic transfusions were needed.66 In 
two series of newborns in need of surgery shortly after birth, allogeneic transfusions could be 
avoided in respectively 36% (9 out of 25 patients) and 70% (7 out of 10) of the cases.49,67 In all 
reported cases, no adverse reactions were observed. Brune et al examined the efficacy and safety 
of autologous UCB transfusions in a series of 52 newborns consisting of 30 premature infants 
and 22 newborns in need of surgery. The mean increase in Hb after transfusion and the Hb 
decline the days after autologous UCB transfusion were compared with allogeneic transfusion. 
They found a similar Hb increase after autologous or allogeneic transfusion, respectively 3.1 and 
3.0 g/dL. However, the Hb decline was significantly accelerated after autologous transfusion, 
0.32 compared to 0.24 g/dL. Based on their findings, they estimated that homologue transfusion 
could be replaced by autologous UCB in 40% of the premature infants with a birth weight of 
1000-2500 g and newborns in need of surgery to correct congenital malformations.67 Their first 
finding could however not be supported by the only randomised study available, which reported 
that in case of infants born after 30 weeks of gestation, autologous blood was only available 
in 19% of the infants with a transfusion indication.51 In the case of extreme low birth weight 
infants or newborns in need of more complex abdominal or heart surgery, additional allogeneic 
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Regarding the collection of premature UCB for autologous RBC transfusion there are two 
important limitations which should be outlined. First, although mothers with an increased risk 
of infection, i.e. maternal fever or prolonged rupture of the membranes, were excluded from 
UCB collection, there was still an increased likelihood of microbial contamination compared 
to standard allogeneic RBC products.51 This increased risk of non-sterility resulted in products 
that were discarded and should be accounted for in the production costs. Secondly, as already 
mentioned, collection of UCB from premature placenta’s resulted in less blood volume compared 
to UCB collection after term deliveries. Considering the lower volumes that can be collected, the 
volume anticoagulant in the collection system could be adjusted to avoid low blood to CPDA 
ratios. Weisbach et al showed that too much CPDA with respect to the blood volume, could result 
in an increased hemolysis rate and lower pH.68 Although such data are however not available yet 
for UCB, on should consider this. 
Clinical use of UCB derived red cells for allogeneic transfusion purposes
Transfusion of UCB in the allogeneic setting has been extensively studied by a research group in 
India. From 1999 onwards, this group has administered fresh whole blood cord blood transfusions 
and studied is safety and efficacy.69-78 In their research setting, UCB was only collected after 
caesarean section. After collection, all units were typed for ABO/Rhesus and screened for HBV, HCV, 
HIV and malaria. The collected UCB was stored in CPDA, kept at 1-4°C degrees and transfused 
within 72 hours after collection. The largest reported series consisted of 129 patients, mostly 
adults, suffering from anemia in consequence of advanced cancer, aplastic anemia, thallasaemia, 
ankylosing spondilitis, rheumatoid arthritis or lupus erythromatosis. In this study a total of 413 
UCB units were harvested with a mean volume of 86 ± 7.6 mL. These units had a mean Hb of 
16.2 ± 1.8 g/dL. Before transfusion, the UCB units were bedside filtered. The number of UCB 
transfusions that were administered per patient ranged from 1-33 units. No adverse clinical or 
immunological transfusion reactions were seen.70 Although not studied extensively, and reported 
only in the thallasaemia patients, no pulmonary problems were observed. In view of its higher 
affinity for oxygen, on should consider this in the decision whether or not to use HbF bearing RBC 
in acute hypoxic patients, even when no alternatives are present.
The use of whole blood UCB transfusions as a treatment for paediatric and adult patients suffering 
from malaria has also been studied. In this series, 94 UCB units were harvested and transfused to 
39 patients. The UCB units had a mean volume of 81 ± 6.6 mL and a mean Hb of 16.4 ± 1.6 g/
dL. Each patient received two pooled fresh whole blood UCB units at a time (range 2-6 units per 
patient) depending on availability and compatibility. The age of the patients ranged from 8-72 
years. The post transfusion increase in Hb ranged from 0.5-1.6 g/dL. All transfusions were well 
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Altogether Bhattcharya reported on over 500 fresh whole blood filtered cord blood transfusions 
administered to anaemic paediatric and adult patients suffering from a variety of underlying 
conditions. During follow up of these patients no transfusion related hazards were observed. 
These data suggest that in case of resource restricted areas, the use of allogeneic whole blood 
cord blood may be a good alternative when adult donor RBC products are scarce. 
Conclusion and recommendations
The clinical use of UCB for RBC transfusion purposes is still limited. In neonatal transfusion practice, 
efforts have been made to provide premature infants, especially those born before 32 gestational 
weeks, with autologous RBC.48,50-53 For another group of neonates, those with antenatal confirmed 
anomalies which can be corrected short after birth, UCB collection for autologous transfusion has 
been shown more efficient in avoiding allogeneic transfusions compared to infants suffering 
from anemia of prematurity.49,67 Experience with UCB in the allogeneic setting is still limited. In 
India no adverse transfusion effects were seen in a wide variety of patients that received (pooled) 
allogeneic fresh whole blood UCB transfusions.69-78 Altogether, the clinical feasibility of using 
UCB for transfusion purposes depends on the intended patient groups. A better evaluation on 
the collection method efficiency pointed at harvesting the largest possible UCB volume would be 
of benefit for the transplantation setting but would also enlarge the possibilities for transfusion 
purposes. Besides whole blood transfusion and bedside filtration; hollow fiber in-line filtration 
seems to be a possibly attractive option to process UCB into an easy and ready available RBC 
product, although due to the availability of filters suiting this purpose, this method is currently 
only effective for total volumes greater than or equal to 60 mL.62
The use of UCB for small volume allogeneic transfusions in anaemic children in Africa or in 
malaria endemic areas has also been proposed.79 A preclinical study showed that donation and 
transfusion of UCB would be acceptable to women living in Mombasa, Kenya.80 Planning of cord 
blood donation programs as suggested by Hassall et al could be of benefit of many children in 
sub-Saharan Africa. Immediately cord clamping after birth seems however mandatory for efficient 
UCB collection. The possible advantages and disadvantages of immediate cord clamping should 
be weighed and discussed with the mother before donation. An important point of concern is 
that in case of small for gestational age infants, who are more likely to have a increased morbidity, 
the beneficial effects of delayed clamping have not been demonstrated yet. For autologous 
transfusion in neonates, it is probably only worth the effort to collect and store UCB in the 
neonatal surgery setting. In view of the small volumes RBC per unit that can be collected, it is 
most likely that anaemic children in need of small volume transfusions in resource-restricted 
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Abstract
Background & Objective: The use of umbilical cord blood (UCB) for transfusion purposes 
has gained interest the past years. UCB transfusion could serve premature infants, who often 
need red blood cell (RBC) transfusions early in life.
Material & Methods: We investigated the suitability of different storage media. UCB 
was collected after 25 0/7 – 35 6/7 gestational weeks and centrifuged to concentrate RBC 
subsequently stored in saline-adenine-glucose-mannitol (SAG-M) or in additive-solution-3 
(AS-3), or stored as whole blood in citrate-phosphate-dextrose-adenine-1. Quality parameters 
were measured at 7 day intervals during 35 days, and compared to the standard RBC product. 
Results: White blood cell- and platelet counts were higher in the UCB products. In the 
fractionated units, hemolysis remained below 1.0% in 64% after 14 days, and in 30% after 
21 days. Storage in SAG-M or AS-3 showed similar quality. Whole blood UCB showed better 
pH and hemolysis rates after 21 days.
Conclusion: UCB can be processed into autologous products for premature infants. Shelf-life 
is limited to 14-21 days and compares unfavourably to stored whole blood. Considering the 
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Introduction
In the past years, the use of umbilical cord blood (UCB) for transfusion purposes has gained the 
interest of clinicians.1-4 UCB could be used for either autologous or allogeneic transfusion purposes. 
For allogeneic use, whole blood UCB from term newborns has been used for paediatric and adult 
patients suffering from malaria.5 In the autologous setting, the use of UCB for transfusion has 
shown to be effective in avoiding allogeneic transfusions in neonates in need of surgery after 
birth.6-7 Next to these infants, autologous UCB could serve transfusion requirements in premature 
infants.1, 8-10 Despite the use of transfusion guidelines with restrictive triggers, premature 
infants are still frequently transfused.11-14 Allogeneic red blood cell (RBC) transfusions have 
been incriminated to have adverse effects on the neonatal outcome, in particular on ‘oxidative’ 
diseases like bronchopulmonary dysplasia and retinopathy of prematurity.15-17 Whether the use 
of autologous RBC may overcome these possible side effects is still unknown. Several studies 
showed that it is feasible to collect UCB after premature birth for autologous RBC transfusion.2,9-10 
In a randomized study we reported earlier on the logistics and the costs to incorporate autologous 
UCB transfusion for anemia of prematurity in standard blood bank practice.9
In this paper we present storage and quality parameters of UCB derived RBC, collected after 
premature birth, and stored in different extended storage media. 
   
Material and Methods
UCB collection from premature infants
UCB was collected after deliveries between 25 0/7 - 35 6/7 gestational weeks. Exclusion criteria 
were active blood group incompatibility, hemoglobinopathies, maternal infections (HIV, HBV, 
HCV, HTLV, and syphilis), premature rupture of the membranes with fever treated with antibiotics, 
and congenital infections (CMV, Parvovirus B19, Toxoplasmosis). Informed consent for study 
participation was obtained from (one of) the parents before delivery. After a vaginal delivery, 
premature UCB (P-UCB) was collected from the undelivered placenta. In case of a caesarean 
section, collection was performed after the placenta had been delivered. The collection system 
consisted of a 150 mL bag (Fresenius, Bad Homburg, Germany) containing 5 ml of citrate-
phosphate-dextrose-adenine-1 (CPDA-1) (Baxter, IL), a collection tubing system with 2 attached 
needles (Medisize, Hillegom, the Netherlands) and a syringe (Medisize, Hillegom, the Netherlands) 
containing (additional) 5 ml CPDA-1. The umbilical cord was sterilized with iodine, the cord vein 
was punctured and P-UCB was collected by gravity. After collection, the additional 5 mL CPDA-1 
in the syringe was added to the collected P-UCB. The collection bag was then stored at 2-6 ° C, 
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Fractionation of the P-UCB
A half mL whole blood was used to perform complete blood counts (Beckman Coulter Onyx, 
Brea, USA) and blood group typing (ABO-RhD, Diamed, Cressier, Switzerland). The remaining 
P-UCB was transferred to a closed centrifuge circuit (15 minutes at 1010x g, Biosafe Sepax, 
Eysins, Switzerland). This procedure was started if the collected total blood volume was at least 
15 mL (excluding anticoagulant). RBCs were separated from buffy-coat and plasma and adjusted 
with either saline-adenine-glucose-mannitol (SAG-M) (Fresenius, Bad Homburg, Germany) 
or additive solution 3 (AS-3) (Braintree, MA) to a red blood cell concentrate (RBCC) with a 
hematocrit between 0.55 and 0.65 L/L. At least 10 mL of the removed CPDA-1-plasma was used 
for aerobic and anaerobic bacterial culture (BacTalert, Durham, USA).18 P-UCB was not tested 
on contamination of maternal cells. All processing was done within 24 hours after collection. 
Subsequently, P-UCB products were stored during 35 days at 2-6°C. At 7 day intervals 0.5 mL 
was removed for quality parameters. 
Whole blood storage
UCB collections with a CPDA-1 : blood ratio of 1: < 4 were discarded. Twelve P-UCB collections 
with an anticoagulant : blood ratio of 1: ≥ 4, were stored as whole blood during 21 days at 2-6°C. 
Prior to storage, a volume of 10 mL whole blood UCB was used for aerobic and anaerobic bacterial 
culture (BacTalert, Durham). At 7 day intervals 0.5 mL was removed for quality parameters. 
Storage stability
For the quality control we performed an automatic blood cell count (Beckman Coulter Onyx). 
Undiluted RBCC or whole blood P-UCB was used for sodium, potassium, free Hb and pH 
measurements. Hemolysis, lactate, glucose and osmotic resistance measurements were done 
using diluted RBCC or whole blood UCB (5 times diluted in NaCl 0.9%). Samples were centrifuged 
at 10.000 rpm (9615 x g) for 3 minutes. After centrifugation, the supernatant was kept at minus 
80º C until analysis. Sodium and potassium supernatant levels were determined using a standard 
flame photometry method. The pH was measured on a blood gas analyzer (Bayer rapidlab, 
Siemens Healthcare Diagnostics, Deerfield, IL). Glucose, lactate, free Hb, hemolysis and osmotic 
resistance were measured by optical density on a Versamax® plate reader. (Molecular Devices, 
Silicon Valley, CA) For osmotic resistance measurement, a series of 0.2% - 0.8% NaCl was used 
to determine the NaCl concentration resulting in 50 % hemolysis. 
Storage parameters were compared with pre-expiration values from 10 standard pedi-packs 
stored for 35 days under the same conditions. The standard pedi-pack consisted of 65 mL 
adult donor pre-storage leukocyte-depleted, RBC stored in SAG-M. Pedi-pack products have a 
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Statistical and data analysis
Data are presented as mean ± SD unless indicated otherwise. SPSS (version 16, Chicago, IL) for 
Windows was used for data analysis. Continuous variables were analyzed using independent 




Fifty-nine collections were used for the validation study. Forty-seven of these were processed 
using a closed centrifuge circuit (Biosafe Sepax, Eysins, Switzerland), of which 34 were stored in 
SAG-M, with a mean volume of 34.4 ± 13.4 mL (including anticoagulant); and 13 in AS-3 with 
a mean total volume of 32.2 ± 20.5 mL (including anticoagulant), during 35 days at 2-6º C. 
Twelve P-UCB collections were stored as whole blood during 21 days, mean volume 52.1 ± 20.9 
mL (median anticoagulant : blood ratio 1:6, range 1:4 – 1:8). Seven percent of all products were 
microbially contaminated (4 of 59). The time interval in which we detected positive blood cultures 
was 13.2 hours – 74.4 hours after processing. The pathogens were identified as Coagulase 
negative staphylococcus species, Escherichia Coli species and Streptococcus agalactiae B species 
(2x). 
Storage and quality characteristics - fractionated P-UCB products
The fractionated P-UCB products had a mean hematocrit of 0.605 ± 0.04 L/L. At the start, the 
RBCC products differed in lactate, sodium and potassium levels depending on the storage media 
(p<0.01). (Figure 1A-B) Remarkably, also the hemolysis rate at the start was higher in RBCC stored 
in AS-3 compared to SAGM (p<0.001). (Figure 1C) 
During storage, we observed similar increases in lactate, potassium and hemolysis, as well as 
decreases in glucose, sodium and pH, when either stored in SAG-M or AS-3. (Figure 1A-C) After 
14 days of storage, 47% (22 of 47) of the fractionated units had a hemolysis rate below 0.8%, 
and 64% (30 of 47) of the units below a rate of 1.0 %. After 21 days of storage, these hemolysis 
rates were respectively 21% (10 of 47 ) below 0.8% and 30 % (14 of 47) below 1.0% hemolysis. 
After 35 days of storage the mean corpuscular volume (MCV) of RBC stored in SAG-M was 
higher, compared to the RBC stored in AS-3 (p=0.018) (Table 1).
The P-UCB product storage data at 21 and 35 days were compared with data at pre-expiration 
day 35 from standard pedi-packs. WBC and platelet counts were higher in all P-UCB products. 
(Table 1). During storage the hematocrit of the P-UCB products gradually increased as did the 
MCV. (Table 1) Compared to the standard pedi-pack, the SAG-M products displayed significant 
differences in pH, hemolysis, and free Hb after 21 storage days (p<0.01). In addition, after 35 
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compared to the standard pedi-pack (p<0.01). Storage of the P-UCB products in AS-3 showed 
significantly higher free Hb and sodium levels after 21 days of storage (p<0.01) compared to the 
standard pedipack. At day 35, pH, hemolysis rate and potassium were also significantly different 
(p<0.01). (Table 2) Although the higher hemolysis rates indicated that the P-UCB derived RBC 
degraded significantly during storage, this was not seen in the osmotic resistance measurements. 
Storage in SAG-M or AS-3 showed no significant differences in osmotic resistance compared to 
the standard pedi-pack. Gestational age at the time of P-UCB collection had no influence on the 
storage parameters (data not shown).
Figure 1: Quality parameters of fractionated P-UCB products (stored in SAG-M or AS-3) and whole blood 









Figure 1A: Lactate and glucose levels during storage
Whole blood lactate at day 21 was significantly lower than SAG-M and AS-3 (p<0.001)
Whole blood glucose at day 21 was significantly higher than AS-3 (p<0.001)
Abbreviations:P-UCB: premature umbilical cord blood; SAG-M: Saline Adenin Glucose Mannitol; AS-3: 


















































Figure 1B: Sodium and potassium levels during storage
Sodium levels in SAG-M was significantly lower compared to AS-3 and whole blood (p<0.01)
Potassium levels in whole blood was significantly lower compared to SAG-M and AS-3 (p<0.01) 
Abbreviations:P-UCB: premature umbilical cord blood; SAG-M: Saline Adenin Glucose Mannitol; AS-3: 








Figure 1C: Hemolysis rate and pH during storage 
AS-3 hemolysis rate at day 0 was significantly lower than SAG-M (p<0.001)
Whole blood hemolysis rate at day 21 was significantly lower than SAG-M and AS-3 (p<0.001)
Whole blood pH at day 21 was significantly higher than SAG-M and AS-3 (p<0.001)
Abbreviations:P-UCB: premature umbilical cord blood; SAG-M: Saline Adenin Glucose Mannitol; AS-3: 
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After 21 days of storage
RBC concentration, x10e12/l 5.4 ± 0.48 5.6 ± 0.49 3.7 ± 0.88#
MCV, fl 117.9 ± 6.67 113.8 ± 6.39 110.8 ± 5.98
Hematocrit, l/l 0.64 ± 0.05 0.64 ± 0.06 0.41 ± 0.08 #
WBC concentration, x10e9/l 4.5 ± 2.27 4.5 ± 1.74 7.1 ± 4.48
Thrombocyte concentration, x10e9/l 94 ± 40.7 96 ± 44.6 175 ± 102.4
After 35 days of storage
RBC concentration, x10e12/l 5.5 ± 0.50 5.6 ± 0.45 Na 6.5 ± 0.51
MCV, fl 122.1 ± 7.6 116.1 ± 6.9 Na 90.5 ± 3.87
Hematocrit, l/l 0.67 ± 0.05 0.65 ± 0.06 Na 0.58 ± 0.03
WBC concentration, x10e9/l 3.9 ± 2.16 3.7 ± 1.51 Na <0.001
Thrombocyte concentration, x10e9/l 83.3 ± 37.7 96 ± 43.9 Na <0.015
Data are indicated as mean ± standard deviation, or as indicated otherwise
RBC: red blood cells; MCV: mean corpuscular volume; WBC: white blood cell; SAG-M: saline adenine glucose 
mannitol; AS-3: additive solution 3; Na: not applicable
*: only pre-expiration measurement at day 35; ^: p<0.01 compared to Standard pedipack; #: p<0.0001 
compared to SAG-M/AS-3/ standard pedi-pack
P-UCB whole blood storage
After 21 days of storage, the increase in hemolysis and MCV and the decrease in pH, were 
less pronounced in P-UCB stored as unprocessed whole blood, compared to the P-UCB RBCC 
in storage solutions. (Figure 1-C) In addition, the whole blood P-UCB products had significant 
lower lactate-, maintained higher glucose- and had lower potassium levels (Figure 1 A-B). The 
pH and hemolysis rate in the whole blood products after 21 days were not statistically different 
when compared to the pre-expiration data of the standard product. The osmotic resistance of the 
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Discussion
In this study we collected P-UCB which was either fractionated using a closed centrifugation 
circuit and stored in extended storage medium SAG-M or AS-3 or stored as whole blood in 
CPDA-1. Quality parameters were compared to the standard pedi-pack, consisting of leukocyte-
depleted filtered adult donor RBC after 35 days of storage, which are validated for neonatal 
transfusions. 
Comparison of the P-UCB products stored in either SAG-M or AS-3 showed no differences in 
biochemical parameters. Fractionated P-UCB stored in SAG-M or AS-3 showed a higher hemolysis 
rate and increase in MCV compared to the standard pedi-pack. The mean hematocrit of the 
fractionated P-UCB products fulfilled product release requirements of standard pedi-packs. 
However, residual WBC and platelet counts in the P-UCB products were significantly higher as 
compared to pre-storage filtered pedi-packs19 (Tables 1 and 2), indicating that the centrifugation 
method aiming to remove the buffy-coat with a low loss of RBC, in fact removed few WBCs 
and platelets. Hemolysis rates after 14 days of storage maintained below the European limit of 
0.8% in 47% of the fractionated P-UCB units and below the American limit of 1.0% in 64% 
of the fractionated P-UCB units. After 21 storage days, 21% of the fractionated P-UCB product 
remained below 0.8% hemolysis and 30 % below 1.0% hemolysis. This indicates that these 
P-UCB products have a significant shorter shelf life, and frequent quality control is necessary 
if these products are used in clinical practice. The osmotic resistance, also an indicator of RBC 
fragility, did however not differ compared to the standard pedi-pack. This could suggest that 
mechanical stress, due to collection and/or processing, contributes more to the vulnerability of 
the cord blood red cells, rather than the fragility caused by swelling of the cells during storage.
The storage parameters from the whole blood P-UCB stored in CPDA-1 showed a better pH, 
lower hemolysis rate and lower lactate and potassium levels up to 21 days, when compared to 
the fractionated P-UCB. This may be the result of a lower RBC concentration, resulting in a more 
diluted cell product including nutrients, or that fetal RBC are less resistant to the mechanical stress 
of centrifugation. An advantage of whole blood storage is furthermore that it is a less laborious 
product and there is no RBC loss due to processing, while immature hematopoietic precursor 
cells, probably of benefit for the infant are not removed along with the leukocytes. The drawback 
is that stored whole blood showed variability in cell count and in the ratio CPDA-1: collected 
blood. Despite higher as well as lower ratio’s (median 1:6; range 1:4 to 1:8) compared to standard 
RBCC products ( anticoagulant: blood ratio - 1:7), the biochemical parameters maintained rather 
well up to 14-21 days of storage. However, in view of the lower and variable hematocrit and the 
high WBC content, it is more complicated to formulate quality parameters under blood bank 
conditions to use whole blood as an alternative for allogeneic RBC transfusion in premature 
infants. In comparison to leuko-reduced UCB products, the higher platelet and WBC count 
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and exert immunomodulation.20 The WBC in cord blood are more naïve and immature. As such 
it might be that these cells would have less potential to induce an immunosuppressive effect in 
a recipient as compared to allogeneic adult WBC. However, studies in adults showed that the 
clinical immunomodulatory effects on post transfusion infections and mortality of allogeneic and 
autologous leukocyte-(aggregate)-containing RBC products are controversial.21
Another drawback of using whole blood is the volume needed for appropriate microbial testing, 
in contrast to the waste plasma that was used after P-UCB fractionation. Although a volume of 
10 mL (even 20 mL) is optimal for bacterial culture18; the use of a smaller volume for microbial 
testing, for instance 1-2 mL blood, as is used in neonatal practice22; is acceptable in cord blood 
banking. In this study we observed a contamination rate of 7%, which is not at variance with 
collections for cord blood bank purposes.23 The pathogens that were identified are known to 
cause neonatal sepsis. In clinical practice an incubation period of 72 hours is kept before a blood 
culture is released, as this interval is sufficient to detect all clinically important pathogens.22 To 
prevent transfusion of a contaminated autologous product, a similar quarantine period could be 
held for product release, as most pathogens were found within this time interval.
A few studies on storage of cord blood RBC have been reported. Our P-UCB products stored in 
SAG-M had significant higher hemolysis rates after 35 days of storage compared to the studies 
by Garritsen et al, Brune et al and Widing et al, who also stored fractionated cord blood RBC 
in SAG-M. We found after 35 storage days, a mean hemolysis rate of 2.2 ± 0.67%, compared 
to their observations, respectively 1.1 ± 0.8%, 1.0 ± 0.7% and 0.9% (range 0.6-1.1). 3, 20,24 The 
pH in our SAG-M stored P-UCB was comparable to the centrifuged UCB products in the study 
by Garritsen et al and the filtrated UCB products in the study by Brune et al; 6.23 ± 0.16 versus 
respectively 6.1 ± 0.1 and 6.4 ± 0.1.3, 24 It may be that the premature RBC we collected may be 
more fragile after processing compared to RBC derived from full term cord blood, which generally 
contains a mean proportion of 30% HbA.25 Also the more fragile vessels in the preterm placenta 
may enhance RBC damage during UCB collection. 
Similarly, in whole blood P-UCB, hemolysis rate after 21 days of storage (0.79 ± 0.42%) exceeded 
the rate reported by Bifano et al after 28 days of storage of whole blood UCB collected at term 
(0.39 ± 0.05%), despite similar mean hematocrit and pH of our whole blood products compared 
to Bifano et al (Ht, 0.41 ± 0.08 L/L versus 0.41 ± 0.02 L/L and pH 6.67 ± 0.19 versus 6.51 ± 0.12, 
respectively).26
Brune et al have shown that filtration of UCB is also feasible, but RBC loss was only acceptable 
when at least 60 mL UCB was available.3 Premature placentas are smaller and several studies 
showed that the volume of UCB that can be collected is either related to gestational age or birth 
weight.1-2, 10, 27-28 Subsequently, the collected volumes are often less than 60 mL and would need 
adjusted filters to prevent significant RBC loss.
P-UCB products stored in either SAG-M or AS-3 showed a significant increase in hemolysis and 
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may be more vulnerable during storage. In particular, in SAG-M, this swelling was evident. (Table 
1) Osmotic fragility was, however, not different when compared to the standard pedi-pack. This 
vulnerability was not related to the degree of prematurity of the cord blood RBC.
In our clinical study we used the autologous P-UCB products stored in SAG-M for transfusion 
needs in the first 21 days after birth, under the condition that in case of product release between 
14 and 21 days of storage, hemolysis rate was < 0.8%. We showed that premature infants, in 
particular born before 30 weeks, could be treated with autologous UCB. The first transfusion 
needs in these infants were at median day 6 after birth (interquartile range 2-13, total range 
0-33).9 Considering the early transfusion needs of these premature infants, the shorter shelf life 
of autologous P-UCB would not be a major obstacle. 
In conclusion, P-UCB can be collected and RBC can be stored for approximately 14 – 21 days 
for autologous transfusion to premature infants. SAG-M or AS-3 as extended storage media for 
packed P-UCB cells had no advantage over whole blood storage on the quality of the RBC. P-UCB 
derived RBC seem more vulnerable for mechanical stress and/or storage at higher hematocrit in 
extended storage media. Although we showed that the use of autologous P-UCB red cells under 
blood bank qualifications, including viral testing, is cost-increasing9, the use of an autologous 
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Abstract
Background: To investigate the use of autologous red blood cells (RBC) derived from 
umbilical cord blood (UCB), as an alternative for allogeneic transfusions in premature infants 
admitted to a tertiary neonatal center.
Study design and Methods: UCB collection was performed at deliveries <32 weeks of 
gestation and processed into autologous RBC products. Premature infants requiring a RBC 
transfusion were randomized to an autologous or allogeneic product. Primary endpoint was 
a ≥50% reduction in allogeneic transfusion needs.
Results: 57% of the collections harvested enough volume (≥15mL) for processing. After 
processing, autologous products (≥10mL/kg) were available for 36% of the total study 
population and for 27% of the transfused infants, and could cover 58% (range 25-100%) 
of the transfusion needs within the 21 day product shelf life. 
Availability of autologous products depended most on the gestational age. Infants born 
between 24 and 28 weeks had the lowest availability (17%). All products however would 
be useful in view of their high transfusion needs. Availability was highest (48%) for the total 
group of infants born between 28 and 30 weeks. For 42% of the infants with transfusion 
needs in this group, autologous products were available. For the infants born between 30 
and 32 weeks, autologous products were available for 36% of the infants. Transfusion needs 
in this group were however much lower compared to the other gestational groups. 
Conclusion: Autologous RBC derived from UCB could not replace 50% of allogeneic 
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Introduction
The combination of an impaired erythropoietin response to anemia1-2, a shorter life span of 
hemoglobin F bearing erythrocytes and high phlebotomy losses2-4 results in a rapid decline in 
hemoglobin concentration in premature infants. More than 50% of these infants receive allogeneic 
blood transfusions early in life5-8, placing them at risk to presumed negative transfusion effects, 
such as transmittance of infectious agents and immune suppression.9 Umbilical cord blood (UCB) 
has often been suggested as a source for autologous transfusions. 10-12 Due to increasing use of 
cord blood for transplantation purposes, progress has been made on aseptic collection of UCB 
and processing of small bloodvolumes.13-15
Approximately 20 mL of UCB per kg of body weight can be harvested irrespective of birth 
weight13 and several infants have been transfused with autologous UCB safely.16-20 We previously 
investigated the potential coverage of autologous UCB in transfusion needs in a preclinical pilot 
study. This study suggested that UCB collection could be efficient for infants born between 29 
and 31 weeks of gestation.21 However, feasibility of the clinical application of autologous UCB 
remained to be investigated. To answer this question we performed a randomized clinical trial 
on the use of autologous cord blood red cell transfusions in premature infants. Our objective 
was to assess the practical and economical feasibility of autologous red blood cell transfusion 
and to investigate whether this application could result in a meaningful reduction in the use of 
allogeneic blood products. 
Materials and Methods
This double-blind randomized controlled trial was conducted between January 2005 and October 
2006 at the Leiden University Medical Center. The Medical Ethical Committee of the Leiden 
University Medical Centre approved the study protocol. This trial is registered as PUCB-trial 
ISRCTN01566504 (www.trialregister.nl).
Study population
Informed consent for study participation was obtained from (one of) the parents before delivery. 
Infants included were expected to be born before 32 weeks of gestation. According to Sanquin 
Blood bank guidelines for release of blood products22, maternal blood was tested for TPHA 
(treponema pallidum agglutination assay), anti-HBV, anti-HTLV, anti-HIV and anti-HCV antibodies 
and nucleic acid testing on HIV and HCV. In the weekends STAT testing was performed. Exclusion 
criteria were maternal antibodies against minor blood group antigens, hemoglobinopathies, 
maternal infections (HIV, HBV, HCV, HTLV, and syphilis), premature rupture of the membranes 
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Outcomes
Primary outcome parameter was a reduction of ≥50% in the use of allogeneic RBC products in the 
first 21 days after birth. Secondary outcome parameters were composite neonatal complications 
(bronchopulmonary dysplasia, retinopathy of prematurity, intraventricular hemorrhage), length of 
hospitalization, mortality and cost efficacy. 
UCB collection
A specially trained student team collected UCB. After a vaginal delivery, UCB was collected 
from the undelivered placenta. In case of a cesarean section, collection was performed after the 
placenta had been delivered. The collection system consisted of a 150 ml bag (Fresenius, Bad 
Homburg, Germany), a collection tubing system (Medisize, Hillegom, the Netherlands) with 5 
mL CPDA-1 (Baxter, Illinois, USA) and a syringe (Medisize, Hillegom, the Netherlands) with 5 mL 
CPDA-1. The umbilical cord was sterilized with iodine, the cord vein was punctured and UCB was 
collected by gravity. 
In monochorionic deliveries, UCB of both infants was collected in one bag for potential use for 
both infants. In dichorionic deliveries, two separate collection systems were used.
Blood processing by the Biosafe Sepax
A half mL whole blood was used to perform complete blood counts (Beckman Coulter Onyx, 
Miami, USA) and blood group typing (ABO-RhD, Diamed, Cressier, Switzerland). The remaining 
UCB was processed using a closed centrifuge circuit (Biosafe Sepax, Eysins, Switzerland). The 
procedure was started if total blood volume was at least 15 mL (excluding anti-coagulant). 
RBCs were separated from buffy-coat and plasma and adjusted with SAG-M to a red blood 
cell concentrate (RBCC) with a hematocrit between 55% and 65%. At least 10 mL of CPDA-1-
plasma was used for aerobic and anaerobic bacterial culturing (BacTalert, Durham, USA).23 UCB 
was not tested on contamination of maternal cells. 
All processing was done within 24 hours after collection. Autologous RBC in SAG-M with a final 
volume of ≥ 10mL per kg of body weight of the child were stored for 21 days at 2-6°. Upon 
request, products were released with a negative bacterial screening or if request was within 7 
days, with a negative culture up to date. The requested volume was transferred by sterile docking 
to a syringe (Medisize, Hillegom, the Netherlands). Autologous RBC products were not irradiated 
before transfusion, in contrast to the allogeneic donor products. All processes were performed 
under responsibility of the Sanquin Blood bank. Data regarding the product parameters (ATP, 2.3 
DPG, hemolysis and pH) will be published separately, but were within allowed limits for standard 
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Randomization
All patients with parental consent remained in the study, even if delivery occurred beyond 32 
weeks of gestation, to calculate total costs, including the extra costs for maternal virology. All 
live born infants were stratified according to gestational age, respectively 24-28, 28-30 and 30-
32 weeks and were registered as “premature experimental product” (PEP) patients, each with a 
unique study number. Upon request for a transfusion, the request form was marked with a PEP 
label and sent to the hospital blood transfusion service. An employee of the blood transfusion 
department drew a sealed envelope in the correct gestational age group. The infants were 
randomly assigned to a standard or an autologous product. If an autologous product was not 
available, a standard product (irradiated leukodepleted packed RBC in SAG-M with a hematocrit 
between 55% and 65%) was delivered. Both types of transfusion products were delivered in a 
syringe (Medisize, Hillegom, the Netherlands) to guarantee blinding of the clinical staff of the 
neonatal intensive care unit. 
Transfusion protocol
All infants were transfused according to the Dutch consensus guidelines for blood transfusion.24 
This is the same protocol that was used before start of the study. Transfusion volume according to 
the guideline was 10-15 mL per kg body weight. Allogeneic blood products were cross-matched 
with maternal serum and irradiated with 25 Gy. All transfusions were monitored and untoward 
reactions recorded, according to the hospital hemovigilance protocol. 
Clinical data collection
Information on gestational age, gender, Apgar scores, birth weight, umbilical arterial pH, method 
of delivery, singleton or multiple birth, CRIB II score (Clinical Risk Index for Babies)25, length of 
stay, mechanical ventilation and supplemental O2, were systematically registered in clinical request 
forms. Data on RBC transfusions ≤ 21 days and > 21 days after birth and neonatal complications 
(infections, use of antibiotics, retinopathy of prematurity26, bronchopulmonary dysplasia27, 
intraventricular hemorrhage) were obtained from the clinical charts and computerized medical 
records. Six months after birth, standardized information on medical complications was collected 
from the parents and from the secondary hospital after transfer from our center.
Sample size
We anticipated a reduction of ≥ 50% in the use of allogeneic RBC products to be worth the 
effort. To detect this reduction, with a power of 90% and α <0.05, two groups of 85 eligible 
transfused premature infants had to be included. Taking into account that ± 40% of the infants 
will not require any RBC transfusion and an expected mortality of 10-15%, a total of 325 infants 
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Statistical and data analysis
Data are presented as mean ± SD unless indicated otherwise. SPSS (version 12) for Windows 
was used for data analysis. Data were analyzed on an intention to treat basis and a secondary 
analysis was performed comparing autologous and allogeneic transfused neonates (according to 
treatment (ATT) analysis). Continuous variables were analyzed using independent t-tests. Other 
variables were analyzed using the Fisher’s exact test or non-parametric tests. A p-value <0.05 
was considered significant. Interim analysis was planned 1.5 year after the start of the study to 
confirm feasibility. 
Results 
UCB collection and processing
From January 2005 until September 2006, 427 women were admitted with imminent preterm 
delivery. One hundred and eighty women delivered in our hospital before 32 weeks of gestation. 
Three women were excluded directly post partum because of sepsis and one infant was excluded 
because of a congenital CMV infection. A total of 176 women (and 215 infants) met the study 
criteria for UCB collection (Figure 1). Within this group, 195 collections (from 132 singleton, 24 
mono- and 20 dichorionic deliveries, in one dichorionic delivery was only one collection due to 
intra-uterine mortality) were possible. In 176 cases an attempt was made to collect UCB (Table 
1). In 19 cases, there was no collection attempt due to several factors: student team not called 
in (n=12), umbilical cord torn off (n=3), placenta not intact (n=2) or reason not recorded (n=2). 
In 58 cases UCB was collected from an intra-uterine placenta and 98 times from an extra-uterine 
placenta (of which 76 after cesarean sections). In 19 cases an intra-uterine attempt was followed 
by an additional extra-uterine collection. In one case the record on the placenta was missing.
Of the 176 attempts, 101 (57.4%) harvested a UCB volume of ≥ 15 mL, suitable for Sepax 
processing. Total volumes, including CPDA-1, from the processed UCB in the three groups 
according to gestational age were respectively, 32 ± 7.7 mL (16 collections for 18 infants born 
between 24 and 28 weeks), 44 ± 27.4 mL (32 collections for 36 infants born between 28 and 30 
weeks) and 33 ± 13.3 mL (53 collections for 58 infants born between 30 and 32 weeks).
Harvested UCB (excluding anti-coagulant) was respectively 16 ± 15 mL/kg for infants with a birth 
weight <1000g; 18 ± 18 mL/kg for infants weighing between 1000-1250g and 20 ± 23 mL/kg 
for infants with a birth weight >1250g. Collected UCB volume was not well correlated with birth 
weight (r2=0.24). 
Thirty-four blood processing procedures did not result in an approved autologous product 
(technical failure n=4; final volume too small n=27; other reasons n=3). In total 67 autologous 
products remained (66.3%, of 101) of which three were withdrawn due to a positive bacterial 
culture (Coagulase-negative staphylococci n=2, Gram-negative rods n=1). All three cultures 
were positive within 24 hours. Thus after processing and quality control, 64 suitable autologous 
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Admitted for imminent delivery
N=427
Preterm delivery 32-36 wks N=125
Term delivery N=11
No informed consent N=45
Language barrier N=6
Blood group antagonism N=15
No delivery in this hospital N=45
Exclusion <32 wks
Maternal exclusion post partum N=3
Neonatal exclusion N=1
Delivered <32 wks N=176
Premature infants
with RBC Tx <21 days N=94
Incorrect not randomized N=27
1st Tx >21 days N=5
1st Tx after transfer to another
hospital N=27
Did not require any Tx N=89
Allocated to
autologous RBC products N=35
Allocated to















Figure 1: Flow chart – Patient Selection and Randomization scheme
Abbreviations: Tx: transfusion; ITT: intention to treat analysis; ATT: analysis according to transfusion; RBC: red 
blood cells
Table 1: Collected UCB and autologous RBCC processing
Total 24-28 weeks 28-30 weeks 30-32 weeks
Eligible infants born <32 weeks, n 215 45 72 98
Possible collections, n 195 41 64 90
No collection attempt, n 19 6 8 5
Collection attempts, n 176 35 56 85
UCB volume < 15 ml 75 (43%) 19 (54%) 24 (43%) 32 (38%)
UCB volume ≥ 15 ml & processed 101(57%) 16 (46%) 32 (57%) 53 (62%)
Autologous RBCC 
after processing
67 6 27 34
Products with a positive bacterial culture 3 0 0 3
Available autologous RBCC for the total 
study population
64 (36%) 6 (17%) 27 (48%) 31 (36%)
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Study population
In the study period, 215 infants were born before 32 weeks of gestation. Of these, five infants 
required RBC transfusions after 21 days, 27 received their first RBC transfusion after transfer 
to another hospital, and 89 infants required no transfusions at all. Ninety-four infants required 
transfusions within 21 days after birth and should have been randomized upon transfusion 
request. However 27 infants that met the entry criteria for randomization were missed (Figure 
1). For these infants, the standard RBC product, a pedi-pack of 65 ml irradiated leukodepleted 
packed RBC, was requested instead of a study product. In 9 of these cases the urgent transfusion 
indication within 24 hours after birth could have been the reason for these violations. For the 
other 18 protocol violations no specific cause was found. The 27 eligible, but non-randomized 
infants were compared with the two randomized groups to exclude possible confounding factors. 
All transfused patients remained included in the follow-up analysis, except one infant in the non-
randomized group who was lost to follow-up. Baseline demographic and clinical characteristics 
of all transfused patients were comparable (Table 2). Sixty-seven randomized infants remained, 
35 in the autologous arm and 32 in allogeneic arm (Figure 1). 
Table 2: Demographic and clinical variables of infants with transfusion indication ≤21days (n=94)






Birth weight, g, mean ± SD 1050 ± 357 1080 ± 317 1045 ± 358
Gestational age, weeks (range) 28+2 (25+0-31+5) 28+1 (25+2-31+6) 28+4 (25+3-31+5)
 -24-28 weeks, n 13 15 11
 -28-30 weeks, n 16 12 8
 -30-32 weeks, n 6 5 8
Male n, % 26 (74.3%)* 20 (62.5%)* 13 (48.1%)*
Live born infants
from twin pregnancy, n
15 12 11
- Monochorionic 8 8 6
- Dichorionic 7 4 5
Vaginal delivery/Cesarean section, n 18:17 21:11 14:13
AS 1’ median (IQR) 6 (4-8) 6 (4-7) 7 (3-8)
AS 5’ median (IQR) 8 (7-9) 8 (7-8) 8 (6-9)
Arterial pH, mean ± SD 7.27 ± 0.1 (n=21) 7.27 ± 0.1 (n=24) 7.28 ± 0.1 (n=18)
Hematocrit after birth %, mean ± SD 44 ± 7 41 ± 10 42 ± 6
Cord clamping time, sec, mean ± SD 7 ± 4 (n=28) 8 ± 4 (n=27) 8 ± 6 (n=22)
CRIB II, median (IQR) 9 (8-11) 10 (7-12) 10 (7-12)
Infants with supplemental O2, n 33 31 24
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Primary outcome
Transfusion triggers in the groups were comparable (Table 3). In the autologous group 2.5 ± 1.4 
RBC transfusions were given, 2.7 ± 2.2 transfusions in the allogeneic group (p=0.65) and the 
non-randomized group received 2.3 ± 1.6 standard pedi-packs. Intention to treat analysis showed 
that the total number of allogeneic transfusions given was 2.3 ± 1.4 in the autologous group and 
2.7 ± 2.2 transfusions in the allogeneic group. This mean difference of 0.4 allogeneic units (15%) 
in the autologous group was not significant (p=0.38). A reduction of allogenic RBC of 25% was 
present in infants born between 28 and 32 weeks of gestation (Table 3).







Total transfusions ≤21days 
Mean ± SD 
2.5 ± 1.4 2.7 ± 2.2 0.65 2.3 ± 1.6
-24-28 weeks 3.1 ± 1.1 3.1 ± 2.4 0.98 2.6 ± 1.0 
-28-30 weeks 2.5 ± 1.7 2.8 ± 2.2 0.74 2.0 ± 2.1
-30-32 weeks 1.3 ± 0.5 1.6 ± 0.9 0.58 2.4 ± 1.9
Pre hematocrit, % mean ± SD 35.5 ± 4.2 34.4 ± 6.4 0.99 36.1 ± 4.0
Post hematocrit, % mean ± SD 45.7 ± 6.1 44.5 ± 6.5 0.49 44.5 ± 5.2
1st transfusion, day, median (IQR) 4 (2-9) 3 (2-9) 0.25 4 (2-10)
Interval till next transfusion, days, median (IQR) 3 (2-6) 4 (2-8) 0.93 4 (2-6)
Allogeneic RBC
Allogeneic transfusions ≤21days
mean ± SD 
2.3 ± 1.4 2.7 ± 2.2 0.38
-24-28 weeks 3.0 ± 1.1 3.0 ± 2.4 1.00
-28-30 weeks 2.1 ± 1.6 2.8 ± 2.2 0.41
-30-32 weeks 1.2 ± 0.4 1.6 ± 0.9 0.36
Abbreviations: RBC: red blood cells; IQR: interquartile range
* autologous versus allogeneic group
Analysis according to autologous or allogeneic transfusion
Eight infants (23%) in the autologous group received the allocated product. For 27 (77%) 
infants an autologous product was not available. One infant in the allogeneic group received 
erroneously an autologous product. After transfusion of the autologous RBC products (n=9) 
the average hematocrit increase was 9.8% ± 5.5 %, comparable with the increase after an 
allogeneic transfusion of 10% ± 5.2 %. Median interval until the next transfusion in these infants 
was 3 days, comparable to the infants who only received allogeneic products. For two infants 
the available autologous RBC volume only covered 1 of the 4 transfusions they required in the 
first 21 days. In three infants available autologous RBC covered half of the required transfusions. 
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Because the study was randomized, 11 autologous products were available for infants assigned 
to allogeneic RBC and 6 products for non-randomized infants. The potential transfusion coverage 
of these products was estimated. If this had not been a randomized study, the available products 
would have covered 58% (range 25-100%) of the transfusion needs ≤ 21 days per infant (Table 
5).
Table 4: Transfused autologous RBC products and reduction in allogeneic transfusion








1 (24-28 weeks) 4 1 3 25%
2 (24-28 weeks) 2 1 1 50%
3 (28-30 weeks) 4 1 3 25%
4 (28-30 weeks) 2 1 1 50%
5 (28-30 weeks) 2 1 1 50%
6 (28-30 weeks) 2 1 1 50%
7 (28-30 weeks) 1 1 0 100%
8 (28-30 weeks) 1 1 0 100%
9 (30-32 weeks) 1 1 0 100%
Pre hematocrit, % mean ± SD 37.5 ± 5.2 36.0 ± 6.0 39.0 ± 4.0
Post hematocrit, % mean ± SD 46.5 ± 7.3 45.8 ± 8.3 47.2 ± 6.5
Abbreviations: Tx: transfusion; Autol: autologous; Allog: allogeneic, IQR: interquartile range
Table 5: Premature infants with available autologous RBC product in relation to the actually received 
transfusions
Stratum Tx needs
≤21 days, n 
Infants, n Autologous RBC 
ml/kg, mean ± SD
Coverage in 
Tx needs (%) 
24-28 weeks No tx 0 - -
1 tx 1 14 ± 0 100%
2 tx 2 13 ± 3 50%
>2 tx 3 11 ± 3 25-33%1
28-30 weeks No tx 12 16 ± 4 -
1 tx 7 27 ± 12 100%
2 tx 5 18 ± 8 50-100%2
>2 tx 3 30 ± 11 25-71%3
30-32 weeks No tx 27 17 ± 8 -
1 tx 3 19 ± 9 100%
2 tx 1 11 ± 0 50%
>2 tx 0 - -
Abbreviation: Tx: transfusion
1: 2 infants required 4 transfusions and 1 required 3 transfusions; coverage was respectively 25% and 33%
2: 4 infants with 50% coverage, 1 with 100%
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Secondary outcomes
Clinical outcome variables are shown in Table 6. Length of stay was registered in our center. 
Neonatal complications were registered during the complete hospital stay and the six-month 
follow-up period. The most unequally distributed variable in intention to treat analysis was length 
of stay (p=0.19), in favor of the allogeneic group and the composite mortality and morbidity 
(p=0.20) in analysis according to transfusion, in favor of the autologous transfused infants. 
Analysis of the outcome variables showed no significant differences between the groups.













and mortality, n, %
27 (77%) 24 (75%) 5 (56%)§ 46 (79%)§ 19 (70%)
Mortality n 3 (9%) 4 (13%) 0 (0%) 7 (12%) 3 (11%)
IVH n 10 (29%) 14 (44%) 2 (22%) 22 (38%) 9 (33%)
  ≥ grade 3 4 (11%) 4 (13%) 0 (0%) 8 (14%) 1 (4%)
ROP n 8 (23%) 5 (16%) 1 (11%) 12 (21%) 2 (7%)
  ≥ grade 3 1(3%) 1 (3%) 0 (0%) 2 (3%) 1 (4%)
BPD n 20 (57%) 10 (31%) 4 (44%) 26 (45%) 14 (52%)
  ≥ grade 2 11 (31%) 5 (16%) 1 (11%) 15 (26%) 6 (22%)
Length of stay,
  Median (IQR) days
30 (15-48)* 23 (13-39)* 30 (14-37) 28 (15-44) 21 (9-48)
in NICU 19 (14-30) 20 (10-30) 18 (11-31) 20 (11-29) 16 (8-30)
ITT: intention to treat analysis; ATT: according to treatment; Autol: autologous; Allog: allogeneic. *: most 
unequally distributed parameter in ITT analysis, p=0.19
§: most unequally distributed parameter in ATT analysis, p=0.20
Collection and Production efficacy
Overall successful UCB collection rate (≥ 15ml blood excluding anti-coagulance) was low (57%). 
Most of the collections were performed from an extra-uterine placenta. Analysis of harvested 
volume per collection method showed that collections from an intrauterine placenta resulted 
in higher UCB volumes (37.7 ± 20.2 ml) than collections from an extra-uterine placenta (30.6 ± 
22.1 ml). Hence, the proportion processed UCBs after an intra-uterine collection was larger. We 
also analyzed production efficacy of the Sepax device. Of the 101 successful UCB collections, 
64 autologous products remained after processing, mainly because of loss of RBC during the 
procedure. Efficacy per group was lowest in the 24 and 28 wks group, 16 productions resulted in 
only 6 RBCC with the required volume and hematocrit. However, each of these infants required 
transfusions. Processing of the UCBs from the 30 and 32 week group resulted in the highest 
number of products, but as the infants in this group had much lower transfusion needs, most of 
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born between 28-30 weeks. In particular, 69% of the intrauterine collections in this group were 
large enough for processing to red cell concentrates and resulted all in autologous products. 
More than half of the available products in this group were intended for infants with transfusion 
needs and could cover approximately 75% of the transfusion needs in this group (Table 5). 
Estimation of costs
Maternal virology testing was performed for 202 cases. For 26 cases testing was performed, 
but the delivery occurred beyond 32 weeks. In 18 cases UCB was processed in the weekend 
for which STAT testing was performed, resulting in a huge increase of the total costs. The costs 
for UCB collection disposables were made for 176 cases, the costs for Sepax processing for 101 
cases and the costs for quality control for 67 products. Ultimately the direct cost for 25 indicated 
RBC products were almost 15 times higher than to the costs of a standard pedi-pack (Table 7). 
Without STAT testing, the costs would be 6.5 times higher. 
Table 7: Autologous RBCC cost estimation
N € per unit Total costs
Maternal virology (regular) 202 € 15.50 € 3.131
STAT maternal virology (weekends) 18 € 1.330 € 23.940
UCB collection disposables 176 € 14.17 € 2.494
Sepax kit for processing 101 € 117.09 € 11.826
Quality control (ABO-RhD, BacTalert) 67 € 7.31 € 490
Available autologous products 64 € 654
Cost per indicated product 25 € 1.675
Cost per indicated product (excluded STAT) 25 € 729
Standard pedi-pack, irradiated € 114
RBCC: red blood cell concentrate
Interim analysis
Interim analysis revealed low availability of autologous products due to a low number of successful 
UCB collections. This availability of < 40 % autologous products for all premature infants with 
collected UCB would preclude that the primary endpoint of a reduction of at least 50% in use 
of allogeneic RBC products would be attainable. Therefore we decided to stop enrollment in 
October 2006 after inclusion of 215 infants and 94 transfused infants.
Discussion
In this clinical trial we collected UCB after premature deliveries < 32 weeks and randomized 
premature infants who required a RBC transfusion to either an autologous or allogeneic product. 








































A clinical study on the feasibility of autologous cord blood transfusion for anemia of prematurity  |  107
7
worth the effort. Interim analysis revealed that for 27% of the transfused premature infants 
an autologous RBC product was available for at least one transfusion. Therefore this trial was 
stopped prematurely. 
Eight out of 35 patients received autologous RBC in the group assigned to autologous products. 
Possible clinical benefits of these autologous transfusions could therefore not be evaluated, 
although post-transfusion hematocrit increment, interval until next transfusion, incidence 
of adverse events and composite neonatal complications were not at variance. This was in 
accordance with the results observed by other groups.17-20 Unfortunately, 27 infants were not 
randomized. This high number of protocol violations can not be fully explained. However, analysis 
of the non-randomized infants showed comparable demographics and outcome, suggesting no 
selection bias.
Our collection methods resulted in 101 UCBs that could be processed, of which only 25 available 
products were intended for transfused infants. This implies that for each effective product three 
extra products were made unnecessary. Considering all products would have been used for 
patients with a transfusion indication (in case of a non-randomized study), 21 of the 25 products 
would have been large enough to cover at least 50 % of the transfusion needs per infant in the 
first 21 days after birth.
Despite the lower number of successful UCB collections for the infants born between 24 and 28 
weeks, almost every available product would be useful, in view of the large number of infants 
(87%) with transfusion needs (39 out of 45). For the infants born between 28 and 30 weeks, 
UCB collection volumes were more often sufficient for processing. In this group of infants, 50% 
(36 out of 72) had transfusion needs. UCB collections for the infants born between 30 and 32 
weeks were most successful according to our definition of ≥ 15ml whole blood. After processing 
however, a smaller number of products remained available. In addition, transfusion needs in this 
group were much lower compared to the other gestational groups (Tables 1 and 2). Taken this all 
together, UCB collection and autologous RBCC production was most efficient for the infants born 
between 28 and 30 weeks compared to the other gestational groups. In this group autologous 
RBC was available for 42% of the infants that required transfusions. Harvested UCB was not 
enough to cover the transfusion needs of the smallest infants and the autologous products made 
for infants born between 30 and 32 weeks remained unused due to lower transfusion needs. 
Some possible improvements of efficacy need to be considered. Only 57% of all collection 
attempts resulted in a UCB volume large enough for Sepax processing. Most of the successful 
collections were harvested from an intrauterine placenta. Restriction of UCB collection to only 
intrauterine harvesting28 would increase production efficacy by 25%. In addition, this resulted 
for infants born between 24 and 28 weeks, in a 10% lower RBC recovery compared to the 
other processed UCBs, because of relative higher cell losses in these smaller collections (data 
not shown). RBC separation by filtration has been described as an alternative.29-30 However; the 
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regular maternal virology testing instead of expensive STAT testing can reduce the costs. In this 
study, the release of 18% of the UCB collections suitable for Sepax processing would be delayed 
for a maximum of 72 hours.
For future exploration of the possible clinical effects of autologous cord blood, UCB harvesting 
must be more efficient. Additional placental perfusion with heparinized saline after UCB collection 
has been described as an effective method for enlarging the total collected volume.31 Whether 
this method is also useful in the smaller and more fragile placentas after premature deliveries 
remains to be investigated. The restriction to infants born before 30 weeks of gestation, the 
use of intrauterine collections only (also after cesarean sections) and a processing procedure 
with higher red cell recovery could result in higher volumes and available products expecting to 
cover > 50% of the transfusion needs. Another approach of autologous transfusion is placental 
transfusion by delayed cord clamping.32-36 Recent studies show that delayed cord clamping is 
associated with reduced transfusion needs and a lower risk of IVH in premature infants.32, 35 
However, the described time range of delayed clamping was broad and varied from 30 till 120 
seconds.32 Although the results seem promising, it is desirable that they are confirmed by larger 
studies with a uniform definition and method of delayed cord clamping, in particular in critically 
ill children with a low Apgar score and a high risk of transfusion probability.21 
In conclusion, autologous RBC derived from UCB could replace allogeneic transfusions for 27% 
of the infants in need of transfusions. Whether an autologous product was available for an infant 
with transfusion needs depended most on the gestational age. UCB collection and processing 
for infants born between 28 and 30 weeks was most efficient. In this trial a small number of 
autologous RBCC were actually transfused, therefore no clinical benefits could be determined. 
Whether premature infants may benefit clinically from autologous blood remains a question 
unanswered at this moment. 
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Abstract
Background: Autologous cord blood (CB) red blood cells (RBCs) can partly substitute 
transfusion needs in premature infants suffering from anemia. To explore whether expanded 
CB cells could provide additional autologous cells suitable for transfusion, we set up a simple 
one-step protocol to expand premature CB cells.
Study design and methods: CB buffy coat cells and isolated CD34 positive (CD34pos) cells 
from premature and full-term CB and adult blood were tested with several combinations 
of growth factors while omitting xenogeneic proteins from the culture medium. Cell 
differentiation was analyzed serially during 21 days using flow cytometry, progenitor assays, 
and high performance liquid chromatography.
Results: Expanded CB buffy coat cells resulted in a threefold higher number of erythroblasts 
than the isolated CD34poscells. However, the RBCs contaminating the buffy coat remained 
present during the culture with uncertain quality. Premature and full-term CB CD34poscells had 
similar fold expansion capacity and erythroid differentiation. With the use of interleukin-3, 
stem cell factor, and erythropoietin, the fold increases of all CD34poscell sources were similar: 
CB 3942 ± 1554, adult peripheral mobilized blood 4702 ± 1826, and bone marrow (BM) 
4143 ± 1908. The proportion of CD235a expression indicating erythroblast presence on Day 
21 was slightly higher in the adult CD34poscell sources: peripheral blood stem cells (96.7 ± 
0.8%) and BM (98.9 ± 0.5%) compared to CB (87.7 ± 2.7%; p = 0.002). We were not able 
to induce further erythroid maturation in vitro.
Conclusion: This explorative study showed that fairly pure autologous erythroid expanded 
cell populations could be obtained by a simple culture method, which should be optimized. 
Future challenges comprise obtaining ex vivo enucleation of RBCs with the use of a minimal 
manipulating approach, which can add up to autologous RBCs derived from CB in the 
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Introduction
Potentially deleterious effects of allogeneic red blood cell (RBC) transfusions have led to the 
development of alternatives for RBC transfusion. Explored alternatives are the use of hemoglobin 
(Hb)-based oxygen carriers, recombinant human erythropoietin (EPO), and intra- or postoperative 
RBC salvage. For the treatment of anemia of prematurity these options are however no suitable 
alternatives.1-5 Currently, ex vivo expansion of CD34positive (CD34pos) hematopoietic stem cells 
derived from adult blood or cord blood (CB) embodies the center of research on transfusion 
alternatives. Clinical-grade RBCs have been generated ex vivo, and also the use of expanded 
erythroblasts as an alternative transfusion product has been suggested.6-12 Clinical application of 
these expanded cells is, however, still held back due to the high costs, the complex production 
process, and the presence of xenogeneic material in the culture medium.12 Alongside the 
potential use of ex vivo expanded RBCs for allogeneic transfusion purposes, these cells could 
also serve for autologous transfusions for patients with a high probability of transfusion needs, 
that is, premature infants suffering from anemia of prematurity.13,14 A therapeutic allogeneic 
RBC transfusion for adults contains approximately 2 ± 1012 RBCs preserved in 350 mL of storage 
medium. Premature infants receive, depending on the hospital transfusion practice, 10 to 20 mL of 
RBC product per kg of body weight per transfusion. Extremely low birth weight infants weighing 
less than 1000 g are most often in need of transfusions. For these infants approximately 5x1010 
to 10x1010 RBCs would be enough for a transfusion. We previously showed that autologous RBCs 
could be harvested from CB collected after premature birth and, if successful, could cover up to 
58% of the transfusion needs.15 These premature CB-derived RBC transfusion products had a 
shorter shelf life (maximally 21 days) compared to adult RBCs, which can be stored for 35 days.16 
To obtain RBCs, the premature CB was buffy coat depleted by centrifugation and the removed 
buffy coats contained approximately 40% of the white blood cells (WBCs). We evaluated whether 
this WBC fraction or the isolated CD34pos cells could provide additional expanded autologous 
RBCs. We aimed to set up a simple one-step culture protocol using only human proteins and 
recombinant human cytokines in the culture medium. In view of the practical transfusion needs 
of premature infants, we focused on the cultured cells that could be obtained within 21 days of 
expansion, which could theoretically supplement autologous CB RBCs, which have a shelf life 
up to 21 days.16 To test the efficiency and efficacy of this culture protocol, we compared both 
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Material and methods
Cell sources
Premature CB units were obtained after parental consent as part of our prospective clinical study.15 
CB units from full-term deliveries were obtained from the Umbilical Cord Blood Bank Leiden from 
donors who consented for experimental use of the CB. Mobilized peripheral blood stem cell 
(PBSC) samples were obtained from healthy adult donors. Before donation, patient consent was 
obtained for experimental use of a small part of the collection for research (approx. 2%). Adult 
BM samples were obtained from Stem Cell Technologies, Grenoble, France.
Cell isolation and culture medium
Buffy coat preparation
To produce a transfusion product from premature CB, the autologous RBCs and buffy coat were 
separated by centrifugation.16 The recovery of autologous CB RBCs was 75 ± 8%. Consequently, 
the premature CB buffy coats contained a relatively large RBC fraction. Further RBC depletion 
from the buffy coat by hydroxyethyl starch (HES) sedimentation (ratio 1:4, HES:blood) and 
centrifugation at 50 ± g for 10 minutes at room temperature resulted in a further RBC reduction 
of 45 ± 18%. The remaining buffy coat fraction after HES sedimentation was washed with 
phosphate-buffered saline (PBS; Hospital Pharmacy LUMC, Leiden, the Netherlands) and 500,000 
total nucleated cells (TNCs) per well were seeded on 24-well culture plates.
CD34pos cell isolation
Mononuclear cells (MNCs) were separated by a Ficoll-Isopaque gradient (1.079 g/cm3; Hospital 
Pharmacy LUMC) centrifuged and enriched in CD34pos cells by using columns (MiniMACS,Miltenyi 
Biotec, Bergisch Gladbach, Germany). Purity of the enriched cells was 77 to at least 95%; 50,000 
CD34pos cells were seeded per well.
Culture medium and growth factors
The HES buffy coat fraction and the isolated CD34pos cells were incubated at 37°C and 5% 
CO2 humidified atmosphere for 21 days. The culture medium consisted of Iscove’s modified 
Dulbecco’s medium (Invitrogen, Carlsbad, CA), supplemented with 20% human AB-citrated 
plasma (Sanquin Blood Bank South West, Rotterdam, the Netherlands), 0.165 mg/mL CaCl2 
(Sigma, Steinheim, Germany), 1% penicillin-streptomycin (Invitrogen), 0.34% human serum 
albumin (Sanquin Blood Bank, Amsterdam, the Netherlands), 10 U/mL heparin (Hospital Pharmacy 
LUMC), 0.5 mg/mL human transferring (Sigma), 0.05 mmol/L 2b-mercaptoethanol (Sigma), and 
0.001 mol/L dexamethasone (Hospital Pharmacy LUMC). Cells were cultured in presence of 
several combinations of recombinant human 3 ng/mL thrombopoietin (TPO; KIRIN Brewery Co. 
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IL), or/and 10 ng/mL recombinant human interleukin-3 (IL-3; Peprotech, London, UK), as early 
acting growth factors, in combination with 4 IU/mL human recombinant EPO (Eprex, Janssen-
Cilag, Tilburg, the Netherlands). Half of the medium was refreshed at least once weekly or more 
often if cell proliferation increased. Both TPO and IL-3 were removed by washing after 6 days of 
culture. SCF and EPO were present during the entire 21-day culture period. The cultured cells 
were harvested on Days 4, 7, 10, 14, and 21. TNCs were counted on an automated blood cell 
counter (AcT 10 cell analyzer, Beckman Coulter, Woerden, the Netherlands). Expansion rate was 
calculated as follows: harvested TNCs, divided by the original number of seeded cells per well and 
corrected for the dilution factor for well transfer.
Induction of enucleation
To induce further differentiation and maturation of the expanded erythroblasts, we added 
thyroid hormone and insulin in the last week of culture.17-19 CD34pos CB cells were cultured 
during 10 days in the standard medium with IL-3, SCF, and EPO to induce erythroid expansion. 
On Day 10 the expanded cells were washed with PBS and reseeded in the standard medium 
without dexamethasone and additionally supplemented with 10 mg/mL insulin (Sigma-Aldrich, 
Zwijndrecht, the Netherlands) and 1 mmol/L thyroid hormone (T3; Sigma-Aldrich). The culture 
media of these cells were refreshed every other day. On Day 17 all wells were harvested for 
counting, phenotypic analysis, and cell smear preparation.
Phenotypic analysis
After being harvested and counted, the expanded cells were both washed and resuspended 
in PBS. The cells were incubated with fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-
conjugated antibodies for 20 minutes at room temperature and resuspended in PBS before 
measurement. Anti-CD45-FITC, anti-CD34-PE, anti-CD14-FITC, anti-CD15-PE, anti-CD62p-FITC, 
anti-CD41-PE, anti-CD34-FITC, anti-CD71-PE, anti-CD36-FITC, 7-aminoactinomycin D (Beckman 
Coulter), and CD235a (glycophorin A)-PE (Dako, Glostrup, Denmark) were used for analysis. 
Controls were isotype FITC and PE antibodies.
Nucleated RBCs (NRBCs) were enumerated by flow cytometry using propidium iodide and CD45-
FITC identified cells with a low forward and side scatter.20 All analyses were performed on a flow 
cytometer (FC 500, Beckman Coulter).
Colony-forming assay
Colony-forming unit (CFU) and erythroid burst-forming unit (BFU-E) progenitors were assayed 
in methylcellulose cultures (Methocult GF H4434, Stem Cell Technologies) on Day 0 and after 
7, 10, 14, and 21 days of ex vivo expansion. Cell concentrations of 0.32x104/mL on Day 0; 
0.32x105/mL on Day 7; and 0.32 x106/mL on Days 10, 14, and 21 were seeded. The cultures were 
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Unless otherwise specified, all erythroid colonies (BFU-E; CFU-granulocyte, erythrocyte; CFU-
megakaryocyte, erythrocyte; and CFU-granulocyte, erythrocyte, monocyte, megakaryocyte) were 
combined and counted as total erythroid colony formation expressed per 103 plated (expanded) 
cells.
Cell morphology
Cell morphology was analyzed on Days 17 and 21 on smears of the expanded cells. The smears 
were stained with May-Grunwald-Giemsa. Photographs were made with a digital camera 
(AxioCam MRc5, Zeiss, Gottingen, Germany), enlargement 100 ± /1.30 oil, ∞/0.17.
Hb analysis
Harvested cells were washed with NaCl 0.9% and kept at minus 80°C until processing. The 
separation by reversed phase high-performance liquid chromatography (HPLC) of the globin chains 
was performed with HPLC (AKTA Purifier 100, GE Healthcare Europe, Diegem, Belgium) with a 
sample injector and a variable UV detector operating at 215 nm. A LiChrospher 100 RP-8 column 
(VWR, Amsterdam, the Netherlands) was used and elution was obtained in a linear gradient of 
25 column volumes of acetonitrile, methanol, NaCl in ultrapure water (milliQ, Millipore Corp., 
Billerica, MA) at a flow rate of 0.8 mL/ min. The gradient started with 30% Solvent B (acetonitrile, 
methanol, 0.155 mol/L NaCl 68:4:28) and 70% Solvent A (acetonitrile, methanol, 0.077 mol/L 
NaCl 26:33:41) and ended with 55% Solvent B. 
Statistical analysis
Data are presented as mean ± SD from generally three separate experiments unless indicated 
otherwise. Computer software (SPSS for Windows, Version 18, Chicago, IL) was used for data 
analysis. Continuous variables were analyzed using independent t tests or one-way analysis of 
variance (ANOVA) for differences between more than two groups. Bonferroni correction was 
used to correct for multiple testing if applicable. A p-value of less than 0.05 was considered 
significant.
Results
Premature CB cells after fractionation
After processing of the autologous CB products as described in our earlier clinical study, 
approximately 40% of the WBCs were removed by buffy coat depletion. The premature CB RBCs 
had a mean cell volume of 117 ± 5 fL. The products had hematocrit levels of 0.60 ± 0.05 L/L and 
contained a median of 5.1 ± 109 CB RBCs/mL (range, 3.6x109- 6.6x109/mL).16 The absolute RBC 
number per product was (median) 10.8x1010 (range, 2.8x1010- 3.5x1011). The residual buffy coats 
(n = 10) contained a median of 1.9x108 TNCs (range, 2.4x107-6.8x108) and a median of 2.5x106 
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Expansion of premature CB buffy coats
Expansion of the premature CB buffy coat HES fraction was performed with the use of SCF and 
EPO (n = 3). Cells expressing both CD36 and CD235a could be distinguished from the native RBCs 
that were present at the start of the culture. After 21 days, the mean fold TNC increase was 48.3 
± 16.8. Total CD235ahigh expression on Day 21 was 91.4 ± 9.6%, of which a minor proportion of 
5.4 ± 7% coexpressed CD36high (indicative of basophilic or polychromatic erythroblasts). The major 
proportion of these cells were CD36negCD235ahigh (indicative of polychromatic or orthochromatic 
erythroblasts). CD71 (transferrin receptor) expression was 80.7 ± 16%. The fold increase of 
CD34pos fractions from the premature CB buffy coats with SCF and EPO was 1324 ± 1295, with 
total CD235ahigh expression of 92.7 ± 5.6% on Day 21 of which 13 ± 2.1% coexpressed CD36high. 
Total CD71 expression was 96.7 ± 1.5%. Thus the buffy coat HES fractions yielded approximately 
three times more erythroblasts than the CD34pos fractions without obvious differences in purity 
and erythroblast maturation.
Premature and full-term CD34pos CB cells
We then compared CD34pos fractions from premature and full-term CB. Addition of SCF and EPO 
to the culture medium resulted in a higher expansion rate compared to TPO and EPO (p < 0.001). 
Premature and full-term CB had a similar fold increase. Also the appearance of erythroid cell 
markers was similar (Fig. 1). SCF-EPO cultures had a higher fold increase with similar proportions 
of CD36highCD235ahigh cells and CD36low/negCD235ahigh cells, respectively, 19 ± 5.6% in full-term CB 
and 13 ± 2.0% in premature CB, and 75.7 ± 7.2% in full-term CB and 80 ± 6% in premature CB, 
respectively (n = 6 full-term CB vs. n = 3 premature CB). In the premature CB cultures expanded 
with SCF and EPO, we counted a similar amount of NRBCs per harvested well, respectively, 
1.5x106 ± 0.9x106 NRBCs in premature CB and 1.3x106 ± 1.2x106 NRBCs in full-term CB. Given 
the similar fold expansion rate and generation of erythroid cells in both premature and full-term 
CB cultures, full-term CB was used for subsequent experiments.
Growth factor combinations: erythroid cell expansion and differentiation
Addition of TPO to SCF and EPO did not result in a substantial synergistic effect, in contrast to 
supplementation of IL-3, which resulted in a higher expansion rate of full-term CB compared to 
the other combinations (one-way ANOVA for differences between the groups p = 0.04; Fig. 1). 
Erythroid marker expression in the tested growth factor combinations were almost similar. The 
TPO-EPO combination resulted in a higher percentage of CD41 positive cells (10.2 ± 2.6%) as 
well as in residual CD34pos cells after 21 days of culture compared to the other combinations. 
There was no difference in lineage negative cells (defined as CD235a/CD45-negative cells; Table 
1). Although statistically not different, the proportion of CD36highCD235ahigh cells in the IL-3-SCF-
EPO combination was higher, suggestive for less advanced erythroblast maturation. Expanded 
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± 3.2x106/well), and IL-3-SCF-EPO (5.9 x105 ± 4.5x105/well; one-way ANOVA for differences 
between the groups, p = 0.779; after correction for fold expansion, p = 0.545). Because of the 
optimal expansion rate of the TNCs, the combination IL-3-SCF-EPO was used for subsequent 
experiments to compare CB and adult CD34pos cell sources. Removal of dexamethasone and 
addition of insulin and thyroid hormone to the culture medium was compared to the standard 
medium. Fold expansion of the TNCs was similar, respectively, 192 ± 210 for standard and 188 
± 257 for the two-step method. NRBCs were respectively 7x105 ± 2.4x105/well for the standard 
medium and 6.6x105 ± 2.2x105/well for the two-step method. After correction for well passaging 
the NRBC yield was also similar. We observed small differences in erythroid surface marker 
expression. Total CD235a expression was, respectively, 97.7 ± 1.2% for standard and 99.4 ± 
0.3% for two-step method (p = 0.067). CD36high coexpression was, respectively, 11.7 ± 6% and 
3.8 ± 2.4% (p = 0.052), indicating more mature erythroid cells in the two-step method. Total 
CD71 expression was similar; 98.2 ± 0.6% in standard and 97.3 ± 1.7% in the two-step method. 
However, cell smears showed similar erythroid morphology without reticulocytes or RBCs in either 
of the cultures (not shown).









Fold expansion 47 ± 41 988 ± 842 802 ± 364 3942 ± 1554
CD36 pos-CD235a neg 11.4 ± 3.5 %* 4.4 ± 2 % 6.0 ± 1.7 % 9.4 ± 1.2 %
CD36 pos-CD235a pos 8.4 ± 6.3 % 17.6 ± 7.8 % 17 ± 10.4 % 37.2 ± 2.4 %
CD36 neg-CD235a pos 75.2 ± 8 % 76.2 ± 9.2 % 75.7 ± 11.5 %  50.6 ± 0.2 %
CD36 neg-CD235a neg 5.1 ± 5.9 % 1.8 ± 1.3 % 1.3 ± 1.2 % 2.8 ± 1.5 %
CD235aneg –CD45neg 5 ± 3.9 % 2.9 ± 1.1 % 2.7 ± 0.6 % 5.1 ± 0.8 %
CD71pos 86.7 ± 4.8 % 92 ± 5.3 % 92.3 ± 4.0 %  93 ± 0.9 %
CD41pos 10.2 ± 2.6 %† 0% 0.7 ± 1.1 %  0.2 ± 0.2 %
CD34pos 2.8 ± 1.6 % 0.3 ± 0.4 % 0.3 ± 0.6 % 0.6 ± 0.3 %
         
*: TPO-EPO compared SCF-EPO and SCF-TPO-EPO p=0.01 after correction for multiple testing. †: TPO-EPO 
compared to all other combinations p<0.001 after correction for multiple testing. 




























































Figure 1. Fold expansion of premature and term cord blood
Abbreviations: TPO: Thrombopoietin, EPO: erythropoietin, SCF: Stem Cell Factor; CB: cord blood, IL3: 
interleukin 3
Erythroblast formation from adult PBSC-, BM-, and CB-derived CD34pos cells
After 21 days of expansion with IL-3-SCF-EPO we observed similar fold expansion rates between 
the three CD34pos cell sources: 3942 ± 1554 fold for full-term CB, 4702 ± 1826 fold for mobilized 
PBSCs, and 4143 ± 1908 for BM (one-way ANOVA for differences between the groups, 
p = 0.82; Fig. 2). Erythroid total CD235a expression on Day 21 is depicted in Table 2. Adult CD34pos 
cell cultures were more purely erythroid compared to CB; CD235a expression was, respectively, 
87.7 ± 2.7% in CB, 96.7 ± 0.8% in mobilized PBSCs, and 98.9 ± 0.5% in BM (p = 0.002 
after correction for multiple testing). In the CB cultures there were more lineage-negative cells, 
depicted as both CD235a/CD45 negative, instead of remaining CD34pos cells. CD71 expression, 
indicative of proliferating cells, was higher in the adult cell cultures compared to the CB cultures 
(p = 0.032 after correction for multiple testing; Table 2). The development of CD235apos expression 
was plotted against CD36pos cell expression. In adult BM and PBSC cultures we observed earlier 
presence of CD36highCD235ahigh cells, indicative of basophilic and/or polychromatic erythroblast 
formation (Fig. 3). NRBC counts on Day 21 were 5.9x105 ± 4.5x105/well in CB, 9.4x105 ± 0.6x105/
well in mobilized PBSCs, and 2.6x106 ± 1.3x106/well in BM. After correction for the number of 
cell passages and fold expansion, the absolute NRBC numbers in the BM cultures were statistically 
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by CD14 and CD15 expression was similar: 2 ± 0.9% in CB, 0.7 ± 0.5% in mobilized PBSCs, and 






























Figure 2. Comparison of fold expansion of cord blood and adult blood
Abbreviations: EPO: erythropoietin, IL3: interleukin 3, SCF: Stem Cell Factor; CB: cord blood, PBSC: mobilized 
peripheral blood; BM: bone marrow 
Table 2: Cell surface marker expression after 21 days of expansion with IL3, SCF and EPO, in relation to adult 
(PBSC/BM) or CB derived CD34pos cell source
CB PBSC BM p-value
Fold expansion 3942 ± 1554 4702 ± 1826 4143 ± 1908 ns
CD36 pos-CD235a neg 9.4 ± 1.2 %* 2.7 ± 0.7 % 0.9 ± 0.5 % <0.001
CD36 pos-CD235a pos 37.2 ± 2.4 % 54.4 ± 11.2 % 48.2 ± 9.3 % ns
CD36 neg-CD235a pos  50.6 ± 0.2 % 42.4 ± 11.9 % 50.4 ± 9.4% ns
CD36 neg-CD235a neg 2.8 ± 1.5 %† 0.6 ± 0.1 % 0.3 ± 0.1 % 0.04
CD235aneg –CD45neg 5.1 ± 0.8 %‡ 1.0 ± 0.2 % 0.4 ± 0.1 % 0.002
CD71pos  93 ± 0.9 %§ 97.9 ± 1.5 % 96.8 ± 1.5 % 0.032
CD41pos  0.2 ± 0.2 % 0.1 ± 0.1 % 0.4 ± 0.2 % ns
CD34pos 0.6 ± 0.3 % 5.1 ± 4.2 % 3.3 ± 2.5 % ns
*: CB statistically significant different compared to both PBSC and BM after correction for multiple 
testing; †: CB statistically significant compared to BM after correction for multiple testing. ‡: CB statistically 
significant different compared to both PBSC and BM after correction for multiple testing; §: CB statistically 
significant different compared to both PBSC and BM after correction for multiple testing
Abbreviations: CB: cord blood, PBSC: mobilized peripheral blood; BM: bone marrow; EPO: erythropoietin, 
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Colony-forming capacity of expanded cells
The colony-forming capacity of the expanded adult and CB cells were measured on Days 7, 10, 
14, and 21 of culture. After 10 days of expansion only few CD34pos cells could be detected in the 
CB cultures (0.4 ± 0.4%), compared to PBSCs (8.2 ± 2%) and BM (21.5 ± 3%). Nevertheless, 
after 7 and 10 days of expansion, both the expanded adult and the CB cells were still able to form 
BFU-E, although between Day 7 and Day 10 the colony-forming capacity sharply declined. After 
Day 10 there were almost no colonies formed. The expanded BM cells were less able to form 
BFU-E colonies after 7 days of expansion compared to CB and PBSCs (Table 3).
Table 3: Colony forming capacity of expanded adult and cord blood cells
Material Colonies per 1000 seeded cells Days of culture
Day 0 Day 7 Day 10
CB Total HPC colonies 438 ± 13* 152 ± 4 13 ± 3*
Total Erythroid colonies 169 ± 18* 104 ± 31 4 ± 4
  BFU-E colonies 59 ± 22 91 ± 39 4 ± 3
PBSC Total HPC colonies 118 ± 119 120  ± 53 4  ± 3
Total Erythroid colonies 27 ± 33 79  ± 25 2  ± 2
  BFU-E colonies 25 ± 30 79 ± 25 2  ± 2
BM Total HPC colonies 138 ± 77 17 ± 4† 3 ± 4
Total Erythroid colonies 72 ± 46 11 ± 2† 3 ± 3
  BFU-E colonies 62 ± 38 11 ± 1‡ 3 ± 3
*CB significantly different compared to PBSC and BM (p<0.04) after correction for multiple testing; † BM 
significantly different compared to PBSC and CB (p<0.03) after correction for multiple testing; ‡BM significantly 
different compared to CB (p<0.03) after correction for multiple testing. 
Abbreviations and symbols: CB: cord blood; PBSC: mobilized peripheral blood; BM: bone marrow; HPC: 
hematopoietic progenitor cell colonies; BFU-E: erythroid burst forming unit; Total erythroid: BFU-E, CFU-GE, 
CFU-ME and CFU-GEMM
Hb analysis
On Days 11, 14, and 21, the globin chain expression was examined by reversed-phase HPLC. The 
HbA:HbF expression rates in the CB cultures were, respectively, 49:51 on Day 11, 37:63 on Day 
14, and 24:76 on Day 21. In the adult CD34pos cell cultures the HbA:HbF expression rates on Day 
21 were 82:18 for BM and 84:16 for PB.
Cell morphology
We observed several stages of erythropoiesis. The majority of the cells were polychromatic 
erythroblasts, but also basophilic and orthochromatic erythroblasts were present. We also 
detected a few proerythroblasts. Reticulocytes and mature RBCs were not detected. Besides the 
expected stages of erythropoiesis we also detected a trinuclear cell in one of the smears, which 
can be a sign of either dyserythropoiesis or stress erythropoiesis. The cell membrane of this last 






















































Figure 4. Erythroid progenitor cells after 21 days of expansion
A: pro-erythroblast
B: several basophilic erythroblasts
C: orthochromatic erythroblast
D: trinuclear cell 
Potential quantitative erythroblast formation after ex vivo expansion
The buffy coats contained an absolute number of 2.4 ± 107 to 6.8 ± 108 nucleated cells and 
contained an absolute range of 1.2 ± 105 to 1.1 ± 107 CD34pos cells (n = 10). With the use of the 
optimal combination of IL-3, SCF, and EPO, this would lead to a range of 4.8 ± 108 to 4.4 ± 1010 
expanded erythroblasts when isolated CD34pos cells from the premature buffy coats are cultured. 
Based on the threefold higher yield of erythroblasts when the buffy coat was used instead of 
CD34pos cells, this could imply approximately 5 ± 1010 cells if the premature buffy coats could have 
been cultured without RBC contamination.
Discussion
Current research on in vitro production of RBCs provides methods to expand adult or CB MNCs 
and CD34pos cells into mature RBCs suitable for transfusion.6-12 The use of expanded erythroblasts 
has also been mentioned as an alternative transfusion product, as these cells seem to mature in 
vivo when a suitable mouse model was used.21,22 In an earlier study we showed that autologous 
RBCs derived from premature CB could be used for transfusion purposes. This amount of harvested 
autologous RBCs is limited. The premature CB buffy coat that was removed during autologous RBC 
production contained CD34pos and other progenitor cells. We aimed for a simple one-step culture 
intended to obtain additional RBCs. Ideally these expanded autologous cells would be available 
within 14 to 21 days when the shelf life of CB RBCs had expired.16 Expansion of the premature 
CB buffy coat yielded three times more erythroblasts than CD34pos cells, confirming the results of 
van den Akker and colleagues.17 However, the CB buffy coats contained a relatively large amount 
of CB RBCs. During 21 days of culture these RBCs may have acquired “storage” lesions posing 
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our one-step protocol with CD34pos cells. In line with previous studies, the combination of IL-3, 
SCF, and EPO was most effective.11,23 Premature and full-term CB had similar expansion potential 
and erythroid marker appearance. The premature CB buffy coats contained a median of 2.5 ± 
106 CD34pos cells (range, 1.2x105-1.1x107). With the observed mean fold expansion rate of 3942 
± 1554, a range of 4.8x108 to 4.4x1010 (median, 1.2x1010) erythroblasts could be generated 
in theory. Only the maximum of this range would provide just enough RBCs for one neonatal 
transfusion for very low birth weight neonates. We were unable to induce further differentiation 
and enucleation of the CD36negCD71highCD235ahigh polychromatic erythroblasts by adjustment 
of the culture medium with insulin and thyroid hormones and removal of dexamethasone. It 
is possible either that a density purification step is essential for further differentiation of the 
erythroblasts or that our supplemented growth factor combination was still too simple.17,18 Adult 
PBSC-, BM-, and CB-derived CD34pos cells all had a similar fold increase. The adult cells had a 
more accelerated erythroid differentiation compared to CB (Fig. 3). Moreover, a higher residual 
lineage negative fraction remained in the CB cultures, whereas more CD34pos cells remained in 
adult cultures. Loss of CD34 expression, with maintenance of expansion depending on growth 
factors toward hematopoietic particular lineages, has been previously observed to be typical for 
CB.24 Myeloid cell presence was low in all cultures. All cultures finally consisted of greater than 
90% erythroid cells. The colony forming capacity was not diminished at least until up to 10 
culture days, indicating that in vivo erythroid proliferation and differentiation could be possible 
after 10 days of expansion. The increased HbF expression during culture was expected in view 
of the erythropoietic stress conditions present during culture and was also shown in the adult 
cultures.25 The cell smears at the end of the culture showed a few proerythroblasts and all stages 
of erythroblasts through normoblast. We did not observe reticulocytes or RBCs. We also observed 
signs of dyserythropoiesis or stress erythropoiesis, which may be explained due to the continuous 
drive to proliferate in the cultures. 
Recently the literature on ex vivo expansion of CD34pos and MNCs has been summarized, 
showing that MNCs from both adult and CB could generate on average 10 to 100 times more 
erythroblasts than the corresponding CD34pos cells.18 Compared to other studies, we generated 
a lower number of erythroblasts aiming for a single-step culture method suitable for standard 
blood bank conditions in closed systems. Only a minority of the studies, reviewed by Migliaccio 
and colleagues18 used xenofree medium. The fold increase varied between factors of 50 and 
1.106 depending on the cell source or growth factor combination used; enucleation rate was 
either not given or ranged between 30 and 100%.10,11,18,26 Baek and coworkers9 also used non 
xenogeneic proteins but these cells were cultured upon human mesenchymal stem cells. They 
reached approximately 104-fold increase with an enucleation rate of greater than 60%. The 
combination IL-3, SCF, and EPO was used in all of these studies and seems to be fundamental for 
ex vivo expansion.9-11,26 Furthermore, an extensive set of steroids and cytokines, addition of lipids 








































Exploring the use of expanded erythroid cells for autologous transfusion for anemia of prematurity  |  125
8
culture phases resulted in complex procedures.10,11,18,26 Of these, the highest fold expansion was 
reached by Miharada and coworkers10 who used vascular endothelial growth factor and insulin 
growth factor-2. With our approach, we did not reach a 100% CD235a positive cell population, 
in view of the remaining lineage negative cells. For autologous use, however, this is not an 
obstacle. Expanded erythroblasts have been suggested as an alternative for transfusion.12,27 Most 
in vivo mice models, however, are not all suitable for studying expanded human erythroblast 
maturation and enucleation, as human erythroid cells are removed by the mouse spleen.21,22,28 
Although the splenectomized NOD/SCID/ IL2Rgnull mice model seems more suitable for in vivo 
human erythroblast tracking, in this model human RBC counts in peripheral mouse blood also 
remained low. Alongside improving our culture method, our production process of autologous CB 
products should be adapted. During processing approximately 60% of the total WBCs remained 
in the RBC product16 and, vice versa a relatively large amount of autologous RBCs remained in the 
buffy coats. A better separation method, preferentially by filtration and recovery of WBCs from 
the filter29 would lead to a larger product for autologous transfusion and an increased proportion 
of nucleated cells suitable for ex vivo expansion.
Hence, next to salvage of CB RBCs to prepare an autologous transfusion product, we provide 
preliminary results indicating the potential use of the remaining progenitor cells to obtain an 
additional RBCs in the early neonatal period during which most transfusions are required. 
Despite apparently suboptimal harvest and culture conditions, our results suggest that it may be 
worthwhile to put effort in further optimization and generation of clinical-grade culture conditions 
and in vivo differentiation and functionality testing. It should be emphasized, however, that the 
expansion experiments we performed merely indicate the possible feasibility of this approach. 
Obviously, major hurdles must be overcome before ex vivo expanded CB cells can actually 
supplement autologous CB RBCs in the treatment of anemia of prematurity. The use of premature 
CB for autologous RBC transfusion purposes has been critically summarized.30 Nevertheless both 
our previous and current feasibility study suggest that complete avoidance of allogeneic RBC 
transfusions for anemia of prematurity may be in reach in the future when combining a more 
efficient RBC separation with a larger availability of residual CD34pos and progenitor cells that can 
be used for both transfusion and ex vivo expansion. Where there is a will, there will be a way. In 
our opinion, the full potential of premature CB for autologous use has not been fully explored yet 
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Premature infants are among the most frequently transfused patients. The number of 
administered red blood cell (RBC) transfusions is inversely related to gestational age; resulting 
in the most immature infants being exposed to the most RBC transfusions.1 Allogeneic RBC 
transfusions have been associated with a negative clinical outcome. A correlation between RBC 
transfusion and accompanying morbidity due to prematurity, such as intraventricular hemorrhage 
(IVH), retinopathy of prematurity, chronic lung disease and necrotizing enterocolitis (NEC), has 
been reported.2-7 In addition, RBC transfusion has been associated with increased respiratory 
support needs in neonates.8 An association between RBC transfusion and neonatal mortality 
has also been brought up. Although transfusion was stated to be an independent predictive risk 
factor, causality remains to be proven.9 RBC transfusion however as a co-factor which can worsen 
clinical outcome is not completely unlikely.10 During the last decades, transfusion guidelines have 
been implemented with more restrictive transfusion triggers, adjusted for postnatal age and 
cardio-respiratory condition. Use of these guidelines resulted in a significantly lower number 
of RBC transfusions administered to premature infants; without an increase in length of stay or 
morbidity.11-13 Although these guidelines have positive effects on donor exposure and risk for 
blood transmissible infectious diseases, these guidelines are more empirically based than evidence 
based. Consequently, uniformity in neonatal transfusion practice is still not within reach.14-16 
Recent clinical trials have provided some evidence that the use of restrictive transfusion triggers 
are feasible.17-19 Restrictive transfusion practice, according to the lower thresholds reported in 
these trials, did not have a significant impact on neonatal morbidity and mortality.20 
However, neonatal and in particular long-term outcome yielded controversial results depending 
on the postnatal age of evaluation. Restrictive triggers were associated with short term negative 
neurological sequelae including grade 3-4 IVH17 and liberal triggers were associated with a 
possible better neurodevelopment at the age of 18-21 months corrected age.21 In contrast, the 
infants in the liberal group showed a reduced brain volume at an average age of 12 years and 
the infants included in the restrictive group had better cognitive functions.22-23 These results 
should be interpreted with caution. For instance, the Bayley Scale for Infant Development Mental 
Development Index used 18-21 month after birth has a poor prognostic value for long term 
outcome.24 In addition, in an earlier study Cooke et al showed that there was no relation between 
cognitive function at the age of 12-13 years and perinatal brain damage.25 Consequently, the 
relation between neonatal transfusion practice and neuro-cognitive outcome still needs other 
well designed clinical trials with long follow-up. 
Alternative strategies in the treatment and prevention of anemia of prematurity, are the use of 
recombinant Human Erythropoietin (EPO), the use of micro-techniques to minimize phlebotomy 
losses and delayed cord clamping.26-32 Use of recombinant Human EPO for treatment of anemia 
of prematurity has shown to be ineffective with respect to blood sparing. 26-28 In contrast, 
minimizing blood losses for diagnostics and late cord clamping resulted in fewer administered 
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Late cord clamping was associated with more clinical benefits, including an improved circulatory 
stability, less IVH and a lower risk for NEC.30 The use of near infra red spectroscopy (NIRS) or 
doppler sonography to identify which infants are in need of transfusion showed promising 
results.33-34
In summary, the administration of allogeneic RBC transfusions to premature infants has been 
reduced during the past decade. Whereas the survival rate of premature infants has continued to 
improve, the clinical effects of allogeneic RBC transfusions on neonatal outcome are still under 
scrutiny over its possible impact on long term outcome. 
In this thesis, we analyzed RBC transfusion practice in two Dutch tertiary centers and its effects 
on neonatal outcome of premature infants born before 32 gestational weeks. Furthermore, we 
investigated the use of autologous umbilical cord blood (UCB) as an alternative for allogeneic 
RBC transfusions.
Neonatal transfusion practice in the Netherlands
In Chapter 2 we describe the implementation of the transfusion guideline, set up by the Dutch 
Institute for Health Care Improvement in 2004, in two neonatal intensive care units.35-36 Besides 
recommended transfusion triggers, a transfusion volume range of 10 to 15 ml/kg bodyweight 
was advised. In other guidelines a wider range of 10 to 20 ml/kg bodyweight is recommended.37 
The two tertiary neonatal centers in our study used the same transfusion triggers and the same 
RBC products but a different transfusion volume per kg bodyweight. 
The proportion of transfused infants was significantly different, 59% vs. 77%, surprisingly 
with the lowest percentage in the center using a smaller transfusion volume of 15 ml per kg 
bodyweight. In the younger infants born between 25 0/7 and 27 6/7 gestational weeks, we 
observed no differences, despite the difference in RBC transfusion volume, in the percentage 
of transfused patients and in transfusion events. The percentage of transfused infants born 
between 28 0/7 and 31 6/7 gestational weeks was significantly higher in the center using a larger 
transfusion volume (74% vs.49%). Transfusion with 20 ml per kg resulted in a mean reduction of 
one transfusion episode per infant. The higher percentage of transfused infants was associated 
with a higher pre-transfusion hematocrit in less premature infants, which suggests the use of 
different triggers based on interpretation of clinical indicators. A larger transfusion volume of 20 
ml per kg prolonged the interval until the next transfusion and could reduce donor exposure in 
infants born between a gestational age of 28 0/7 weeks and 31 6/7 weeks.36
On the other hand reduction of donor exposure is also obtainable by implementation of a 
pedipack reservation approach using the same donor for all transfusions until expiration date 
of 35 days. These differences in neonatal transfusion practice are not peculiar.15,38 To evaluate 
short and long term clinical effects of RBC transfusion; standardization of transfusion practice 
with regard to transfusion trigger, RBC product hematocrit and transfusion volume is crucial. 
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implementation of the care-givers perception in the transfusion trigger and on the other hand use 
of a computerized transfusion product ordering and monitoring.39-40 But also other parameters 
like heart rate, regional tissue oxygenation or blood flow velocity could be included in the decision 
to transfuse.33,41-42 Further studies are necessary to identify whether these advices can contribute 
to better compliance to the transfusion guideline.
Recently, the national Dutch transfusion guideline has been revised. Strategies attending a 
decrease in neonatal anemia such as late cord clamping and the use of micro-techniques for 
diagnostics to reduce the phlebotomy volumes, have been included in the transfusion guideline. 
Recommendations on transfusion triggers and transfusion volume have also been adjusted. The 
earlier recommendation to maintain an hemoglobin (Hb) level ≥ 8 mmol/l during the first 24 
hours has been abandoned. A low Hb level direct post-partum is caused by either acute blood 
loss or acute hemolysis due to i.e. rhesus antagonism. It is now recommended that the decision 
to transfuse RBCs within 24 hours after birth should be based on clinical grounds, rather than 
the Hb level at that moment. Transfusion of a higher volume per kg bodyweight (15ml/kg vs 
20ml/kg) did not lead to significant better outcome or reduction in transfusion episodes for 
premature neonates with the highest transfusion needs. Aiming to a more distinct guideline, the 
earlier recommended range (10-15ml/kg) in transfusion volume has been adjusted to 15 ml/kg 
bodyweight.43 
Transfusion effects on neonatal clinical outcome
The relation between RBC transfusion and clinical outcome has been studied in different ways. 
Earlier mentioned “trigger studies” investigated the safety of the transfusion threshold and 
related this to clinical outcome.17-19 Target studies, in which the efficacy and effects of the total 
administered RBC volume are investigated, are available in only a few studies with a small number 
of patients.44-46 
Short term clinical outcome
In our observational comparative study (Chapter 2) we evaluated the effect of the total 
administered RBC transfusion volume on short-term neonatal outcome, consisting of a composite 
of mortality, IVH, retinopathy of prematurity and chronic lung disease. Clinical neonatal outcome 
was similar, regardless of a higher proportion of transfused patients and a higher total amount 
of RBCs transfused in one of the centers and despite the difference in transfusion volume. This 
suggests that an absolute larger transfused RBC volume was not associated with a worse short-
term clinical outcome in the two cohorts studied.36 
To establish appropriate transfusion triggers and to estimate when to use which trigger in 
premature infants is extremely complex. Recent studies using NIRS to monitor tissue oxygen 
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and splanchic tissues.47-49 This technique could theoretically assist in evaluating the timing of 
a RBC transfusion to prevent hypoxia and to avoid possible transfusion related oxidative stress 
in premature infants. Early transfusions have been associated with the development of IVH.50-51 
RBC transfusion in the first week of life doubled the risk of worsening of grade 1 IVH.51 Late RBC 
transfusions have been related to the incidence of NEC.6,52 More studies investigating the causal 
relation between RBC transfusions; including timing of transfusion and transfusion volume; and 
these neonatal complications are essential for establishment of future transfusion guidelines. 
Long-term clinical outcome
There are few studies available which investigate the relation between RBC transfusion and long-
term outcome in premature infants. Whyte et al compared neurodevelopmental outcome at a 
corrected age of 18-21 months among premature infants transfused to maintain high or low 
hemoglobin levels during early neonatal care. They observed a non-statistically significant better 
outcome when a more liberal transfusion strategy was used.21 The long-term evaluation of infants 
in the study by Bell et al showed opposite results, but these children were also evaluated at a 
different age.17,22-23 The infants in the Iowa study included in the liberal transfusion group had a 
smaller brain volume and a worse neurocognitive profile compared to the restricted transfusion 
group.22-23 These studies investigated the effect of a lower transfusion Hb threshold and did not 
correlate the actual total administered RBC volume and the Hb target with long-term clinical 
outcome. 
We performed an observational follow-up study (Chapter 3) of a group of extremely premature 
infants at a corrected age of 24 months in two tertiary neonatal centers using a RBC transfusion 
volume of either 15 or 20 ml/kg bodyweight. One cohort was assessed using the Bayley Scale of 
Infant Development II, all performed by the same psychologist. The other cohort was assessed 
using various validated tests, performed in different hospitals. In the Netherlands it is not yet 
common practice to use the same assessment tool for developmental follow-up. We observed 
no differences in neuromotor development. Our study had several limitations, including a small 
study population, different tools to evaluate neuromotor development and the retrospective 
disposition of the study.53 In view of the earlier mentioned studies, it cannot be ruled out that the 
total volume of administered donor RBC has an effect on neuromotor development in extremely 
premature infants. Future well designed randomized trials, preferentially using the same method 
for neurodevelopmental outcome, are pivotal to evaluate whether there is an optimal Hb target 
and thus transfusion volume in relation to long-term neonatal outcome.54
Erythropoietin response to RBC transfusion
RBC transfusions suppress endogenous erythropoietin (EPO) production.55 Most (older) studies 
report a transfusion associated decrease in EPO levels, however this has been measured late in 
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transfusion practice has changed since these studies were performed.11 The transfusion triggers 
have become more restrictive for stable infants after the postnatal age of 4 weeks and most RBC 
transfusions are now administered in the first month after premature birth.1 Animal studies have 
shown that EPO has neuro-protective properties.61 More restrictive RBC transfusion practices could 
in theory attend endogenous EPO production and consequently help in preventing or overcoming 
brain injury.61 To study these effects we should know more about EPO levels in premature infants. 
In adults with a normal hematocrit, EPO values vary between 2.6 and 18.5 mU/ml.63 In healthy 
children (one month – 16 years old) reference EPO values are slightly higher with a mean value of 
15.8 mU/ml and 95% range of 9.1-27.6 mU/ml.64 For premature infants, in particular during the 
first month of life, no exact data are available. 
We measured EPO levels in 46 premature infants, born in 6 consecutive months (Chapter 4). We 
used waste material, so no extra blood loss was necessary for our measurements. Consequently, 
we were only able to measure EPO levels during the first month of life. Thereafter, most infants 
had been transferred to peripheral centers. None of the infants received recombinant human-
EPO. Thirty six out of 46 received at least one transfusion. EPO levels were not correlated to Hb 
or hematocrit values. EPO is also a marker for stress.65-66 EPO levels >500 mU/ml were associated 
with life threatening conditions. Although we did not find a significant relationship between EPO 
levels and a worse Apgar score, the need for respiratory support or sepsis. EPO levels declined 
after every administered RBC transfusion. We did not find a significant suppressive effect of 
cumulative RBC transfusions in the first month of life. It is however possible that differences in 
transfusion practice (used triggers, transfusion volume or hematocrit of the transfusion product) 
can influence this decline in EPO in variable degrees. 
Umbilical Cord Blood for transfusion purposes
Collection of umbilical cord blood
Umbilical cord blood (UCB) can be collected by puncture of the umbilical cord vessels either before 
(in utero) or after (ex utero) placental delivery. Few randomized studies exist, mainly performed 
in a caesarean section setting (Chapter 5).67-70 These studies showed that in utero collection 
results in significantly higher UCB volumes. This was supported by a large observational study 
by Solves et al.71 Of note, immediate clamping of the cord is an important factor contributing 
to a larger harvested UCB volume. Collection of UCB after caesarean section resulted in less 
contamination.72 Reported microbial contamination of collected UCB in several clinical studies 
was between 0% and 9%.73-77
Processing and storage of UCB for transfusion purposes 
There are few studies reporting on UCB processing into RBC products (Chapter 5). Eichler and 
Garritsen used a centrifugational separation technique.74,78 A minimal net volume of 30 ml UCB 
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by gravity could be an elegant method to be used for RBC separation from UCB, because this 
method is less laborious and may exert less mechanical stress compared to the centrifugation 
method. This technique requires a minimum of 60 ml UCB and is therefore not a suitable 
alternative for processing premature UCB because the collected volumes after premature delivery 
are much smaller.74,79-80 
Several studies have been performed to explore red cell lesions in stored UCB units. After storage 
up to 28 days in citrate-phosphate-dextrose-adenine (CPDA), whole blood UCB using autologous 
plasma has an acceptable mean pH of 6.51 and haemolysis rate of 0.39 ± 0.05 %.81-82 Storage 
of UCB previously processed into RBC products gives different results. UCB derived packed RBC 
units, supplemented and stored in saline-adenine-glucose-mannitol (SAG-M) or phosphate-
adenine-glucose-guanosine-saline-mannitol (PAGGS-M) for 35 days 78-79, 83 had significantly higher 
mean haemolysis rates.78-79 Storage in PAGGS-M resulted in a lower haemolysis rate compared 
to SAG-M.83 In view of the increase in haemolysis and decrease in pH, it can be concluded that 
UCB red cells deteriorate faster during storage than adult red cells. The whole blood storage 
(in autologous CPDA- plasma) parameters suggest that UCB derived RBCs deteriorate faster 
after processing by centrifugation or filtration and storage in preservation medium as compared 
to adult RBCs. The study by Widing et al showed better results when PAGGSM was used as 
storage solution. PAGGSM contains additional phosphate and guanosine compared to SAG-M.83 
This finding suggests that not (only) the manipulation of cord blood, but rather the preservative 
solution may contribute to the storage damage of UCB derived RBCs. 
There is limited data on storage of premature RBCs. For our clinical study on the use of premature 
UCB for autologous transfusion purposes, we first performed a validation study (Chapter 6). We 
stored premature UCB as whole blood in CPDA or as a fractionated RBC component in SAG-M 
or additional solution 3 (AS-3). Fractionation was performed using a closed centrifugation circuit 
(15 min at 1010 g; Biosafe Sepax, Eysins,
Switzerland) suited to use different blood volumes. Stored as whole blood the red cell parameters 
maintained rather well up to 14 days of storage.84 The lower and variable hematocrit and the high 
white blood cell content, is a disadvantage to use whole blood stored RBC as an alternative for 
allogeneic RBC transfusion in premature infants. Moreover as will be later discussed, harvesting 
the white blood cell fraction, which contains the cord blood stem cells, could be of future benefit. 
Storage parameters of UCB derived RBC components in SAG-M or AS-3 were similar, but both 
less optimal than whole blood storage. We observed a higher haemolysis rate compared to the 
studies by Garritsen et al, Brune et al, and Widing et al.78-79,83 The pH during storage in SAG-M 
was similar compared to the studies by Brune and Garritsen.78-79 It is possible that premature UCB 
derived RBCs are more fragile and less resistant to mechanical stress during fractionation. 
Altogether, we can conclude that premature UCB derived RBCs can be collected for transfusion 
purposes. In view of the red cell lesion parameters, shelf life of these products would be maximally 
21 days and therefore much shorter than the standard donor pedi-pack RBCs. In current 
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Clinical implementation - autologous UCB transfusion
We performed a randomized clinical study to investigate the feasibility of autologous premature 
UCB transfusions for the treatment of anemia of prematurity (Chapter 7). Premature UCB was 
collected after deliveries between 25 0/7 – 31 6/7 gestational weeks. In 57% of all collections, 
the harvested UCB volume was adequate for processing into a RBC product. After processing and 
quality control there were autologous products approved for release for transfusion available for 
36% of the total study population. In the context of a blinded RCT, the proportion of transfused 
infants with an available autologous RBC product was 27%. These products could cover a mean 
of 58% of the transfusion needs of these infants (range 25-100%). The transfusion needs from 
the infants born after 30 gestational weeks was low, in our study 19% of these infants received 
RBC transfusions.1 As a result of these findings, we concluded that the collection of premature 
UCB for infants born after 30 gestational weeks was less efficient, resulting in 80% of available 
autologous UCB products which were not used. The collection of UCB for younger infants 
appeared to be more efficient. For infants born before 28 gestational weeks, UCB collection was 
however not often sufficient for successful processing, but in view of the high transfusion needs, 
every available product would be used. For slightly older infants, born between 28 0/7 and 30 6/7 
gestational weeks, the availability of autologous product was most efficient.77
Expansion of UCB derived CD34 positive cells into erythroid cells
UCB contains a large content of CD34 positive hematopoietic stem cells and other progenitor cells. 
These multi-potent cells can be expanded into clinical grade RBCs using specific combinations of 
cytokines and growth factors.86-90 In addition, expanded erythroblasts have been proposed as an 
alternative for the standard transfusion product. Clinical implementation of these expanded cells 
for transfusion is however held back due to the use of xenogeneic proteins in the culture medium 
and expensive complex multistep protocols.91
After processing of the premature UCB into RBC products84, the waste buffy coats were examined 
on CD34 positive cell content. We found a mean count of residual 2.5x106 CD34 positive cells in 
the premature UCB buffy coats (range 1.2x105 – 1.7x107 (n=10)). We evaluated whether expansion 
of these waste buffy coats could provide additional red cells for transfusion to supplement our 
autologous premature UCB cell products that have a shelf life of 14-21 days.84
We have set up a simple one-step liquid culture protocol in which we tested several combinations 
of recombinant human Stem Cell Factor (SCF), Interleukin 3 (IL-3), trombopoietin and EPO, while 
omitting xenogeneic cytokines and proteins from the culture medium (Chapter 8). We tested 
the whole waste buffy coat after premature UCB processing and isolated CD34 positive cells 
from premature and full term cord blood and adult mobilized peripheral blood (PBSC) and bone 
marrow (BM). Expansion of the whole premature UCB buffy coat was more effective in gaining 
erythroblasts and resulted in a ± 3 fold higher number of erythroblasts compared to isolated 
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a significant proportion of native RBCs present in the buffy coat. During culture it cannot be 
precluded that these native cells are subject to red cell storage lesion. Therefore the subsequent 
experiments were performed with isolated CD34 positive cells. Premature and full term CD34 
positive cells isolated from UCB had a similar fold increase and a similar erythroid differentiation 
pattern. The CD34 positive cells from full term UCB and the adult cell sources had similar fold 
expansion rates (between 4000 and 4700 fold) after 21 days of culture with SCF, IL3 and EPO. On 
day 21, the expanded cell cultures were pure erythroid. The proportion of CD235a (Glycophorin-A) 
expressing cells, reflecting erythroblast differentiation and maturation, in adult PBSC (96.7±0.8%) 
and BM (98.9±0.5%) was significantly larger compared to UCB (87.7±2.7%) (p=0.002 after 
correction for multiple testing). Residual cells in the UCB cultures existed of CD71 positive and 
CD235a-CD45 negative cells, reflecting proliferating cells that had not differentiated towards a 
specific cell lineage. Based on the cell surface marker expression of the majority of the expanded 
cells; CD235a positive/CD71 positive/CD36 negative; we concluded that we obtained mostly 
polychromatic erythroblasts in our culture system. Our attempt to induce ex vivo enucleation by 
adding an extra culture phase which included supplementation of insulin and thyroid hormone to 
the culture medium, combined with removal of dexamethason92, was unsuccessful. 
 With the optimal growth factor combination of IL3, SCF and EPO we calculated that expansion 
of CD34 positive cells would lead to a range of 4.8x108- 4.4x1010 expanded erythroblasts. If the 
whole premature UCB buffy coat would have been cultured without native RBC contamination, 
this could imply ± threefold higher number of expanded erythroblasts. As these cells would fully 
differentiate and maturate in vivo, theoretically enough cells could be expanded to obtain for 
extremely low birth infant infants at least one additional red cell transfusion. 
There is however much room for optimization of techniques to increase the yield. Future studies 
should first focus on the in vivo functionality and safety of expanded red cells have to prove 
suitability of expanded cell transfusion. Although our harvesting method and culture conditions 
were suboptimal, the results suggest that it is worthwhile to put effort in further optimization 
and generation of clinical grade culture conditions, and in vivo differentiation and functionality 
testing. Combined with the use of autologous UCB derived RBCs, expansion of autologous cells 
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The association between allogeneic RBC transfusions and a negative clinical outcome in premature 
neonates has contributed to the introduction of blood transfusion guidelines with recommended 
transfusion triggers. Despite the use of a national blood transfusion guideline significant 
differences exist concerning the total amount of allogeneic RBC transfusions administered to 
premature infants. However, as shown by comparison of two Dutch tertiary neonatal centers, 
a more liberal transfusion strategy and a higher transfusion volume was not associated with 
obvious poor short-term outcome, nor delayed neuromotor development at 2 years of age. A 
methodological bias due to the use of different assessment tools for neuromotor development or 
a too small study population however cannot be ruled out and long-term follow-up evaluation 
is lacking. 
Due to use of the current transfusion triggers, most transfusions are administered early in life. 
Therefore less suppression of endogenous EPO could be expected. Future studies focusing on 
transfusion triggers and transfused RBC volume can elucidate whether differences in transfusion 
practices result in variable degrees of EPO supression.
Umbilical cord blood may be an easy accessible alternative for allogeneic RBC transfusions 
but can also be used for autologous purposes. Premature infants born < 30 gestational weeks 
suffering from anemia of prematurity can be treated with autologous RBCs derived from UCB. Ex 
vivo expansion of UCB derived CD34 positive stem cells and progenitor cells provides a potential 
source of ex vivo expanded RBC for autologous use, and as such could supplement autologous 
UCB red cells in minimizing allogeneic RBC transfusions. In the future, the culturing methods 
should be optimized for clinical use.
Current neonatal transfusion practice and clinical studies have focused on more restrictive 
transfusion triggers and optimizing RBC product volume and hematocrit to minimize allogeneic 
RBC transfusions. Use of autologous UCB cells and expanded UCB red cells can assist in reducing 
allogeneic blood. However, much remains to be done before this can be achieved. Until then, 
the presumed disadvantages of allogeneic RBCs on neonatal outcome should be further clarified, 
because avoidance of allogeneic transfusions is unattainable in current clinical practice. 
Recommendations
•	 Future studies on RBC transfusion triggers and/or effects should mention transfusion 
volume as well as product hematocrit. As such international data on actual transfused 
RBC effects can be compared in a more precise manner.
•	 Follow up studies on transfusion related outcome should use a uniform method for 
neuro-cognitive testing and also a longer follow up period (at least up to school age) is 
recommended. 
•	 To widen the use of autologous cord blood transfusion; there exist ample possibilities 
for improvement of collection and fractionating techniques of umbilical RBC products 
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Te vroeg geboren baby’s worden vaak behandeld met rode bloedcel (RBC) transfusies vanwege 
bloedarmoede.1 Deze RBCs zijn afkomstig van gezonde volwassen donoren. In de literatuur 
wordt een relatie gelegd tussen deze transfusies en nadelige neonatale klinische uitkomsten.2-6 
Een causaal verband is echter tot nu toe niet bewezen.7 
De invoering van nationale bloedtransfusierichtlijnen heeft er toe geleid dat het aantal toegediende 
RBC transfusies aan te vroeg geboren baby’s significant is verminderd.8-10 De achtergrond van 
deze transfusierichtlijnen is echter empirisch; wetenschappelijke ondersteuning voor het gebruik 
van de geadviseerde transfusiedrempels en transfusievolume ontbreekt. Resultaten van studies 
naar het gebruik van meer restrictieve en liberale transfusiedrempels toonden dat een restrictiever 
transfusiebeleid leidde tot minder toegediende transfusies.11-13 De klinische uitkomsten van een 
restrictief of meer liberaal transfusie beleid waren echter minder eenduidig. Eén studie toonde 
dat een restrictief transfusiebeleid leidde tot meer neurologische problemen op de korte termijn.11 
Alhoewel een liberaal transfusiebeleid geassocieerd was met een mogelijke betere neuro-motore 
ontwikkeling op de gecorrigeerde leeftijd van 18-21 maanden, bleek daarentegen dat dit beleid 
ook geassocieerd is met een kleiner hersenvolume en een minder goed cognitief profiel op de 
schoolgaande leeftijd.14-16 Interpretatie van deze resultaten is niet eenvoudig. De methoden om 
de ontwikkeling op de jonge kinderleeftijd te testen hebben een lage voorspellende waarde voor 
het cognitief functioneren op de schoolgaande leeftijd, waarbij geen relatie is gevonden tussen 
perinatale hersenschade en cognitief functioneren op 12 jarige leeftijd.17-18 Toekomstige studies 
zullen moeten laten zien wat de invloed is van RBC transfusie op cognitieve uitkomsten.
Andere onderzochte methoden in de strijd tegen bloedarmoede bij te vroeg geborenen zijn het 
gebruik van recombinant humaan Erytropoëtine (EPO), vermindering van het bloedverlies door 
afname voor diagnostiek en later afnavelen na een vroeggeboorte. Het gebruik van recombinant 
humaan EPO bij te vroeg geboren baby’s is niet doelmatig en effectief gebleken.19-21 Daarentegen 
leidden zowel minder bloedafnamen voor diagnostiek als later afnavelen wel degelijk tot minder 
toegediende transfusies, alhoewel RBC transfusie niet volledig kon worden voorkomen.22-23 
Kortom, het gebruik van allogene RBC transfusies aan te vroeg geboren baby’s is significant 
verminderd. Aangezien te vroeg geborenen een steeds betere overleving hebben, is het belangrijk 
om zowel de korte als de lange termijn effecten van deze transfusies in kaart te brengen. 
In dit proefschrift hebben we in twee Nederlandse neonatale intensive care units (NICU’s) 
transfusie effecten en uitkomsten in kaart gebracht. Daarnaast hebben we onderzocht of RBCs 
uit eigen navelstrengbloed als alternatief gebruikt kunnen worden voor het standaard donor RBC 
product.
Neonataal transfusie beleid in Nederland
De Nederlandse bloedtransfusierichtlijn is opgesteld door het CBO Kwaliteitsinstituut voor de 
Gezondheidszorg.24 In deze richtlijn worden aanbevelingen gedaan voor de transfusiedrempel, 
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hoger transfusievolume per kg lichaamsgewicht. Daarom hebben we in twee Nederlandse NICU’s 
onderzoek gedaan naar de effecten van een verschillend transfusie volume (15ml/kg vs 20 ml/
kg) op de neonatale uitkomsten. Beide centra hanteerden de Nederlandse transfusierichtlijn en 
gebruikten hetzelfde transfusieproduct. Desondanks zagen we grote verschillen. Het percentage 
te vroeg geboren baby’s dat werd behandeld met transfusies was duidelijk hoger in het centrum dat 
een volume van 20 ml/kg hanteerde (77% van de baby’s) in vergelijking met het andere centrum 
(59% van de baby’s). Dit werd vooral bepaald door een groot verschil in getransfundeerde baby’s 
geboren na 28 tot 32 weken zwangerschapsduur (74% versus 49 %). Bij de jongere prematuren 
geboren vóór 28 weken zwangerschapsduur werd een vergelijkbaar aantal baby’s behandeld met 
RBC transfusies. Ondanks het gebruik van de nationale richtlijn waren er sterke aanwijzingen 
dat frequent transfusies werden toegediend op klinische gronden ondanks dat de aanbevolen 
transfusiedrempel niet was bereikt.
Het effect van een verschillend transfusievolume was niet eenduidig. Bij de jongere baby’s 
geboren vóór 28 weken zwangerschapsduur, resulteerde het hogere volume niet in een geringer 
aantal transfusies. Bij de baby’s geboren tussen 28-32 weken zwangerschapsduur zagen we bij 
transfusie met 20 ml per kg een vermindering van één transfusie episode per kind.25 
In 2011 werd de CBO richtlijn voor bloedtransfusie toediening herzien. De belangrijkste wijzigingen 
in de richtlijn zijn als volgt; de aanbeveling om laat af te navelen (30 tot max. 180 sec) indien 
klinisch mogelijk is opgenomen in de richtlijn; de transfusie drempel van 8 mmol/l voor de eerste 
24 uur na geboorte is verlaten, en het aanbevolen transfusievolume per kg lichaamsgewicht is 
veranderd naar 15 mL/kg lichaamsgewicht in plaats van de eerder aanbevolen range van 10 tot 
15 mL/kg lichaamsgewicht.26
Deze verschillen in transfusiebeleid staan niet op zichzelf. Ook in andere landen is gebleken dat 
er ondanks de invoering van een nationale transfusierichtlijn belangrijke verschillen bestaan in 
de praktijk.27-29 Voorstellen om de compliantie van de zorgverlener te vergroten omvatten onder 
andere het gebruik van een elektronisch transfusieproduct bestel- en monitorsysteem en het 
implementeren van de klinische beoordeling van de zorgverlener binnen de richtlijn.30-31 Met het 
oog op de aangetoonde verschillen met betrekking tot het stellen van de transfusie indicatie 
en het effect van het gebruikte transfusie volume op de blootstelling aan donorbloed, is het 
belangrijk om uit te zoeken welke aanpassing bijdraagt aan de beste compliantie.
Transfusie effecten op neonatale klinische uitkomsten
Korte en lange termijn klinische uitkomsten
In bovengenoemde neonatale cohorten hebben we gekeken naar de invloed van het aantal 
RBC transfusies en het toegediende transfusievolume op zowel korte als lange termijn neonatale 
uitkomsten. Op de korte termijn zagen we geen verschillen tussen beide groepen met betrekking 
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dysplasie, ondanks dat er in één centrum een significant grotere groep kinderen werd behandeld 
met RBC transfusies en een groter transfusievolume.25
Er is weinig bekend over de relatie tussen RBC transfusie en neonatale uitkomsten op de langere 
termijn. Zoals eerder genoemd is de literatuur niet eenduidig.14-16 
Wij hebben de relatie tussen transfusie volume en neuro-motore ontwikkeling geëvalueerd in 
twee groepen extreem te vroeg geboren baby’s, geboren vóór 28 weken zwangerschapsduur. 
Het aantal toegediende transfusies was vergelijkbaar tussen beide groepen. We vonden geen 
verschil in neuro-motore ontwikkeling op de gecorrigeerde leeftijd van (mediaan) 24 maanden 
bij een groter of kleiner toegediend transfusievolume. Echter, onze studie had een aantal 
beperkingen waaronder een relatief kleine studiepopulatie, verschillen in evaluatie methoden en 
het observationele karakter van de studie.32 Het kan dus niet worden uitgesloten dat het totale 
volume van een RBC transfusie invloed heeft op de neuro-motore ontwikkeling van extreem te 
vroeg geboren kinderen. Goed opgezette gerandomiseerde klinische studies zijn essentieel om 
dit verder te kunnen onderzoeken. 
Het effect van RBC transfusie op EPO
Meerdere (oudere) studies hebben laten zien dat RBC transfusies bij premature pasgeborenen de 
endogene EPO productie kunnen onderdrukken. Dit EPO onderdrukkend effect werd echter pas 
na een aantal weken postnataal gemeten, wanneer de kinderen al een groot aantal transfusies 
hadden gekregen.33-36
Het huidige neonatale transfusie beleid is aanzienlijk anders dan in deze oudere studies. Dankzij 
de invoering van nationale transfusierichtlijnen, met aanbevolen transfusiedrempels, is het 
aantal toegediende RBC transfusies significant gedaald.8-10 Dit heeft ertoe geleid dat de meeste 
transfusies worden toegediend in de eerste maand na geboorte. 
Meerdere dierexperimentele studies hebben laten zien dat EPO neuro-protectieve eigenschappen 
heeft.37-38 Een restrictiever transfusiebeleid zou in theorie de endogene EPO productie minder 
onderdrukken en kunnen bijdragen aan betere neuro-protectie en het voorkomen van 
hersenschade op de langere termijn. Om deze theorie te ondersteunen zouden we meer moeten 
weten van EPO waarden bij te vroeg geboren baby’s. Volwassenen zonder bloedarmoede hebben 
EPO waarden tussen de 2.6 – 18.5 mU/mL.39 Kinderen (tussen 1 maand -16 jaar) hebben iets 
hogere EPO waarden, tussen de 9.1-27.6 mU/mL.40-42 Van te vroeg geboren baby’s geboren 
hebben we beperkt beschikbare gegevens.
We hebben daarom bij 46 prematuur geboren baby’s EPO concentraties gemeten in plasma. We 
hebben alleen spijtmateriaal gebruikt, dat wil zeggen, bloed wat over was van bloedafnamen 
voor reguliere diagnostiek. Hierdoor waren we alleen in staat om vooral in de eerste maand na 
geboorte onze metingen te verrichten, omdat enerzijds veel kinderen daarna werden overgeplaatst 
naar ziekenhuizen elders, en anderzijds omdat in de eerste maand de meeste bloedtesten 
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wel transfusies kregen toegediend hadden hogere EPO waarden dan de niet-getransfundeerde 
te vroeg geboren zuigelingen. Dit reflecteert de diepere bloedarmoede bij deze kinderen en 
mogelijk een compensatoire EPO respons op deze anemie. Anderzijds is ook bekend dat EPO een 
marker is voor stress. Ook klinisch zieker zijn zou dus in theorie kunnen bijdragen aan een hogere 
EPO productie. De waarden laten zien dat vroege transfusies in de eerste levensmaand de EPO 
productie niet duidelijk onderdrukken. 
 
Navelstrengbloed voor transfusiedoeleinden
Het afnemen van navelstrengbloed
Navelstrengbloed kan afgenomen worden vóór (in utero) of na (ex utero) de geboorte van de 
placenta. In utero afname van navelstrengbloed leidt tot aanzienlijk hogere bloedvolumes, zowel 
na een vaginale bevalling als na een keizersnede.43-46 Daarnaast is het vroeg afklemmen van de 
navelstreng ook een belangrijke factor die bijdraagt aan een groter volume van de bloedafname.47 
Bacteriële contaminatie komt voor in 0 tot 9% van de navelstrengbloedafnames.48-52
 
Het verwerken en bewaren van navelstrengbloed voor transfusiedoeleinden 
Navelstrengbloed kan met behulp van centrifugatie bewerkt worden tot een RBC concentraat.49,53 
Ook zonder centrifugeren is scheiding van RBCs uit navelstrengbloed mogelijk. Deze techniek 
heet ‘hollow-fibre in-line’ filtratie en maakt alleen gebruik van zwaartekracht. Deze methode 
veroorzaakt mogelijk minder schade aan rode bloedcellen, maar is alleen doelmatig met een 
minimaal afgenomen volume van 60 mL navelstrengbloed, aangezien anders relatief teveel 
RBCs achterblijven in het filtersysteem.54 Aangezien de afgenomen volumina na een premature 
geboorte kleiner zijn, lijkt deze methode vooralsnog niet geschikt voor het opwerken van 
prematuur navelstrengbloed.52
Voor het bewaren van navelstrengbloed RBC zijn verschillende bewaarvloeistoffen getest. Het 
bewaren van volbloed uit de navelstreng in citraat-fosfaat-dextrose-adenine en autoloog plasma 
toonde goede parameters na een bewaarduur van 21-28 dagen; een gemiddelde pH van 6.6 na 
21 dagen, en een gemiddelde pH van 6.51 en een hemolyse van 0.39 ± 0.05% na 28 dagen.55-56 
Aangezien in Nederland geldt dat de hemolyse <0.8% moet zijn ten tijde van een transfusie, 
hebben deze studies laten zien dat het bewaren van volbloed navelstrengbloed voldoet aan deze 
strenge eis. 
Het bewaren van door centrifugatie opgewerkte navelstrengbloed RBC in bewaarvloeistoffen, 
zoals gebruikt voor RBCs van bloeddonoren, leidde tot minder goede resultaten. Bij het bewaren 
van navelstrengbloed RBCs in saline-adenine-glucose-mannitol (SAG-M) of phosphate-adenine-
glucose-guanosine-saline-mannitol (PAGGS-M) werd gezien dat de hemolyse aanzienlijk toenam 
in de tijd.53,57 PAGGS-M bleek een betere bewaarvloeistof dan SAG-M, met lagere hemolyse 
waarden.57 Gezien de toename in hemolyse en de pH daling kunnen we concluderen dat 
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worden onder omstandigheden die zijn geoptimaliseerd voor volwassen RBCs. Aangezien 
PAGGS-M de beste resultaten gaf, concluderen we dat niet alleen de opwerkprocedure middels 
centrifugatie, maar ook het bewaarmedium kan bijdragen aan schade aan foetale RBCs tijdens 
het bewaren. 
Er is weinig bekend over de optimale bewaarcondities van afgenomen navelstrengbloed van 
prematuur geborenen. Voor onze klinische studie over het gebruik van prematuur navelstrengbloed 
voor autologe transfusie, hebben we eerst een navelstrengbloedproduct validatie studie 
opgezet.58 We hebben prematuur navelstrengbloed opgeslagen als volbloed in CPDA of als, 
door centrifugatie gefractioneerd, RBC component in SAG-M of Additional Solution 3 (AS-3). 
De volbloed RBC kwaliteitparameters na 21 dagen waren beter dan van de RBC componenten. 
Echter, gezien de lagere en variabele hematocriet en de hoge witte bloedcel contaminatie, die na 
centrifugatie verlaagd werd met gemiddeld 37%, is volbloed minder aantrekkelijk voor autologe 
transfusie. SAG-M of AS-3 waren even goed als bewaarvloeistof. De hemolyse in onze studie 
was hoger in vergelijking met andere studies53-54, 57, maar de pH was wel vergelijkbaar.53-54 Het is 
mogelijk dat navelstrengbloed RBC van prematuren kwetsbaarder zijn en minder bestand tegen 
mechanische stress tijdens centrifugering. Al met al kunnen we concluderen dat navelstrengbloed 
RBC van prematuur geborenen geschikt is voor autologe transfusie. Met het oog op de RBC 
bewaarparameters, is de houdbaarheid van deze producten aanzienlijk korter (tot maximaal 21 
dagen) dan van standaard volwassen RBC bewaard als ‘pedi-pack’. Maar aangezien premature 
baby’s vrij snel na geboorte transfusie behoefte hebben1, is dit geen praktisch bezwaar.
 
Klinische toepasbaarheid – Autologe navelstrengbloedtransfusie
In een gerandomiseerde studie hebben we de haalbaarheid van autologe navelstrengbloed 
transfusies onderzocht voor de behandeling van anemie van de prematuriteit. Prematuur 
navelstrengbloed werd afgenomen na bevallingen bij een termijn van 25 tot 32 weken 
zwangerschap. In 57% van de gevallen was er voldoende ( > 15 ml) navelstrengbloed geoogst voor 
verdere bewerking tot een autoloog RBC product. Na het opwerken, het uitvoeren van dezelfde 
kwaliteitstesten als voor volwassen donor RBCs en bacteriële testen van alle navelstrengbloed 
RBC producten, waren er goedgekeurde autologe producten beschikbaar voor 36% van de totale 
studie populatie. Voor 27% van de prematuren met een daadwerkelijke transfusiebehoefte was 
er een autoloog RBC product beschikbaar, dat gemiddeld 58% van de transfusiebehoefte van 
deze pasgeborenen kon dekken (range van 25-100%).52
 
Het kweken van navelstrengbloed CD34 positieve cellen naar rode cellen
Navelstrengbloed is een belangrijke bron voor CD34 positieve hematopoïetische stamcellen en 
van andere voorlopercellen. Deze multipotente cellen kunnen ondermeer worden opgekweekt 
tot RBC geschikt voor transfusie.59-63 Het gebruik van gekweekte rode voorlopercellen uit 








































156  |  Samenvatting
wordt geëxploreerd als een toekomstig alternatief voor het standaard transfusie product. De 
daadwerkelijke toepasbaarheid van deze gekweekte cellen voor transfusie is nog niet bekend. 
Met name het gebruik van groeimedia die dierlijke eiwitten bevatten en dure complexe 
kweekprotocollen zijn debet aan het feit dat de toepasbaarheid nog niet uitgebreid is onderzocht 
in de kliniek.63
Na het bewerken van het prematuur navelstrengbloed tot een autoloog RBC product hebben 
we in de afgescheiden buffy coat, die een groot deel van de witte bloedcelfractie bevat, het 
aantal CD34 positieve stamcellen bepaald. We vonden gemiddeld 2.5x106 CD34 positieve cellen 
per buffy coat (range 1.2x105-1.7x107; n = 10). Onze hypothese was dat het kweken van deze 
stamcel bevattende buffy coats zou kunnen leiden tot extra rode (voorloper) cellen, geschikt voor 
transfusie na 21 dagen kweek, wanneer de bewaarduur van het autologe RBC navelstrengbloed 
product verlopen zou zijn. 
We hebben hiertoe een eenvoudige 1-staps kweekmethode opgezet met gebruik van recombinant-
humaan Stem Cell Factor (SCF), Interleukine-3 (IL-3) en EPO, zonder het gebruik van dierlijke 
eiwitten. De efficiëntie van onze methode hebben we getest met zowel CD34 positieve cellen 
uit (prematuur en a terme) navelstrengbloed, en uit CD34 positieve celbronnen van volwassenen 
(gemobiliseerd perifeer bloed (PBSC) en beenmerg (BM)). Na 21 kweekdagen hadden we een 
celvermenigvuldiging van gemiddeld 4000 tot 4700 keer in zowel de navelstrengbloed kweken 
als de PBSC en BM kweken. Na 21 dagen kweken bestonden alle kweken uit rode voorlopercellen. 
We berekenden dat met onze gemiddelde vermenigvuldigingssnelheid, we 4.7x108 tot 4.4x1010 
rode voorlopercellen kunnen genereren. Deze voorlopercellen kunnen in vivo verder uitrijpen 
tot rode cellen. In theorie is het aantal CD34 positieve stam en voorlopercellen in de buffy coat 
van navelstrengbloed van prematuren buffy coat met de behaalde celvermenigvuldigingsfactor, 
voldoende voor tenminste één extra neonatale transfusie. Verdere optimalisatie van de 
kweekmedia en het in vivo testen van het patroon van uitrijping en functionaliteit van deze rode 
voorlopercellen, zal ons dichter bij een gekweekt autoloog rode bloedcelproduct brengen. In 
combinatie met ons autologe RBC navelstrengproduct, kan dit leiden tot verder verminderen, of 
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